

National Library of Medicine - Medical Subject Headings

2003 MeSH

MeSH Supplementary Concept Data

[Return to Entry Page](#)

Name of Substance	HER4 protein
Record Type	C
Registry Number	EC 2.7.1.-
Entry Term	c-erbB-4 protein
Entry Term	erbB4 gene product
Entry Term	p180(erbB4) protein
Entry Term	proto-oncogene protein HER-4
Entry Term	proto-oncogene protein erbB-4
Entry Term	HER-4 protein
Entry Term	HER-4 proto-oncogene protein
Entry Term	erbB-4 gene product
Heading Mapped to	*Receptor, Epidermal Growth Factor
Previous Indexing	* PROTEIN-TYROSINE KINASE (93)
Previous Indexing	* RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE (93)
Source	Proc Natl Acad Sci U S A 1993 Mar 1;90(5):1746-50
Frequency	274
Note	amino acid sequence in first source; a 180-kDa transmembrane tyrosine kinase expressed in some breast carcinoma cell lines and various normal tissues; member of the type I family of growth factor receptors
Date of Entry	19930406
Revision Date	20021024
Unique ID	C080076

[Return to Entry Page](#)

[Link to NLM Cataloging Classification](#)

THIS PAGE BLANK (USPTO)

=> fil reg; d stat que l3; d his 15-18; fil capl; d que nos l12; fil uspatf; d que nos l16; fil biosis; d que nos l17

FILE REGISTRY ENTERED AT 10:33:39 ON 21 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2003 HIGHEST RN 607332-91-2

DICTIONARY FILE UPDATES: 20 OCT 2003 HIGHEST RN 607332-91-2


TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>



VAR G2=H/X/CF3/14/15

VAR G4=N/CH

VAR G5=17/20/23/26/29/31/33/36

VPA 11-1/2/5/6 U

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 14

CONNECT IS E1 RC AT 16

CONNECT IS E1 RC AT 35

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L3- 566 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 257155 ITERATIONS

566 ANSWERS

SEARCH TIME: 00.00.05

(FILE 'REGISTRY' ENTERED AT 09:29:51 ON 21 OCT 2003)

L5 0 S L3 AND CANCERLIT/LC
L6 0 S L3 AND MEDLINE/LC
L7 0 S L3 AND EMBASE/LC
L8 0 S L3 AND DRUGU/LC

*have
none of these files contain
references with that contain
any of the Registry #'s from
L3 (structure search
answer set)*

FILE 'CAPLUS' ENTERED AT 10:33:40 ON 21 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2003 VOL 139 ISS 17

FILE LAST UPDATED: 20 Oct 2003 (20031020/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L3 566 SEA FILE=REGISTRY SSS FUL L1
L10 44 SEA FILE=CAPLUS ABB=ON L3
L11 591249 SEA FILE=CAPLUS ABB=ON ?CANCER? OR ?NEOPLAS? OR ?TUMOR?
L12 30 SEA FILE=CAPLUS ABB=ON L10 AND L11

FILE 'USPATFULL' ENTERED AT 10:33:40 ON 21 OCT 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Oct 2003 (20031021/PD)

FILE LAST UPDATED: 21 Oct 2003 (20031021/ED)

HIGHEST GRANTED PATENT NUMBER: US6637033

HIGHEST APPLICATION PUBLICATION NUMBER: US2003196238

CA INDEXING IS CURRENT THROUGH 21 Oct 2003 (20031021/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 21 Oct 2003 (20031021/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<


```
>>> original, i.e., the earliest published granted patents or <<<
>>> applications.  USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL.  A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications.  The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1          STR
L3          566 SEA FILE=REGISTRY SSS FUL L1
L4          278 SEA FILE=REGISTRY ABB=ON  L3 AND USPATFULL/LC
L13         24 SEA FILE=USPATFULL ABB=ON  L4
L14        105408 SEA FILE=USPATFULL ABB=ON  ?CANCER? OR ?NEOPLAS? OR ?TUMOR?
L15        30930 SEA FILE=USPATFULL ABB=ON  (CANCER? OR ANTICANCER? OR NEOPLAS?
          OR ANTINEOPLAS? OR TUMOR? OR ANTITUMOR?)/IT
L16        21 SEA FILE=USPATFULL ABB=ON  L13 AND (L14 OR L15)
```

FILE 'BIOSIS' ENTERED AT 10:33:41 ON 21 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 15 October 2003 (20031015/ED)

FILE RELOADED: 19 October 2003.
Enter HELP RLOAD for information on the reload.

```
L1          STR
L3          566 SEA FILE=REGISTRY SSS FUL L1
L9          1 SEA FILE=REGISTRY ABB=ON  L3 AND BIOSIS/LC
L17         2 SEA FILE=BIOSIS ABB=ON  L9
```

=> dup.rem 112,116,117

FILE 'CAPLUS' ENTERED AT 10:33:44 ON 21 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:33:44 ON 21 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:33:44 ON 21 OCT 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

PROCESSING COMPLETED FOR L12

PROCESSING COMPLETED FOR L16

PROCESSING COMPLETED FOR L17

L41 52 DUP REM L12 L16 L17 (1 DUPLICATE REMOVED)

ANSWERS '1-30' FROM FILE CAPLUS

ANSWERS '31-50' FROM FILE USPATFULL

ANSWERS '51-52' FROM FILE BIOSIS

=> d ibib abs hitstr 1-50; d iall 51-52

L41 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2001:312415 CAPLUS

DOCUMENT NUMBER: 134:326541

TITLE: Synthesis and use of substituted 4-(1H-indol-5-yl)aminoquinazoline derivatives and analogs for treatment of hyperproliferative disorders

INVENTOR(S): Sobolov-jaynes, Susan B.; Arnold, Lee D.

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 953,078, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6225318	B1	20010501	US 1999-449855	19991126
PRIORITY APPLN. INFO.:			US 1996-28881P	P 19961017
			US 1997-953078	B2 19971017

OTHER SOURCE(S): MARPAT 134:326541

GI



AB The title compds. I [R1 is selected from CF3, halo, NO2, OH, NH2, cyano, (C1-C4)alkoxy, etc; Q1 is Ar-Y-X, where Ar is pyridyl, thiophenyl (i.e., thienyl) or pyrazinyl wherein Ar may have up to 3 substituents, X is C2


alkene, C2 alkyne or absent and Y is (CH₂)₀₋₅ and wherein one or two of the CH₂ groups may optionally and independently be replaced by either O, S, SO₂, CO, NH or NMe; R₅ is selected from CH₂F, CHF₂, CF₃, halo, NO₂, OH, NH₂, (C₁-C₄)alkyl, Ph, etc.; or two R₅s together with the carbon atoms to which they are attached, form an imidazole, pyrrole or pyrazole; q is 0-3] and similarly substituted 4-quinazolones are prepd. More than 40 examples are provided. For example, heating (1H-indol-5-yl)-(6-iodo-7-methoxyquinazolin-4-yl)amine with 4-vinylpyridine, Pd acetate and NEt₃ in MeCN gave (1H-indol-5-yl)-[7-methoxy-6-(2-pyridin-4-yl-vinyl)quinazolin-4-yl]amine (II). Compds. I are inhibitors of protein tyrosine kinase. In an EGFR kinase activity assay, I had IC₅₀ values in the range of 0.0001-30 .mu.M. Inhibition of **tumor** growth was detd. in mice (on **tumors** induced by injection of human MDA-MD-468 breast or human HN5 head and neck carcinoma cells) to be >50% at concns. of 10 .mu.M. Treatment of hyperproliferative diseases in a mammal is claimed.

IT 206190-55-8P 206190-63-8P 206190-65-0P
 206190-67-2P 206190-70-7P 206190-72-9P
 206190-74-1P 206190-91-2P 206190-95-6P
 206190-96-7P 206190-99-0P 336624-85-2P,
 (1H-Indol-5-yl)-[7-methoxy-6-(1-oxopyridin-3-yl)quinazolin-4-yl]amine
 336624-87-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and use of substituted 4-(indol-5-yl)aminoquinazoline derivs. for treatment of hyperproliferative disorders)


RN 206190-55-8 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-7-methoxy-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-63-8 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-65-0 CAPLUS


CN 4-Quinazolinamine, N-[3-(5-oxazolyl)phenyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-67-2 CAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 206190-70-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-72-9 CAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-7-methoxy-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-74-1 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-methoxy-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-91-2 CAPLUS

CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-95-6 CAPLUS

CN 7-Quinazolinol, 4-(1H-indol-5-ylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-96-7 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-(2-methoxyethoxy)-6-(3-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 206190-99-0 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-methoxy-6-(6-methoxy-3-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 336624-85-2 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-methoxy-6-(1-oxido-3-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 336624-87-4 CAPLUS
CN 4-Quinazolinamine, N-1H-indol-5-yl-7-(2-thienyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:591156 CAPLUS

DOCUMENT NUMBER: 139:149640

TITLE: Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain

INVENTOR(S): Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Caldwell, Timothy M.; De Lombaert, Stephane

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062209	A2	20030731	WO 2003-US1563	20030117
WO 2003062209	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-349920P P 20020117

US 2002-350527P P 20020122

OTHER SOURCE(S): MARPAT 139:149640

GI



AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions assocd. with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is C0-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered arom. heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered arom. carbocycle or heterocycle, (un)substituted with 1-3 LRa; L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-, -C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-; wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen, cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino, aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph, phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl). Although the methods of prepn. are not claimed, many example prepn. and characterization data for >500 examples of I are included.

IT **573675-62-4P**, [7-(3-Fluoropyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine **573675-64-6P**, (4-tert-Butylphenyl)[7-(pyridin-2-yl)quinazolin-4-yl]amine **573675-71-5P**, (4-tert-Butylphenyl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride **573675-85-1P**, (4-tert-Butylphenyl)[2-methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride **573675-95-3P**, [7-(3-Methylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine **573676-11-6P**, [6-(Propan-2-ylsulfonyl)pyridin-3-yl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine hydrochloride **573676-20-7P**, (5-Trifluoromethylpyridin-2-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine **573676-24-1P**, [2-Methyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](6-trifluoromethylpyridin-3-yl)amine **573676-26-3P**, (6-Trifluoromethylpyridin-3-yl)[7-(3-

trifluoromethylpyridin-2-yl]quinazolin-4-yl]amine 573676-28-5P,
(5-Chloropyridin-2-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-34-3P, [7-(Pyridin-2-yl)quinazolin-4-yl](5-trifluoromethylpyridin-2-yl)amine 573676-36-5P,
(5-tert-Butylisoxazol-3-yl)[7-(pyridin-2-yl)quinazolin-4-yl]amine 573676-42-3P, (4-tert-Butylphenyl)[7-(3-trifluoromethylpyridin-2-yl)quinolin-4-yl]amine 573676-50-3P, [7-(1-Oxo-3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573676-52-5P, [7-(1-Oxopyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573676-67-2P, [2-Ethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][1-(methanesulfonyl)-2,3-dihydro-1H-indol-5-yl]amine 573676-73-0P, N,N-Dimethyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573676-78-5P, [4-(Trifluoromethanesulfonyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-82-1P, [4-[(Pyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-84-3P, [4-[(3-Dimethylaminopyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-86-5P, [4-[(Piperidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-88-7P, [4-[(Morpholin-4-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-92-3P, [4-[(2-Methylpiperidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-94-5P, [4-[(cis-2,6-Dimethylpiperidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-96-7P, [4-[(2-Methylpyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573676-98-9P, [4-[(2,5-Dimethylpyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-00-6P, [4-[(2,6-Dimethylmorpholin-4-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-02-8P, [4-[(2S)-2-Methoxymethylpyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-04-0P, [4-[(2R)-2-Methoxymethylpyrrolidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-06-2P, N,N-Diisopropyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-08-4P, N-(2-Hydroxy-1,1-dimethylethyl)-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-10-8P, N-Cyclohexyl-N'-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]urea 573677-12-0P, N-Ethyl-N'-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]urea 573677-14-2P, [(2S)-1-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-2-yl]methanol 573677-16-4P, [(2R)-1-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-2-yl]methanol 573677-18-6P, (3R)-1-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonyl]pyrrolidin-3-ol 573677-29-9P, 1,1,1,3,3,3-Hexafluoro-2-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]propan-2-ol 573677-31-3P, (4-Trifluoromethoxyphenyl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-33-5P, N-Isopropyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-35-7P, [4-[(4-Methylpiperazin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-37-9P, (Pyrrolidin-1-yl)[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]methanone 573677-39-1P, N,N-Bis(2-methoxyethyl)-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-41-5P, N-(3-Chloropropyl)-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-44-8P, [4-(Methanesulfonyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-49-3P, 4-[4-[(Azetidin-1-yl)sulfonyl]phenyl][7-


(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-52-8P,
[4-(Propan-1-ylsulfonyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-55-1P, (6-Isobutylpyridin-3-yl)[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-58-4P, N-tert-Butyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-60-8P, [4-[(4-Fluoropiperidin-1-yl)sulfonyl]phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-62-0P, N-tert-Butyl-N-methyl-4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]benzenesulfonamide 573677-64-2P, 2-Methyl-2-[4-[[7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amino]phenyl]propan-1-ol 573677-66-4P, [4-(2,2,2-Trifluoro-1-methylethyl)phenyl][7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl]amine 573677-70-0P, [2-Ethyl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl][4-(2,2,2-trifluoro-1-methylethyl)phenyl]amine 573677-92-6P, (6-Methylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573677-94-8P, [4-(Trifluoromethyl)phenyl][7-(pyridin-2-yl)quinazolin-4-yl]amine 573677-96-0P, (4-tert-Butylphenyl)[7-(3-fluoropyridin-2-yl)quinazolin-4-yl]amine 573677-98-2P, [4-(Trifluoromethyl)phenyl][7-(3-fluoropyridin-2-yl)quinazolin-4-yl]amine 573678-00-9P, (4-tert-Butylphenyl)[7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-02-1P, [4-(Trifluoromethyl)phenyl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-04-3P, [4-(Trifluoromethyl)phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-06-5P, (4-Fluorophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-08-7P, (4-Chlorophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-10-1P, (4-Acetylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-12-3P, (4-Cyanophenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-14-5P, [4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-16-7P, [4-(Trifluoromethyl)phenyl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-31-6P, (4-Isopropylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-33-8P, (6-Methoxypyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-35-0P, (4-Isopropyl-3-methylphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-37-2P, [4-(Trifluoromethyl)phenyl][7-(3-methoxypyridin-2-yl)quinazolin-4-yl]amine 573678-39-4P, [4-(Trifluoromethyl)phenyl][7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-41-8P, (4-Isopropylphenyl)[7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-51-0P, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-55-4P, (3-Methoxyphenyl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-57-6P, (6-tert-Butylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-59-8P, (6-tert-Butylpyridin-3-yl)[7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine 573678-61-2P, (6-tert-Butylpyridin-3-yl)[7-(3-propoxypyridin-2-yl)quinazolin-4-yl]amine 573678-63-4P, [4-(Isopropylsulfonyl)phenyl][7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-65-6P, [5-(Trifluoromethyl)pyridin-2-yl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-67-8P, (6-tert-Butylpyridin-3-yl)[2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-69-0P, [6-(Trifluoromethyl)pyridin-3-yl][2-(trifluoromethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-71-4P, [6-(Trifluoromethyl)pyridin-3-yl][2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-73-6P, (6-tert-Butylpyridin-3-yl)[2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-75-8P, [5-(Trifluoromethyl)pyridin-2-yl][2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573678-77-0P, [6-

(Trifluoromethyl)pyridin-3-yl][2-ethyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-79-2P**, (6-tert-Butylpyridin-3-yl)[2-(trifluoromethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-81-6P**, [4-(tert-Butylaminosulfonyl)phenyl][2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-83-8P**, (6-Isopropylpyridin-3-yl)[7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-85-0P**, (6-Isopropylpyridin-3-yl)[2-propyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-87-2P**, (6-Isopropylpyridin-3-yl)[2-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573678-91-8P**, [6-(Trifluoromethyl)pyridin-3-yl][2-chloro-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine **573679-02-4P**, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-nitropyridin-2-yl)quinazolin-4-yl]amine **573679-08-0P**, [6-(Trifluoromethyl)pyridin-3-yl][2-methyl-7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine **573679-10-4P**, [4-[(Trifluoromethyl)sulfonyl]phenyl][7-(3-chloropyridin-2-yl)quinazolin-4-yl]amine **573679-14-8P**, (4-tert-Butylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine **573679-16-0P**, [6-(Trifluoromethyl)pyridin-3-yl][7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine **573679-18-2P**, (4-Isopropylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine **573679-20-6P**, (4-Ethylphenyl)[7-(3-methylpyridin-2-yl)quinazolin-4-yl]amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate and receptor detector; prepn. of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting the receptors)

RN 573675-62-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-fluoro-2-pyridinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 573675-64-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573675-71-5 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 573675-85-1 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 573675-95-3 CAPLUS
CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 573676-11-6 CAPLUS
CN 4-Quinazolinamine, N-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 573676-20-7 CAPLUS


CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 573676-24-1 CAPLUS

CN 4-Quinazolinamine, 2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573676-26-3 CAPLUS

CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573676-28-5 CAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-pyridinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 573676-34-3 CAPLUS


CN 4-Quinazolinamine, 7-(2-pyridinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 573676-36-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-7-(2-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 573676-42-3 CAPLUS

CN 4-Quinolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573676-50-3 CAPLUS

CN 4-Quinazolinamine, 7-[1-oxido-3-(trifluoromethyl)-2-pyridinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-52-5 CAPLUS

CN 4-Quinazolinamine, 7-(1-oxido-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-67-2 CAPLUS


CN 4-Quinazolinamine, N-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]-2-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573676-73-0 CAPLUS
CN Benzenesulfonamide, N,N-dimethyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 573676-78-5 CAPLUS
CN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[4-((trifluoromethyl)sulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 573676-82-1 CAPLUS
CN Pyrrolidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-84-3 CAPLUS

CN 3-Pyrrolidinamine, N,N-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-86-5 CAPLUS

CN Piperidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-88-7 CAPLUS

CN Morpholine, 4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573676-92-3 CAPLUS


CN Piperidine, 2-methyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573676-94-5 CAPLUS


CN Piperidine, 2,6-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 573676-96-7 CAPLUS

CN Pyrrolidine, 2-methyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573676-98-9 CAPLUS

CN Pyrrolidine, 2,5-dimethyl-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573677-00-6 CAPLUS


CN Morpholine, 2,6-dimethyl-4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573677-02-8 CAPLUS

CN Pyrrolidine, 2-(methoxymethyl)-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 573677-04-0 CAPLUS

CN Pyrrolidine, 2-(methoxymethyl)-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573677-06-2 CAPLUS
CN Benzenesulfonamide, N,N-bis(1-methylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-08-4 CAPLUS
CN Benzenesulfonamide, N-(2-hydroxy-1,1-dimethylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-10-8 CAPLUS
CN Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 573677-12-0 CAPLUS
CN Benzenesulfonamide, N-[(ethylamino)carbonyl]-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-14-2 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 573677-16-4 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 573677-18-6 CAPLUS


CN 3-Pyrrolidinol, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 573677-29-9 CAPLUS

CN Benzenemethanol, .alpha.,.alpha.-bis(trifluoromethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-31-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethoxy)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-33-5 CAPLUS


CN Benzenesulfonamide, N-(1-methylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-35-7 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 573677-37-9 CAPLUS
CN Pyrrolidine, 1-[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 573677-39-1 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-41-5 CAPLUS

CN Benzenesulfonamide, N-(3-chloropropyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-44-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(methylsulfonyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-49-3 CAPLUS

CN Azetidine, 1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573677-52-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(propylsulfonyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-55-1 CAPLUS

CN 4-Quinazolinamine, N-[6-(2-methylpropyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-58-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-60-8 CAPLUS

CN Piperidine, 4-fluoro-1-[[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 573677-62-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-N-methyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-64-2 CAPLUS

CN Benzeneethanol, .beta.,.beta.-dimethyl-4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573677-66-4 CAPLUS

CN 4-Quinazolinamine, N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-70-0 CAPLUS

CN 4-Quinazolinamine, 2-ethyl-N-[4-(2,2,2-trifluoro-1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573677-92-6 CAPLUS

CN 4-Quinazolinamine, N-(6-methyl-3-pyridinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573677-94-8 CAPLUS


CN 4-Quinazolinamine, 7-(2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573677-96-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(3-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)

pyridinyl)-. (9CI) (CA INDEX NAME)




RN 573677-98-2 CAPLUS

CN 4-Quinazolinamine, 7-(3-fluoro-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 573678-00-9 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573678-02-1 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 573678-04-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-06-5 CAPLUS


CN 4-Quinazolinamine, N-(4-fluorophenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-08-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


(9CI) (CA INDEX NAME)



RN 573678-10-1 CAPLUS
CN Ethanone, 1-[4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 573678-12-3 CAPLUS
CN Benzonitrile, 4-[[7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573678-14-5 CAPLUS
CN 4-Quinazolinamine, N-[4-[1,2,2,2-tetrafluoro-1-

(trifluoromethyl)ethyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)




RN 573678-16-7 CAPLUS

CN 4-Quinazolinamine, 2-methyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-31-6 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-33-8 CAPLUS

CN 4-Quinazolinamine, N-(6-methoxy-3-pyridinyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-35-0 CAPLUS

CN 4-Quinazolinamine, N-[3-methyl-4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-37-2 CAPLUS


CN 4-Quinazolinamine, 7-(3-methoxy-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573678-39-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-propoxy-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)

RN 573678-41-8 CAPLUS


CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-propoxy-2-pyridinyl)-
(9CI) (CA INDEX NAME)

RN 573678-51-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-55-4 CAPLUS

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-
(9CI) (CA INDEX NAME)


RN 573678-57-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-59-8 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[6-(1,1-dimethylethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-61-2 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-7-(3-propoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 573678-63-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[(1-methylethyl)sulfonyl]phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-65-6 CAPLUS


CN 4-Quinazolinamine, 2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 573678-67-8 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-69-0 CAPLUS

CN 4-Quinazolinamine, 2-(trifluoromethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-71-4 CAPLUS

CN 4-Quinazolinamine, 2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-73-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-75-8 CAPLUS

CN 4-Quinazolinamine, 2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 573678-77-0 CAPLUS


CN 4-Quinazolinamine, 2-ethyl-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(1,1-dimethylethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-79-2 CAPLUS

CN 4-Quinazolinamine, N-[6-(1,1-dimethylethyl)-3-pyridinyl]-2-(trifluoromethyl)-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-81-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[2-methyl-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 573678-83-8 CAPLUS

CN 4-Quinazolinamine, N-[6-(1-methylethyl)-3-pyridinyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-85-0 CAPLUS


CN 4-Quinazolinamine, N-[6-(1-methylethyl)-3-pyridinyl]-2-propyl-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573678-87-2 CAPLUS


CN 4-Quinazolinamine, 2-methyl-N-[6-(1-methylethyl)-3-pyridinyl]-7-[3-

(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573678-91-8 CAPLUS

CN 4-Quinazolinamine, 2-chloro-7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573679-02-4 CAPLUS


CN 4-Quinazolinamine, 7-(3-nitro-2-pyridinyl)-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573679-08-0 CAPLUS


CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-2-methyl-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-10-4 CAPLUS

CN 4-Quinazolinamine, 7-(3-chloro-2-pyridinyl)-N-[4-
[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 573679-14-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)phenyl]-7-(3-methyl-2-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 573679-16-0 CAPLUS

CN 4-Quinazolinamine, 7-(3-methyl-2-pyridinyl)-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 573679-18-2 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylethyl)phenyl]-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 573679-20-6 CAPLUS


CN 4-Quinazolinamine, N-(4-ethylphenyl)-7-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



L41 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:532545 CAPLUS
DOCUMENT NUMBER: 139:95455
TITLE: Combined therapy against **tumors** comprising
substituted acryloyl distamycin derivatives and
protein kinase (serine/threonine kinase) inhibitors
INVENTOR(S): Geroni, Maria Cristina; Fowst, Camilla; Cozzi, Paolo
PATENT ASSIGNEE(S): Pharmacia Italia SpA, Italy
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055522	A1	20030710	WO 2002-EP13092	20021218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: EP 2002-75052 A 20020102
OTHER SOURCE(S): MARPAT 139:95455
GI




AB The present invention provides the combined use of acryloyl distamycin derivs., in particular .alpha.-bromo- and .alpha.-chloro-acryloyl distamycin derivs., and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of **tumors**. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of **tumors** by inhibition of angiogenesis. An example protein kinase inhibitor is STI 571 and a distamycin deriv. is brostallicin (I).

IT 231277-92-2, GW572016

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined **antitumor** therapy comprising acryloyl distamycin derivs. and protein kinase (serine/threonine kinase) inhibitors)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:376831 CAPLUS

DOCUMENT NUMBER: 138:385442

TITLE: Preparation of (anilino)quinazolines as **antitumor** agents

INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 275 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040109	A2	20030515	WO 2002-GB4932	20021031
WO 2003040109	A3	20030626		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-26433 A 20011103
 OTHER SOURCE(S): MARPAT 138:385442
 GI



AB Title compds. I [wherein m = 0-2; n = 1-2; L = a bond or [C(R22)2]n; R1 = halo, CF3, CN, NC, NO2, OH, SH, NH2, CHO, CO2H, CONH2, or (un)substituted alkyl(oxy), alkenyl(oxy), alkynyl(oxy), alkylthio, alkylsulfinyl, alkylsulfonyl, (di)alkylamino, alkoxycarbonyl, (di)alkylcarbamoyl, alkanoyl(oxy), (alkyl)alkanoylamino, (alkyl)alkenoylamino, (alkyl)alkynoylamino, (di)alkylsulfamoyl, (alkyl)alkanesulfonylamino, or Q3X1; or (R1)m = alkylenedioxy; with the proviso that adjacent alkylene C atoms within a R1 substituent are optionally interrupted by O, S, SO, SO2, NR5, CO, CHOR5, CONR5, NR5CO, SO2NR5, NR5SO2, CH=CH, or C.tplbond.C; R2 = H; R3, R4, R5, R11, R12, and R22 = independently H or alkyl; Q1 and Q3 = independently (un)substituted (hetero)aryl(alkyl), cycloalkyl(alkyl), cycloalkenyl(alkyl), or heterocyclyl(alkyl); with the proviso that adjacent alkylene C atoms within the Q1Z group are optionally interrupted by O, S, SO, SO2, NR12, CO, CHOR12, CONR12, NR12CO, SO2NR12, NR12SO2, CH=CH, or C.tplbond.C; Q2 = (un)substituted Ph, bicyclic (hetero)aryl, or bicyclic heterocyclyl; X1 = a bond, O, S, SO, SO2, NR4, CO, CHOR4, CONR4, NR4CO, SO2NR4, NR4SO2, OC(R4)2, SC(R4)2, or NR4C(R4)2; Z = a bond, O, S, SO, SO2, NR11, CO, CHOR11, CONR11, NR11CO, SO2NR11, NR11SO2, OC(R11)2, SC(R11)2, or NR11C(R11)2; and pharmaceutically acceptable salts thereof] were prepd. for use in the prevention or treatment of **tumors** which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 3-(R)-(+)-dimethylaminopyrrolidine with 3,4-dihydro-5-hydroxy-7-fluoroquinazolin-4-one.bul.CF3CO2H in NMP gave the pyrrolidinylquinazolinone (41%). Addn. of chloromethyl pivalate in the presence of NaH in DMF afforded the 3-substituted deriv. (62%), which was condensed with 4-hydroxy-N-methylpiperidine using PPh3 and di-tert-Bu azodicarboxylate in DCM to give the piperidinyloxyquinazolinone (77%). Deprotection (66%) using NH3 in MeOH, followed by chlorination with POCl3 and di-isopropylethylamine in dichloroethane provided 4-chloro-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-

xyloxy)quinazoline (81%). Coupling of the chloroquinazoline with 3-bromoaniline in the presence of HCl and IPA in dioxane yielded II.bul.HCl (43%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-contg. polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 .mu.M - 10 .mu.M. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 .mu.M - 20 .mu.M. In addn., I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.


IT 525590-12-9P 525590-14-1P 525590-51-6P,
4-(3-Chloro-4-fluoroanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline 525590-57-2P,
4-[3-Chloro-4-(3-fluorobenzoyloxy)anilino]-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline 525590-58-3P,
4-(3-Chloroanilino)-7-(3-(S)-dimethylaminopyrrolidin-1-yl)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525593-38-8P,
4-(3-Chloroanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline 525593-40-2P,
4-(3-Bromoanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; prepn. of (anilino)quinazolines as erbB receptor tyrosine kinase inhibitors for treatment of cancer)

RN 525590-12-9 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 525590-14-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 525590-51-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 525590-57-2 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 525590-58-3 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 525593-38-8 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 525593-40-2 CAPLUS
 CN 4-Quinazolinamine, N-(3-bromophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:607455 CAPLUS

DOCUMENT NUMBER: 139:159940

TITLE: Use of tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions

INVENTOR(S): Jung, Birgit; Puschner, Hubert

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: Ger. Offen., 24 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10204462	A1	20030807	DE 2002-10204462	20020205
WO 2003066060	A2	20030814	WO 2003-EP814	20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003149062 A1 20030807 US 2003-353616 20030129

PRIORITY APPLN. INFO.: DE 2002-10204462 A 20020205

OTHER SOURCE(S): MARPAT 139:159940


AB The invention discloses the use of quinazoline derivs. (Markush included), or the compds. (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylaminocyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine; (3) 4-[(3-Chloro-4-(3-fluoro-4-benzyloxy)phenyl)amino]-6-[5-((2-methansulfonylethyl)amino)methyl]-furan-2-yl]quinazoline; or the antibody cetuximab C225, trastuzumab, ABX-EGF, Mab ICR-62 and EGFR antisense, their tautomers, their stereoisomers and their salts, in particular their physiol. compatible salts with inorg. or org. acids or bases, for the prodn. of a medication for prevention or treatment of diseases of the respiratory system or the lung. Prepn. of quinazoline compds. is included.

IT 231277-92-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(tyrosine kinase inhibitors for treatment of pulmonary inflammatory
conditions)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX
NAME)



L41 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:189366 CAPLUS

DOCUMENT NUMBER: 139:62609

TITLE: Discovery and Biological Evaluation of Potent Dual
ErbB-2/EGFR Tyrosine Kinase Inhibitors:
6-Thiazolylquinazolines

AUTHOR(S): Gaul, Micheal D.; Guo, Yu; Affleck, Karen; Cockerill,
G. Stuart; Gilmer, Tona M.; Griffin, Robert J.;
Guntrip, Stephen; Keith, Barry R.; Knight, Wilson B.;
Mullin, Robert J.; Murray, Doris M.; Rusnak, David W.;
Smith, Kathryn; Tadepalli, Sarva; Wood, Edgar R.;
Lackey, Karen

CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709,
USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
13(4), 637-640

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have identified a novel class of 6-thiazolylquinazolines as potent and
selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity,
with IC50 values in the nanomolar range. These compds. inhibited the
growth of both EGFR (HN5) and ErbB-2 (BT474) over-expressing human
tumor cell lines in vitro. Using xenograft models of the same
cell lines, we found that the compds. given orally inhibited in vivo
tumor growth significantly compared with control animals.


IT 231277-87-5P 231277-89-7P 231278-07-2P

388082-81-3P 552334-83-5P 552334-84-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 6-thiazolylquinazolines as dual ErbB-2/EGFR tyrosine kinase inhibitors for use in **cancer** treatment)


RN 231277-87-5 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 231277-89-7 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231278-07-2 CAPLUS


CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 388082-81-3 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 552334-83-5 CAPLUS
 CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 552334-84-6 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:8967 CAPLUS
DOCUMENT NUMBER: 139:62338
TITLE: Small molecule tyrosine kinase inhibitors: clinical development of **anticancer** agents
AUTHOR(S): Laird, A. Douglas; Cherrington, Julie M.
CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA
SOURCE: Expert Opinion on Investigational Drugs (2003), 12(1), 51-64
CODEN: EOIDER; ISSN: 1354-3784
PUBLISHER: Ashley Publications Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Numerous small mol. synthetic tyrosine kinase inhibitors are in clin. development for the treatment of human **cancers**. These fall into three broad categories: inhibitors of the epidermal growth factor receptor tyrosine kinase family (e.g., Iressa and Tarceva), inhibitors of the split kinase domain receptor tyrosine kinase subgroup (e.g., PTK787/ZK 222584 and SU11248) and inhibitors of tyrosine kinases from multiple subgroups (e.g., Gleevec). In addn., agents targeting other tyrosine kinases implicated in **cancer**, such as Met, Tie-2 and Src, are in preclin. development. As experience is gained in the clinic, it has become clear that unleashing the full therapeutic potential of tyrosine kinase inhibitors will require patient preselection, better assays to guide dose selection, knowledge of mechanism-based side effects and ways to predict and overcome drug resistance.

IT 231277-92-2, GW-572016
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. tyrosine kinase inhibitors and clin. development of **anticancer** agents)

RN 231277-92-2 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 127 THERE ARE 127 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L41 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:555376 CAPLUS
 DOCUMENT NUMBER: 137:119644
 TITLE: 4-Quinazolineamine derivative combination with other antineoplastic agent for cancer treatment, and compound preparation.
 INVENTOR(S): Lackey, Karen Elizabeth; Spector, Neil; Wood, Edgar Raymond, III; Xia, Wenle
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056912	A2	20020725	WO 2002-US1130	20020114
WO 2002056912	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-262402P P 20010116

OTHER SOURCE(S): MARPAT 137:119644

AB A method of treating **cancer** is described which includes administration of a 4-quinazolineamine (prepn. included) and at least one other **antineoplastic** agent. Also described is a pharmaceutical combination including the 4-quinazolineamines.


IT 231278-84-5P 320337-27-7P 443883-07-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction; quinazolineamine deriv. combination with other antineoplastic agent for cancer treatment, and compd. prepn.)


RN 231278-84-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 320337-27-7 CAPLUS


CN 2-Furancarboxaldehyde, 5-[4-[[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 443883-07-6 CAPLUS

CN Acetamide, N-[[4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-thiazolyl]methyl]-2,2,2-trifluoro-N-[2-

(methylsulfonyl)ethyl}- (9CI) (CA INDEX NAME)




IT 231277-92-2P 388082-75-5P 388082-77-7P
 388082-78-8P 388082-82-4P 443883-05-4P
 443883-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinazolineamine deriv. combination with other **antineoplastic** agent for **cancer** treatment, and compd. prepn.)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 388082-75-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 231278-84-5


CMF C26 H17 Cl F N3 O3



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 388082-77-7 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 231277-92-2


CMF C29 H26 Cl F N4 O4 S



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 388082-78-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, bis(4-methylbenzenesulfonate), monohydrate (9CI) (CA INDEX NAME)


CM 1

CRN 231277-92-2

CMF C29 H26 Cl F N4 O4 S




CM 2

CRN 104-15-4
CMF C7 H8 O3 SRN 388082-82-4 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-,
bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 388082-81-3
CMF C28 H25 Cl F N5 O3 S2



CM 2

CRN 104-15-4


CMF C7 H8 O3 S



RN 443883-05-4 CAPLUS

CN 4-Quinazolinamine, N-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, dihydrochloride (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 443883-12-3 CAPLUS
 CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 388082-79-9 388082-81-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinazolineamine deriv. combination with other antineoplastic

agent for **cancer** treatment, and compd. prepn.)


RN 388082-79-9 CAPLUS

CN 4-Quinazolinamine, N-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 388082-81-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



IT 388082-76-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction; quinazolineamine deriv. combination with other
antineoplastic agent for **cancer** treatment, and compd.
prepn.)

RN 388082-76-6 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]a

mino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L41 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:31441 CAPLUS

DOCUMENT NUMBER: 136:102396

TITLE: Preparation of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases.

INVENTOR(S): McClure, Michael Scott; Osterhout, Martin Howard; Roschangar, Frank; Sacchetti, Mark Joseph

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002552	A1	20020110	WO 2001-US20706	20010628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1294715	A1	20030326	EP 2001-952304	20010628
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011947	A	20030506	BR 2001-11947	20010628
NO 2002006196	A	20030224	NO 2002-6196	20021223
PRIORITY APPLN. INFO.:			US 2000-215508P	P 20000630
			US 2001-271845P	P 20010227
			WO 2001-US20706	W 20010628
OTHER SOURCE(S):	MARPAT 136:102396			
GI				



AB Title compds. (I; R1 = Cl, Br; X = CH, N, CF; Q = thiazolylene, furylene), were prepd. Thus, 5-[4-[3-chloro-4-(3-fluorobenzyl)oxy]anilino]-6-quinazolinyl]furan-2-carboxaldehyde 4-methylbenzenesulfonate (prepn. given), diisopropylethylamine, and 2-(methylsulfonyl)ethylamine were stirred 1 h in THF/IPA; the preformed imine/THF soln. was transferred to a stirred suspension of NaBH(OAc)₃ in THF. After 90 min, aq. NaOH was added followed by sepn. of the aq. layer treatment of the org. layer with 4-MeC₆H₄SO₃H to give 88% N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furyl-4-quinazolinamine ditosylate. This inhibited EGFr and ErbB2 at <0.10 .mu.M.


IT 231278-84-5P 388082-75-5P 388082-76-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases)

RN 231278-84-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 388082-75-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 231278-84-5


CMF C26 H17 Cl F N3 O3



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 388082-76-6 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



IT 388082-80-2P 388082-82-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases)


RN 388082-80-2 CAPLUS

CN 4-Quinazolinamine, N-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 388082-79-9


CMF C29 H26 Br F N4 O4 S




CM 2

CRN 104-15-4
CMF C7 H8 O3 SRN 388082-82-4 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-,
bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 388082-81-3
CMF C28 H25 Cl F N5 O3 S2

CM 2

CRN 104-15-4
CMF C7 H8 O3 S

IT 388082-77-7P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(x-ray diffraction; prepn. of quinazoline ditosylate salts as
inhibitors of erbB protein tyrosine kinases)


RN 388082-77-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, bis(4-
methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 231277-92-2


CMF C29 H26 Cl F N4 O4 S



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



IT 388082-78-8P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(x-ray diffraction; prepn. of quinazoline ditosylate salts as
inhibitors of erbB protein tyrosine kinases)


RN 388082-78-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, bis(4-
methylbenzenesulfonate), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 231277-92-2


CMF C29 H26 Cl F N4 O4 S



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:31424 CAPLUS
DOCUMENT NUMBER: 136:102393
TITLE: Preparation of quinazolinylureas for treatment of solid tumors.
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Ltd.
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002534	A1	20020110	WO 2001-GB2874	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2002016758 A5 20020114 AU 2002-16758 20010628
PRIORITY APPLN. INFO.: EP 2000-401897 A 20000703
WO 2001-GB2874 W 20010628

OTHER SOURCE(S): MARPAT 136:102393

AB Use of Q1R2NC(:Z)NR3Q2 [Q1 = (substituted) (fused) quinazolinyl, quinolinyl, etc.; Q2 = (substituted) aryl, aralkyl, arylcycloalkyl, heteroaryl, heteroarylalkyl; R2, R3 = H, alkyl; R2R3 = CH2, CH2CH2, (CH2)3] as antiinvasive agents in the containment and/or treatment of solid **tumor** disease is claimed. Thus, 2,6-dichlorophenyl isocyanate was added to a soln. of 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (prepn. given) in CH2Cl2/DMF followed by stirring to give 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea. Title compds. inhibited proliferation of NIH 3T3 fibroblasts with IC50 in the range, for example, of 0.001-10 .mu.M.


IT 320366-53-8P 320366-54-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of quinazolinylureas for treatment of solid **tumors**)


RN 320366-53-8 CAPLUS

CN Quinazoline, 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 320366-54-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:668812 CAPLUS

DOCUMENT NUMBER: 138:280796

TITLE: Anti-**tumor** activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

AUTHOR(S): Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.

CORPORATE SOURCE: GlaxoSmithKline, Department of Discovery Medicine, Research Triangle Park, North Carolina, NC, 27709-3398, USA

SOURCE: Oncogene (2002), 21(41), 6255-6263

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial **tumors**, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent **tumor** cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in **cancer** patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human **tumor** xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent **tumors** by GW572016 may lead to **tumor** regressions when used as a monotherapy, or may enhance the anti-**tumor** activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.


IT 231277-92-2, GW 572016

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GW572016 **antitumor** activity: dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:620025 CAPLUS

DOCUMENT NUMBER: 138:180219

TITLE: Structure-activity relationships of 6-nitroquinazolines: dual-acting compounds with inhibitory activities toward both TNF-.alpha. production and T cell proliferation

AUTHOR(S): Tobe, Masanori; Isobe, Yoshiaki; Tomizawa, Hideyuki; Nagasaki, Takahiro; Obara, Fumihiro; Matsumoto, Mitsuhiro; Hayashi, Hideya

CORPORATE SOURCE: Pharmaceuticals & Biotechnology Laboratory, Japan Energy Corporation, Toda, 335-8502, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2002), 50(8), 1073-1080

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:180219

AB We synthesized various 6-nitroquinazolines by modifying the structure of compd. 1 and evaluated their inhibitory activities toward both TNF-.alpha. prodn. and T cell proliferation responses. The presence of the unsubstituted piperazine ring at the C(7)-position was required for both inhibitory activities. In this series of compds., 5d and 5f, contg. the 4-fluorophenyl and 3,4-difluorophenyl moiety, resp., at the C(4)-position, showed the suppressing effects toward both responses with low cell growth inhibition. Furthermore, the oral administration of these compds. mentioned above at doses of 30 and 100 mg/kg also resulted in significant inhibition of TNF-.alpha. prodn. induced by LPS in vivo.

IT 333400-69-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity relationships of nitroquinazolines as TNF-.alpha. prodn. and T cell proliferation inhibitors)

RN 333400-69-4 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-nitro-7-(1-piperazinyl)- (9CI)


(CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:904160 CAPLUS
DOCUMENT NUMBER: 136:20087
TITLE: Preparation of 4-anilinoquinazoline derivatives for the treatment of tumors
INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 234 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094341	A1	20011213	WO 2001-GB2424	20010601
WO 2001094341	C2	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1292594	A1	20030319	EP 2001-934176	20010601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011335	A	20030610	BR 2001-11335	20010601
BG 107332	A	20030731	BG 2002-107332	20021128
NO 2002005792	A	20021202	NO 2002-5792	20021202
PRIORITY APPLN. INFO.:			EP 2000-401581	A 20000606
			EP 2001-400297	A 20010207
			EP 2001-400565	A 20010305
			WO 2001-GB2424	W 20010601
OTHER SOURCE(S):	MARPAT 136:20087			
GI				



AB The invention concerns quinazoline derivs. (I; e.g. 4-(2-chloro-5-methoxyanilino)-7-methoxy-5-(3-morpholinopropoxy)quinazoline (1)), processes for their prepn., pharmaceutical compns. contg. them and their use in the manuf. of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid **tumor** disease. Although biol. assay methods are described, no test results are reported. It is believed that the **antitumor** activity is due to inhibition of one or more of the non-receptor tyrosine-specific protein kinases of the Src family that are involved in the signal transduction steps that lead to the invasiveness and migratory ability of metastasizing **tumor** cells. In I, according to the 1st claim, m = 0-3; each R1 = halo, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or Q3-X1- (X1 = direct bond, O, S, SO, SO2, N(R4), CO, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, OC(R4)2, SC(R4)2 and N(R4)C(R4)2 (R4 = H or (1-6C)alkyl) and Q3 = aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-, (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R1)m is (1-3C)alkylenedioxy, with addnl. optional substitution and/or insertion possible. R2 = H or (1-6C)alkyl; R3 = H or (1-6C)alkyl; Z = direct bond, O, S, SO, SO2, N(R11), CO, CH(OR11), CON(R11), N(R11)CO, SO2N(R11), N(R11)SO2, OC(R11)2, SC(R11)2 and N(R11)C(R11)2 (R11 = H, or (1-6C)alkyl). Q1 = aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or, when Z is a direct bond or O, Q1 may be (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, halo-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio-(1-6C)alkyl, (1-6C)alkylsulfinyl-(1-6C)alkyl or (1-6C)alkylsulfonyl-(1-6C)alkyl, with addnl. optional substitution and/or insertion possible. Q2 = substituted Ph. More than 50 example preps. are included. For example, 1 was obtained by adding di-tert-Bu azodicarboxylate (0.208 g) dropwise to a stirred mixt. of 4-(2-chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline (0.2 g), 4-(3-hydroxypropyl)morpholine, PPh3 (0.237 g) and CH2Cl2 (3 mL). The reaction mixt. was stirred at ambient temp. for 1 h.

IT **379230-49-6P**, 4-(2-Chloro-5-methoxyanilino)-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazoline trihydrochloride
379230-62-3P, 4-(2,3-Methylenedioxyanilino)-5-(4-methylpiperazin-1-


yl)-7-(2-pyrrolidin-1-ylethoxy)quinazoline trihydrochloride
379230-63-4P, 4-(6-Chloro-2,3-methylenedioxyanilino)-5-morpholino-
7-(2-pyrrolidin-1-ylethoxy)quinazoline 379231-47-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of anilinoquinazoline derivs. for treatment of tumors)

RN 379230-49-6 CAPLUS


CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-5-(4-methyl-1-piperazinyl)-
7-[2-(1-pyrrolidinyl)ethoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 379230-62-3 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-5-(4-methyl-1-piperazinyl)-7-[2-(1-pyrrolidinyl)ethoxy]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 379230-63-4 CAPLUS

CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-5-(4-morpholinyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 379231-47-7 CAPLUS
CN 4-Quinazolinamine, 7-[(2R,5R)-2,5-bis(methoxymethyl)-1-pyrrolidiny]-N-(2-bromo-5-methoxyphenyl)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:265402 CAPLUS
DOCUMENT NUMBER: 134:275758
TITLE: Preparation and effect of novel quinazoline derivatives as TNF-.alpha. inhibitors
INVENTOR(S): Tobe, Masanori; Isobe, Yoshiaki; Tomizawa, Hideyuki; Matsumoto, Mitsuhiro; Nagasaki, Takahiro; Obara, Fumihiro
PATENT ASSIGNEE(S): Japan Energy Corporation, Japan
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025218	A1	20010412	WO 2000-JP6666	20000927
W: AU, CA, JP, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				

PT, SE
AU 2000074465 A5 20010510 AU 2000-74465 20000927
AU 763033 B2 20030710
EP 1229025 A1 20020807 EP 2000-962890 20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
PRIORITY APPLN. INFO.: JP 1999-282078 A 19991001
WO 2000-JP6666 W 20000927
OTHER SOURCE(S): MARPAT 134:275758
GI




AB Title compds. [I; R1 is nitro or halo; R2 and R4 are each hydrogen, C1-4 alkyl, carboxyl, or C2-5 alkoxy carbonyl; R3 is hydrogen, amino, optionally substituted C1-4 alkyl, C1-4 alkanoyl, or C2-5 alkoxy carbonyl; W is carbon or nitrogen; Y = CH₂, CH₂CH₂, CH₂CH₂CH₂; Z = C₆H₅, 4-ClC₆H₄, 4-FC₆H₄, 3,4-OCH₂OC₆H₃, 2-thienyl, 2-furyl, 2-pyridinyl, 3-pyridinyl, 1-naphthyl; m is 0, 1, or 2] and pharmaceutically acceptable salts thereof are prepd. as TNF- α inhibitors. Thus, the title compd. I (R1 = NO₂; R2 = H; R3 = H; R4 = H; W = N; m = 1, Y = CH₂CH₂; Z = 4-ClC₆H₄) was prepd. and biol. tested.

IT 333400-32-1P 333400-61-6P 333400-68-3P
333400-69-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and effect of novel quinazoline derivs.)


RN 333400-32-1 CAPLUS

CN 4-Quinazolinamine, 6-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-61-6 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-fluoro-7-(1-piperazinyl)-
(9CI) (CA INDEX NAME)




RN 333400-68-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluorophenyl)-6-nitro-7-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



RN 333400-69-4 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-nitro-7-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



IT 333400-33-2P 333400-34-3P 333400-35-4P

333400-36-5P 333400-37-6P 333400-38-7P


333400-39-8P 333400-40-1P 333400-41-2P

333400-42-3P 333400-43-4P 333401-49-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and effect of novel quinazoline derivs.)

RN 333400-33-2 CAPLUS


CN 4-Quinazolinamine, N-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-6-nitro-7-
(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 333400-34-3 CAPLUS
CN 4-Piperidinamine, 1-benzoyl-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-
(9CI) (CA INDEX NAME)




RN 333400-35-4 CAPLUS
CN 4-Quinazolinamine, N-[1-(1,3-benzodioxol-5-yl)-4-piperidinyl]-6-nitro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 333400-36-5 CAPLUS

CN 4-Piperidinamine, N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 333400-37-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 333400-38-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 333400-39-8 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-methoxyphenyl)-4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 333400-40-1 CAPLUS

CN 1-Piperidinecarbothioamide, 4-[[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 333400-41-2 CAPLUS

CN 4-Piperidinamine, N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 333400-42-3 CAPLUS


CN 4-Piperidinamine, 1-[(4-methoxyphenyl)sulfonyl]-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 333400-43-4 CAPLUS
CN 4-Piperidinamine, 1-[(4-fluorophenyl)sulfonyl]-N-[6-nitro-7-(1-piperazinyl)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 333401-49-3 CAPLUS
CN 4-Quinazolinamine, 6-fluoro-N-(4-fluorophenyl)-7-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:50639 CAPLUS
DOCUMENT NUMBER: 134:100886
TITLE: Preparation of anilinoquinazolines as protein tyrosine kinase inhibitors
INVENTOR(S): Cockerill, George Stuart; Lackey, Karen Elizabeth
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001004111	A1	20010118	WO 2000-US18128	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192151	A1	20020403	EP 2000-943348	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003504363	T2	20030204	JP 2001-509721	20000630
PRIORITY APPLN. INFO.: GB 1999-16213 A 19990709 GB 1999-16218 A 19990709 WO 2000-US18128 W 20000630				

OTHER SOURCE(S): MARPAT 134:100886
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; X = CR1 and Y = N; or X = N and Y = CR1; X = CR1 and Y = CR2; X = CR2 and Y = CR1; R1 = Ar(CH2)pZCH2CH2SO2R5 (wherein Ar = (un)substituted Ph, furan, thiophene, etc.; Z = O, S, NH, NR6; p = 1-4; R5

= alkyl substituted by 5-10 membered heterocyclic group, 3-10 membered carbocyclic group, etc.; R6 = alkyl, alkoxyalkyl, hydroxyalkyl, etc.); R2 = H, halo, OH, etc.; R3 = pyridylmethoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy; R4 = H, halo, alkyl, etc.; with the proviso that when p = 1 and Z = NH, R5 cannot represent Me] which exhibit protein tyrosine kinase inhibition, in particular erbB family kinase inhibition, and useful in treating **cancer** and psoriasis, were prepd. E.g., a multi-step synthesis of the anilinoquinazoline II was given. Biol. data (erbB-2, erbB-4, EGFr, and cell proliferation inhibition) for the compds. I were presented.


IT 319917-32-3P 319917-33-4P 319917-34-5P
 319917-35-6P 319917-36-7P 319917-38-9P
 319917-39-0P 319917-40-3P 319917-41-4P
 319917-42-5P 319917-43-6P 319917-44-7P
 319917-45-8P 319917-46-9P 320337-09-5P
 320337-10-8P 320337-11-9P 320337-12-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)


RN 319917-32-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[3-[[2-(phenylsulfonyl)ethyl]amino]propyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-33-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-[(1-methyl-1H-imidazol-2-yl)sulfonyl]ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-34-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(phenylsulfonyl)ethoxy]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-35-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(phenylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-36-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(2-pyridinylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-38-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(propylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-39-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[5-[3-[[2-(methylsulfonyl)ethyl]amino]propyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-40-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[3-[[2-[(1-methylethyl)sulfonyl]ethyl]amino]propyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-41-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[3-[[2-(propylsulfonyl)ethyl]amino]propyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-42-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[2-[[2-(methylsulfonyl)ethyl]amino]ethyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 319917-43-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[2-[[2-(methylsulfonyl)ethyl]amino]ethyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-44-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethoxy]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-45-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(ethenylsulfonyl)ethoxy]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 319917-46-9 CAPLUS

CN Acetonitrile, [[[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl][2-(methylsulfonyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 320337-09-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl](phenylmethyl)amino]methyl]-2-furanyl]- (9CI)
(CA INDEX NAME)




RN 320337-10-8 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[ethyl[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 320337-11-9 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[2-(methylsulfonyl)ethyl]propylamino]methyl]-2-furanyl]- (9CI) (CA
INDEX NAME)



RN 320337-12-0 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[2-[(1-methylethyl)sulfonyl]ethyl]amino]methyl]-2-furanyl]- (9CI) (CA
INDEX NAME)




IT 231277-92-2 320337-47-1 320337-48-2
320337-50-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)


RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 320337-47-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-7-fluoro-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 320337-48-2 CAPLUS

CN 2-Furanmethanol, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 320337-50-6 CAPLUS

CN 2-Thiazoleacetic acid, 4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 202196-42-7P 202196-46-1P 202197-80-6P
 231278-28-7P 231278-33-4P 231278-36-7P
 231278-40-3P 231278-46-9P 231278-83-4P
 231278-84-5P 307327-30-6P 320337-25-5P
 320337-26-6P 320337-27-7P 320337-28-8P
 320337-29-9P 320337-30-2P 320337-31-3P
 320337-32-4P 320337-33-5P 320337-34-6P
 320337-35-7P 320337-36-8P 320337-37-9P
 320337-38-0P 320337-39-1P 320337-40-4P
 320337-41-5P 320337-42-6P 320337-43-7P
 320337-44-8P 320337-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)


RN 202196-42-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-80-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-28-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-33-4 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-36-7 CAPLUS


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-40-3 CAPLUS

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-46-9 CAPLUS
 CN 4-Quinazolinamine, 6-[5-[[2-(methylthio)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 231278-83-4 CAPLUS
 CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-84-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 307327-30-6 CAPLUS
CN 2-Thiazolecarboxaldehyde, 4-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 320337-25-5 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro- (9CI) (CA INDEX NAME)



RN 320337-26-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-7-fluoro-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 320337-27-7 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 320337-28-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-bromo-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 320337-29-9 CAPLUS

CN 4-Quinazolinamine, 6-[5-(2-nitroethenyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 320337-30-2 CAPLUS

CN 4-Quinazolinamine, 6-[5-(2-aminoethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 320337-31-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(2-nitroethenyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 320337-32-4 CAPLUS


CN 4-Quinazolinamine, 6-[5-(2-aminoethyl)-2-furanyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 320337-33-5 CAPLUS
CN 2-Thiazoleacetone, 4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 320337-34-6 CAPLUS
CN 4-Quinazolinamine, 6-[2-(2-aminoethyl)-4-thiazolyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 320337-35-7 CAPLUS

CN Acetamide, N-[2-[4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-thiazolyl]ethyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 320337-36-8 CAPLUS

CN Acetamide, N-[2-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]ethyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 320337-37-9 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]-2-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 320337-38-0 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazoliny]-2-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 320337-39-1 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 320337-40-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 320337-41-5 CAPLUS

CN 2-Propenamide, 3-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]-N-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 320337-42-6 CAPLUS

CN 2-Propenamide, 3-[5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 320337-43-7 CAPLUS

CN 2-Propenamide, 3-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]-N-[2-[(1-methylethyl)sulfonyl]ethyl]- (9CI)
(CA INDEX NAME)




RN 320337-44-8 CAPLUS

CN 2-Propenamide, 3-[5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furanyl]-N-[2-(propylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 320337-45-9 CAPLUS

CN 2-Furanmethanol, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-7-fluoro-6-quinazolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:743253 CAPLUS

DOCUMENT NUMBER: 136:79264

TITLE: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

AUTHOR(S): Rusnak, David W.; Affleck, Karen; Cockerill, Stuart G.; Stubberfield, Colin; Harris, Robert; Page, Martin; Smith, Kathryn J.; Guntrip, Stephen B.; Carter, Malcolm C.; Shaw, Robert J.; Jowett, Amanda; Stables,

Jeremy; Topley, Peter; Wood, Edgar R.; Brignola, Perry S.; Kadwell, Sue H.; Reep, Bryan R.; Mullin, Robert J.; Alligood, Krystal J.; Keith, Barry R.; Crosby, Renae M.; Murray, Doris M.; Knight, W. Blaine; Gilmer, Tona M.; Lackey, Karen

CORPORATE SOURCE: Department of Cancer Biology, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Cancer Research (2001), 61(19), 7196-7203
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The type 1 receptor tyrosine kinases constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been implicated in the initiation and progression of several types of human malignancies. The best characterized of these proteins are the epidermal growth factor receptor (EGFR) and ErbB-2 (HER-2/neu). We have developed potent quinazoline and pyrido-[3,4-d]-pyrimidine small mols. that are dual inhibitors of ErbB-2 and EGFR. The compds. demonstrate potent in vitro inhibition of the ErbB-2 and EGFR kinase domains with IC50s <80 nM. Growth of ErbB-2- and EGFR-expressing **tumor** cell lines is inhibited at concns. <0.5 .mu.M. Selectivity for **tumor** cell growth inhibition vs. normal human fibroblast growth inhibition ranges from 10- to >75-fold. **Tumor** growth in mouse s.c. xenograft models of the BT474 and HN5 cell lines is inhibited in a dose-responsive manner using oral doses of 10 and 30 mg/kg twice per day. In addn., the tested compds. caused a redn. of ErbB-2 and EGFR autophosphorylation in **tumor** fragments from these xenograft models. These data indicate that these compds. have potential use as therapy in the broad population of **cancer** patients overexpressing ErbB-2 and/or EGFR.

IT 202196-59-6, GW 5289 386744-56-5, GW 9525
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors and potential therapy for **cancer**)


RN 202196-59-6 CAPLUS

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 386744-56-5 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2000:573671 CAPLUS
 DOCUMENT NUMBER: 133:177183
 TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren
 PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.
 SOURCE: PCT Int. Appl., 346 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1154774	A1	20011121	EP 2000-902730	20000208
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
BR 2000008128	A	20020213	BR 2000-8128	20000208
JP 2002536414	T2	20021029	JP 2000-598164	20000208
EE 200100409	A	20021216	EE 2001-409	20000208
AU 763618	B2	20030731	AU 2000-24475	20000208
ZA 2001006340	A	20021101	ZA 2001-6340	20010801
NO 2001003882	A	20011009	NO 2001-3882	20010809
PRIORITY APPLN. INFO.:			EP 1999-400305	A 19990210
			WO 2000-GB373	W 20000208
OTHER SOURCE(S):		MARPAT 133:177183		
GI				



I



II


AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally contg. 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH₂, or a bond; n = 0-5; m = 0-3; R₂ = H, OH, halo, CN, NO₂, CF₃, alkyl(sulfanyl), alkoxy, NR₃N₄, or R₅X₁; R₃ and R₄ = independently H or alkyl; X₁ = a bond, O, CH₂, OC(O), CO, S, SO, SO₂, NR₆CO, CONR₇, SO₂R₈, NR₉SO₂, or NR₁₀; R₅ = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R₆-R₁₀ = independently H or (alkoxy)alkyl] were prepd. for use in the prodn. of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a no. of disease states including **cancer** and rheumatoid arthritis (no data).

IT **288384-10-1P**, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (angiogenesis inhibitor; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288384-10-1 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:854415 CAPLUS
DOCUMENT NUMBER: 133:362769
TITLE: Preparation of 6-(thiomorpholinomethylfuran-2-yl)-4-quinazolinamines as protein tyrosine kinase inhibitors
INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: Brit. UK Pat. Appl., 151 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2345486	A1	20000712	GB 1999-29973	19991217
PRIORITY APPLN. INFO.:			GB 1999-518	A 19990111
			GB 1999-15510	A 19990703
OTHER SOURCE(S):		MARPAT 133:362769		
GI				




II


AB The title compds. (I) [wherein X = N or CH; V and Y = independently CR1, CR2, or N; and V .noteq. Y; R1 = Q(CH2)qAr; m = 1 or 2; p = 1 or 2; q = 1-4; Ar = (un)substituted Ph, furanyl, thiophenyl, pyrrolyl, or thiazolyl; R2 = H, halo, OH, alkyl(amino) alkoxy, or dialkylamino; U = (un)substituted Ph, pyridyl, (benz)imidazolyl, (iso)indolyl, (iso)indolinyl, indazolyl, or benzotriazolyl] were prep'd. as protein tyrosine kinase inhibitors for the treatment of **cancer** and other disorders mediated by aberrant protein tyrosine kinase activity. For example, II.bul.2HCl was formed in a multi-step sequence involving (1) reaction of 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan with (4-benzyloxyphenyl)(6-bromoquinazolin-4-yl)amine using Pd(PPh3)2Cl2 in dioxane, (2) conversion of the cyclic acetal to the aldehyde with HCl in THF, (3) addn. of thiomorpholine-S-oxide in CH2Cl2 and conversion to the HCl salt. I inhibited EGFR and c-erbB-2 tyrosine kinase with IC50 < 0.10 .mu.M and suppressed cell proliferation against a range of **tumor** cell lines.

IT **307327-34-0P**, (1-Benzyl-1H-indazol-5-yl)(6-(5-(thiazolidin-3-ylmethyl)furan-2-yl)quinazolin-4-yl)amine **307328-02-5P**, (4-Benzyloxyphenyl)-[6-[5-(1-oxothiomorpholin-4-ylmethyl)furan-2-yl]quinazolin-4-yl]amine dihydrochloride
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine **anticancer** agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))

RN **307327-34-0** CAPLUS
 CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(3-thiazolidinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307328-02-5 CAPLUS
 CN 4-Quinazolinamine, 6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 307328-15-0P, (4-Benzyloxyphenyl)-[6-{2-[(1-oxothiomorpholin-4-yl)methyl]thiazol-4-yl}quinazolin-4-yl]amine dihydrochloride
 307328-18-3P 307328-20-7P, (4-Benzyloxyphenyl)-[6-[5-((1,1-dioxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine dihydrochloride 307328-24-1P, (4-Benzyloxy-3-fluorophenyl)-[6-(5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl)quinazolin-4-yl]amine
 307328-27-4P, [4-((3-Fluorobenzyl)oxy)-3-(trifluoromethyl)phenyl]-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
 307328-31-0P, (4-((3-Fluorobenzyl)oxy)-3-chlorophenyl)-[6-(5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl)quinazolin-4-yl]amine
 307328-34-3P, 1-(3-Fluorobenzyl-1H-indazol-5-yl)[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
 307328-38-7P, (4-Benzyloxy-3-chlorophenyl)-[6-[5-((1-oxothiomorpholin-4-yl)methyl)furan-2-yl]quinazolin-4-yl]amine
 307328-41-2P, (4-(3-Fluorobenzyl)oxy)-3-chlorophenyl)-[6-(5-(thiazolidin-3-yl)methyl)furan-2-yl]quinazolin-4-yl]amine dihydrochloride
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of thiomorpholinomethylfuran-yl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocycl-yl)furan-carboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))
 RN 307328-15-0 CAPLUS

CN 4-Quinazolinamine, 6-[2-[(1-oxido-4-thiomorpholinyl)methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 307328-18-3 CAPLUS
CN 4-Quinazolinamine, 6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 307328-20-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 307328-24-1 CAPLUS
CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307328-27-4 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-(trifluoromethyl)phenyl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307328-31-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307328-34-3 CAPLUS

CN 4-Quinazolinamine, N-[3-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307328-38-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[5-[(1-oxido-4-thiomorpholinyl)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 307328-41-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(3-thiazolidinylmethyl)-2-furanyl]-, dihydrochloride (9CI) (CA INDEX NAME)



IT 202196-54-1, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-carbaldehyde 231278-82-3 231278-83-4, [5-[4-[4-(Benzyloxy)-3-chloroanilino]-6-quinazolinyl]-2-


furancarboxaldehyde **231278-84-5**, [5-[4-[4-[(3-Fluorobenzyl)oxy]-3-chloroanilino]-6-quinazolinyl]-2-furancarboxaldehyde **307328-29-6**, [5-[4-[4-[(3-Fluorobenzyl)oxy]-3-(trifluoromethyl)anilino]-6-quinazolinyl]-2-furancarboxaldehyde **307328-36-5**, [[5-(4-[[1-(3-Fluorobenzyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furancarboxaldehyde

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine **anticancer** agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))


RN 202196-54-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-82-3 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-83-4 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-84-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 307328-29-6 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]-3-(trifluoromethyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 307328-36-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 202196-42-7P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 202196-46-1P, 5-[4-(4-Benzyloxyphenylamino)quinazolin-6-yl]furan-2-carbaldehyde 202196-53-0P, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 202197-01-1P 202197-80-6P, 5-[4-(4-Benzyloxyphenylamino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride 202197-83-9P, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride 202198-15-0P, (1-Benzyl-1H-indazol-5-yl)-[7-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine hydrochloride 231278-28-7P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-fluoroquinazolin-4-yl]amine 231278-29-8P, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-fluoroquinazolin-4-yl]amine 231278-30-1P 231278-31-2P, (4-Benzyloxy-3-trifluoromethylphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine 231278-32-3P, 5-[4-(4-Benzyloxy-3-trifluoromethylphenylamino)quinazolin-6-yl]furan-2-carbaldehyde 231278-33-4P, (4-Benzyloxyphenyl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl]amine 231278-34-5P, 4-[4-(4-Phenoxyphenylamino)quinolin-7-yl]thiazole-2-carbaldehyde 231278-36-7P, 5-[4-(4-Benzyloxyphenylamino)-7-methoxyquinazolin-6-yl]furan-2-carbaldehyde hydrochloride 231278-37-8P,

[6-[5-(1,3-Dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl](4-(benzenesulphonyl)phenyl)amine **231278-38-9P**,
5-[4-(4-Phenoxyphenylamino)quinolin-7-yl]furan-2-carbaldehyde **231278-39-0P**, 5-[7-Methoxy-4-((4-(benzenesulphonyl)phenyl)amino)quinazolin-6-yl]furan-2-carbaldehyde hydrochloride **231278-40-3P**,
5-[4-(4-Benzylloxyphenylamino)-7-fluoroquinazolin-6-yl]furan-2-carboxaldehyde hydrochloride **231278-41-4P**, 5-[4-(1-Benzyl-1H-indazol-5-ylamino)-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde hydrochloride **231278-42-5P** **231278-43-6P**,
(4-Phenoxyphenyl)-[7-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinolin-4-yl]amine **231278-44-7P**, (1-Benzyl-1H-indazol-5-yl)-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl]amine **231278-45-8P**
231278-46-9P **307327-30-6P**, 4-[4-[(4-Benzylloxyphenyl)amino]quinazolin-6-yl]thiazole-2-carbaldehyde **307327-37-3P**, (1-Benzyl-1H-indazol-5-yl)(6-(5-(thiomorpholin-4-ylmethyl)furan-2-yl)quinazolin-4-yl)amine **307327-40-8P**,
(4-Benzylloxyphenyl)(6-(5-(thiomorpholin-4-ylmethyl)furan-2-yl)quinazolin-4-yl)amine hydrochloride **307327-44-2P**, [4-(Benzenesulphonyl)phenyl]-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]quinazolin-4-yl]amine **307327-47-5P**, 5-[4-[(4-(Benzenesulphonyl)phenyl)amino]quinazolin-6-yl]furan-2-carbaldehyde **307327-53-3P**
307327-82-8P, [1-N-(3-Pyridylmethyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-85-1P**, [4-(3-Fluorobenzylloxy)phenyl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-87-3P**,
(1-Benzyl-1H-indazol-5-yl)-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-89-5P**, [1-N-(2-Pyridylmethyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-91-9P**, [1-(2,6-Difluorobenzyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-93-1P**, [4-(3,4-Difluorobenzylloxy)phenyl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-95-3P**, [1-(2,3-Difluorobenzyl)-1H-indazol-5-yl]-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine **307327-97-5P**, (4-Phenoxyphenyl)-[6-[(5-thiomorpholin-4-ylmethyl)furan-2-yl]quinolin-4-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine **anticancer** agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))


RN 202196-42-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-01-1 CAPLUS

CN 1H-Pyrrole-2-carboxaldehyde, 1-methyl-5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-80-6 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-83-9 CAPLUS
 CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-15-0 CAPLUS
 CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 231278-28-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-29-8 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231278-30-1 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-31-2 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-32-3 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-33-4 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-34-5 CAPLUS

CN 2-Thiazolecarboxaldehyde, 4-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]-
(9CI) (CA INDEX NAME)



RN 231278-36-7 CAPLUS


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-37-8 CAPLUS


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-38-9 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]- (9CI)
(CA INDEX NAME)




RN 231278-39-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-40-3 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-41-4 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-42-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-43-6 CAPLUS
CN 4-Quinolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231278-44-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 231278-45-8 CAPLUS


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-46-9 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylthio)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 307327-30-6 CAPLUS

CN 2-Thiazolecarboxaldehyde, 4-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 307327-37-3 CAPLUS

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 307327-40-8 CAPLUS


CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 307327-44-2 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 307327-47-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 307327-53-3 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylsulfonyl)phenyl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 307327-82-8 CAPLUS
CN 4-Quinolinamine, N-[1-(3-pyridinylmethyl)-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-85-1 CAPLUS
CN 4-Quinolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 307327-87-3 CAPLUS
CN 4-Quinolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-89-5 CAPLUS
CN 4-Quinolinamine, N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-91-9 CAPLUS
CN 4-Quinolinamine, N-[1-[(2,6-difluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-93-1 CAPLUS

CN 4-Quinolinamine, N-[4-[(3,4-difluorophenyl)methoxy]phenyl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-95-3 CAPLUS

CN 4-Quinolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 307327-97-5 CAPLUS
CN 4-Quinolinamine, N-(4-phenoxyphenyl)-6-[5-(4-thiomorpholinylmethyl)-2-furanyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:592396 CAPLUS
DOCUMENT NUMBER: 133:193157
TITLE: Preparation of aminoquinazolines and related compounds as **anticancer** drugs.
INVENTOR(S): Kath, John Charles; Tom, Norma Jacqueline; Cox, Eric David; Bhattacharya, Samit Kumar
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1029853	A1	20000823	EP 1999-310574	19991224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000309577	A2	20001107	JP 1999-336570	19991126
JP 3270834	B2	20020402		
CA 2290918	AA	20000727	CA 2000-2290918	19991129
BR 9906013	A	20000905	BR 1999-6013	19991229
US 6465449	B1	20021015	US 2000-488378	20000120
US 2003055049	A1	20030320	US 2002-226255	20020822
PRIORITY APPLN. INFO.:			US 1999-117341P	P 19990127
			US 2000-488378	A3 20000120
OTHER SOURCE(S):	MARPAT 133:193157			
GI				



AB Title compds. [I; X = N, CH; A = (substituted) fused 5-7 membered ring optionally contg. 1-4 heteroatoms selected from NR1, O, S, SO, SO2 contg. 1-3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused etc.; R1 = H, alkyl; R3 = (CR1R2)mR8; m = 0, 1; R1R3N = (substituted) 1-indolinyl, 1-indolyl; R4, R8 = (substituted) aryl(alkyl), heterocyclyl(alkyl)], were prepd. as **neoplasm** inhibitors (no data). Thus, 3-[4-(4-phenoxy-quinazolin-6-yl)benzyl]-3-azabicyclo[3.1.0]hex-6-ylmethanol (prepn. given), 1-cyclopropylmethyl-1H-indol-5-ylamine, pyridinium hydrochloride, and phenol were heated at 110.degree. overnight to give 67% [3-[4-[4-(1-cyclopropylmethyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-3-azabicyclo[3.1.0]hex-6-yl]methanol.


IT 289037-01-0P 289037-43-0P 289037-44-1P
289037-45-2P 289037-46-3P 289037-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoquinazolines and related compds. as **anticancer** drugs)


RN 289037-01-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(phenylmethyl)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI)
(CA INDEX NAME)




RN 289037-43-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[(4-phenoxyphenyl)amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-44-1 CAPLUS

CN 1H-Indol-5-amine, N-[6-[6-[[6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]methyl]-3-pyridinyl]-4-quinazolinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 289037-45-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-46-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 289037-47-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:451297 CAPLUS

DOCUMENT NUMBER: 131:102288

TITLE: Bicyclic heteroaromatic compounds [quinazolinamines, pyridopyrimidines, and analogs] useful as protein tyrosine kinase inhibitors

INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935146	A1	19990715	WO 1999-EP48	19990108
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2317589	AA	19990715	CA 1999-2317589	19990108
AU 9922783	A1	19990726	AU 1999-22783	19990108
AU 749549	B2	20020627		
BR 9906904	A	20001017	BR 1999-6904	19990108
EP 1047694	A1	20001102	EP 1999-902522	19990108
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EE 200000411	A	20011217	EE 2000-411	19990108
JP 2002500225	T2	20020108	JP 2000-527545	19990108

JP 3390741	B2	20030331		
JP 2002326990	A2	20021115	JP 2002-92102	19990108
NZ 505456	A	20030630	NZ 1999-505456	19990108
ZA 9900172	A	20000711	ZA 1999-172	19990111
TW 477788	B	20020301	TW 1999-88100388	19990112
NO 2000003561	A	20000911	NO 2000-3561	20000711
HR 2000000469	A1	20010630	HR 2000-469	20000712
BG 104668	A	20010430	BG 2000-104668	20000807
US 2002147205	A1	20021010	US 2002-71358	20020208
US 2003176451	A1	20030918	US 2003-342810	20030115
PRIORITY APPLN. INFO.:			GB 1998-569	A 19980112
			JP 2000-527545	A3 19990108
			WO 1999-EP48	W 19990108
			US 2000-582746	A1 20000630
OTHER SOURCE(S):			MARPAT 131:102288	
GI				



AB Title compds. I and their salts and solvates are disclosed [wherein X = N or CH; Y = CR1 and V = N; or Y = N and V = CR1; or Y = CR1 and V = CR2; or Y = CR2 and V = CR1; R1 = MeSO₂CH₂CH₂NHCH₂-Ar-, wherein Ar = (un)substituted Ph, furan, thiophene, pyrrole, or thiazole; R2 = H, halo, OH, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, or di[C1-4 alkyl]amino; U = Ph, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by R3 and optionally by R4; R3 = (halo)benzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and (halo)benzyloxy, PhSO₂, (trihalomethyl)benzyl, (trihalomethyl)benzyloxy, (R5)n-substituted phthalimido; R4 = OH, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, (di)(alkyl)amino, C1-4 alkylthio, etc.; R5 = halo, C1-4 alkyl, C1-4 alkoxy; n = 0-3]. Also disclosed are methods for their prepn., pharmaceutical compns. contg. them, and their use in medicine. The compds. are inhibitors of protein tyrosine kinases, and as such are useful in the treatment of **cancer**, psoriasis, and rheumatoid arthritis. Over 40 title compds. and numerous intermediates were prepd. For example, 4,6-dichloropyrido[3,4-d]pyrimidine was condensed with 4-[(4-fluorobenzyl)oxy]aniline at the 4-chloro position, followed by Pd-catalyzed coupling with 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan at the 6-chloro position, hydrolysis of the dioxolane protecting group to give an aldehyde, reductive amination of the latter with MeSCH₂CH₂NH₂, and

finally S-oxidn. with Oxone .RTM. and acidification, to give title salt II.2HCl. In a methylene blue growth inhibition assay against 5 tumor cell lines, II.2HCl had an IC50 of < 5 .mu.M against 4 of them, and an IC50 of 25-50 .mu.M against the 5th.


IT 202196-42-7P 202196-46-1P 202196-53-0P
202197-19-1P 202197-80-6P 202197-83-9P
202198-15-0P 231278-28-7P 231278-29-8P
231278-30-1P 231278-31-2P 231278-32-3P
231278-33-4P 231278-34-5P 231278-35-6P
231278-36-7P 231278-37-8P 231278-38-9P
231278-39-0P 231278-40-3P 231278-41-4P
231278-42-5P 231278-43-6P 231278-44-7P
231278-45-8P 231278-46-9P 231278-62-9P
231278-63-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 202196-42-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 CAPLUS


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202197-19-1 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-80-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-83-9 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-15-0 CAPLUS
 CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-28-7 CAPLUS
 CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-29-8 CAPLUS

CN . 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231278-30-1 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-31-2 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-32-3 CAPLUS


CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-33-4 CAPLUS
 CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-34-5 CAPLUS
 CN 2-Thiazolecarboxaldehyde, 4-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]- (9CI) (CA INDEX NAME)




RN 231278-35-6 CAPLUS
 CN 4-Thiazolecarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 231278-36-7 CAPLUS


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-37-8 CAPLUS


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-38-9 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]- (9CI)
(CA INDEX NAME)




RN 231278-39-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-40-3 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 231278-41-4 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-42-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-43-6 CAPLUS

CN 4-Quinolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-(4-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 231278-44-7 CAPLUS


CN 4-Quinolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 231278-45-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[1-(phenylmethyl)-1H-indazol-5-yl]-2-furanyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)


yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-46-9 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylthio)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 231278-62-9 CAPLUS

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-63-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME).




IT 231278-85-6 231278-86-7
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(metabolite; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 231278-85-6 CAPLUS
CN 4-Quinazolinamine, 6-[5-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-86-7 CAPLUS
CN 4-Quinazolinamine, 6-[4-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 231278-71-0 231278-72-1 231278-73-2
231278-75-4 231278-76-5 231278-77-6
231278-78-7 231278-80-1 231278-82-3
231278-83-4 231278-84-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of quinazolinamines and analogs as protein
tyrosine kinase inhibitors)


RN 231278-71-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-
quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 231278-72-1 CAPLUS


CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]-3-
methoxyphenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-73-2 CAPLUS
 CN 3-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]- (9CI) (CA INDEX NAME)




RN 231278-75-4 CAPLUS
 CN 2-Furancarboxaldehyde, 5-[4-[[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]amino]-6-quinazoliny]- (9CI) (CA INDEX NAME)



RN 231278-76-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-77-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-bromophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-78-7 CAPLUS

CN 3-Furancarboxaldehyde, 2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-80-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231278-82-3 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-83-4 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-84-5 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 231277-68-2P 231278-05-0P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(target compd., metab.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 231277-68-2 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 231278-05-0 CAPLUS

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 231277-70-6P 231277-71-7P 231277-72-8P
 231277-73-9P 231277-74-0P 231277-75-1P
 231277-76-2P 231277-77-3P 231277-78-4P
 231277-79-5P 231277-80-8P 231277-81-9P
 231277-82-0P 231277-83-1P 231277-84-2P
 231277-85-3P 231277-86-4P 231277-87-5P
 231277-88-6P 231277-89-7P 231277-90-0P
 231277-91-1P 231277-92-2P 231277-93-3P
 231277-94-4P 231277-95-5P 231277-96-6P
 231277-97-7P 231277-98-8P 231277-99-9P
 231278-00-5P 231278-07-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 231277-70-6 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-71-7 CAPLUS

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

● 2 HCl

RN 231277-72-8 CAPLUS
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-73-9 CAPLUS
 CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 231277-74-0 CAPLUS
 CN 4-Quinazolinamine, 6-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-75-1 CAPLUS
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231277-76-2 CAPLUS
 CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-77-3 CAPLUS
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-78-4 CAPLUS

CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-79-5 CAPLUS

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-80-8 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 231277-81-9 CAPLUS
CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-82-0 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 231277-83-1 CAPLUS


CN 4-Quinazolinamine, 6-[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-84-2 CAPLUS

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 231277-85-3 CAPLUS
 CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-86-4 CAPLUS
 CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-87-5 CAPLUS
 CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 231277-88-6 CAPLUS
 CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-89-7 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-90-0 CAPLUS

CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-91-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-93-3 CAPLUS

CN 4-Quinolinamine, 7-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-94-4 CAPLUS

CN 4-Quinolinamine, 7-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-5-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-95-5 CAPLUS

CN 4-Quinolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-96-6 CAPLUS

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-97-7 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-98-8 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-99-9 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-00-5 CAPLUS

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-07-2 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

Searched by Barb O'Bryen, STIC 308-4291


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:48710 CAPLUS
DOCUMENT NUMBER: 130:125085
TITLE: Preparation of quinazoline analogs and related compounds for treating inflammatory conditions
INVENTOR(S): Palanki, Moorthy S. S.; Suto, Mark J.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901441	A1	19990114	WO 1998-US13483	19980629
W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5939421	A	19990817	US 1997-886198	19970701
AU 9881754	A1	19990125	AU 1998-81754	19980629
US 6150372	A	20001121	US 1999-340557	19990628
PRIORITY APPLN. INFO.:			US 1997-886198 A	19970701
			WO 1998-US13483 W	19980629
OTHER SOURCE(S):		MARPAT 130:125085		
GI				




I




II



III



IV



V

AB The title compds. [I; R10 = II-IV; A = CR7, N; R1, R3 = H, (un)substituted


C1-8 alkyl, C6-12 aryl; R2 = (un)substituted C1-8 alkyl, C6-12 aryl, etc.; R4 = H, C1-8 alkyl; R5-R8 = H, NO2, CN, etc.; R11 = H, (un)substituted C1-8 alkyl, C6-12 aryl; R12 = H, CO2R9, CONHR9; R9 = H, (un)substituted C1-8 alkyl, C6-12 aryl, etc.), having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory (such as rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, and asthma) and autoimmune diseases (such as multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, uveitis, and chronic hepatitis), and trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, **cancer** and viral infection, were prepd. Thus, reaction of 4-chloro-2-(2'-thienyl)quinazoline (prepn. given) with hydrazine in THF followed by treatment of the resulting intermediate with citraconic anhydride in chloroform afforded 98% V which showed IC50 of 0.07 .mu.M against AP-1 and IC50 of 0.04 .mu.M against NF.kappa.B.

IT 219774-04-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazoline analogs and related compds. for treating inflammatory conditions)

RN 219774-04-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(1-piperidinyl)-2-(trifluoromethyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:71133 CAPLUS

DOCUMENT NUMBER: 128:140716

TITLE: Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors.

INVENTOR(S): Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane

PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9802434 A1 19980122 WO 1997-EP3672 19970711
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
 ZA 9706147 A 19990111 ZA 1997-6147 19970710
 AU 9737668 A1 19980209 AU 1997-37668 19970711
 EP 912559 A1 19990506 EP 1997-934458 19970711
 EP 912559 B1 20021106
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
 JP 2000514806 T2 20001107 JP 1998-505596 19970711
 AT 227283 E 20021115 AT 1997-934458 19970711
 ES 2186908 T3 20030516 ES 1997-934458 19970711
 US 6391874 B1 20020521 US 1998-214267 19981231
 US 2002147214 A1 20021010 US 2002-62647 20020131
 PRIORITY APPLN. INFO.: GB 1996-14755 A 19960713
 GB 1996-25458 A 19961207
 WO 1997-EP3672 W 19970711
 US 1998-214267 A1 19981231
 OTHER SOURCE(S): MARPAT 128:140716
 GI



AB Title compds. [I; U = substituted Ph, mono- or bicyclic 5-10 membered (hetero)cyclyl; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)_m, NR_a; R_a = H, alkyl; m = 0-2; R₁ = (substituted) Ph, 5- or 6-membered heterocyclyl contg. 1-4 heteroatoms selected from N, O, S(O)_m; with the provision that the ring does not contain two adjacent O or S(O)_m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring; R₃ = H, amino, halo, OH, NO₂, CO₂H, CHO, cyano, CF₃, OCF₃, carbamoyl, alkoxycarbonyl, Ph, PhO, pyridonyl, pyrrolidinyl, imidazolyl, dioxolanyl, arylsulfonyl, alkylsulfonyl, alkylcarbamoylalkyl, piperidinoalkoxy, thiomorpholino, etc.; 2 adjacent R₃ = methylenedioxy, ethylenedioxy; p = 0-3], were prepd. Thus, (S)-1-[5-[4-(1-benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-ylmethyl]pyrrolidine-2-carboxylic acid amide dihydrochloride (prepn. given) inhibited BT474 human breast **cancer** cell proliferation with IC₅₀ = 2 nM.


IT 202196-33-6P 202196-36-9P 202196-38-1P
 202196-41-6P 202196-42-7P 202196-43-8P
 202196-44-9P 202196-45-0P 202196-46-1P
 202196-47-2P 202196-48-3P 202196-49-4P
 202196-50-7P 202196-51-8P 202196-52-9P
 202196-53-0P 202196-54-1P 202196-55-2P
 202196-56-3P 202196-57-4P 202196-58-5P
 202196-59-6P 202196-60-9P 202196-61-0P
 202196-62-1P 202196-63-2P 202196-64-3P
 202196-65-4P 202196-66-5P 202196-67-6P

202196-68-7P 202196-69-8P 202196-70-1P
202196-71-2P 202196-72-3P 202196-73-4P
202196-74-5P 202196-75-6P 202196-76-7P
202196-77-8P 202196-78-9P 202196-79-0P
202196-80-3P 202196-81-4P 202196-82-5P
202196-83-6P 202196-84-7P 202196-85-8P
202196-86-9P 202196-87-0P 202196-88-1P
202196-89-2P 202196-90-5P 202196-91-6P
202196-92-7P 202196-93-8P 202196-94-9P
202196-95-0P 202196-96-1P 202196-97-2P
202196-98-3P 202196-99-4P 202197-00-0P
202197-01-1P 202197-02-2P 202197-03-3P
202197-04-4P 202197-05-5P 202197-06-6P
202197-07-7P 202197-08-8P 202197-09-9P
202197-10-2P 202197-11-3P 202197-12-4P
202197-13-5P 202197-14-6P 202197-15-7P
202197-16-8P 202197-17-9P 202197-18-0P
202197-19-1P 202197-20-4P 202197-21-5P
202197-22-6P 202197-23-7P 202197-24-8P
202197-80-6P 202197-81-7P 202197-82-8P
202197-83-9P 202197-84-0P 202197-85-1P
202197-86-2P 202197-87-3P 202197-88-4P
202197-89-5P 202197-90-8P 202197-91-9P
202197-92-0P 202197-93-1P 202197-94-2P
202197-95-3P 202197-96-4P 202197-97-5P
202197-98-6P 202197-99-7P 202198-00-3P
202198-01-4P 202198-02-5P 202198-03-6P
202198-04-7P 202198-05-8P 202198-06-9P
202198-07-0P 202198-08-1P 202198-09-2P
202198-10-5P 202198-11-6P 202198-12-7P
202198-13-8P 202198-14-9P 202198-15-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)


RN 202196-33-6 CAPLUS
CN 4-Quinazolinamine, 6-(2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-36-9 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 202196-38-1 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 202196-41-6 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 202196-42-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-43-8 CAPLUS

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-44-9 CAPLUS

CN 4-Quinazolinamine, 6-(4,5-dihydro-2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-45-0 CAPLUS

CN 4-Quinazolinamine, 6-(1-methyl-1H-1,2,3-triazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-47-2 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[4-(4-methyl-1-piperazinyl)methyl]-2-furyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-48-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202196-49-4 CAPLUS
 CN 1,2-Propanediamine, N1,N1-dimethyl-N2-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)



RN 202196-50-7 CAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 202196-51-8 CAPLUS
 CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[(3-pyridinylamino)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-52-9 CAPLUS

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-54-1 CAPLUS


CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-55-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-56-3 CAPLUS

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-57-4 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 202196-58-5 CAPLUS

CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-59-6 CAPLUS

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-60-9 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-61-0 CAPLUS

CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-62-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-63-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-64-3 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-65-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-66-5 CAPLUS

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-67-6 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-68-7 CAPLUS

CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-69-8 CAPLUS

CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-70-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-71-2 CAPLUS

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-72-3 CAPLUS


CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 202196-73-4 CAPLUS
CN 4-Quinazolinamine, N-[1-(phenylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-74-5 CAPLUS
CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-75-6 CAPLUS

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-76-7 CAPLUS

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-77-8 CAPLUS

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 202196-78-9 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-79-0 CAPLUS


CN 4-Quinazolinamine, 6-(5-methyl-1H-1,2,4-triazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-80-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-1H-imidazol-5-yl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-81-4 CAPLUS

CN 4-Quinazolinamine, 6-[5-[(methanesulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-82-5 CAPLUS


CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 202196-83-6 CAPLUS

CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-84-7 CAPLUS

CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)




RN 202196-85-8 CAPLUS

CN 4-Quinazolinamine, 6-[5-[[methyl[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-86-9 CAPLUS


CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 202196-87-0 CAPLUS
CN Ethanesulfonamide, 2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 202196-88-1 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-, methyl ester (9CI) (CA INDEX NAME)




RN 202196-89-2 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-, (9CI) (CA INDEX NAME)




RN 202196-90-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(methoxycarbonyl)phenyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-91-6 CAPLUS

CN Ethanesulfonamide, N-methyl-2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 202196-92-7 CAPLUS


CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-93-8 CAPLUS
CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-94-9 CAPLUS
CN 4-Quinazolinamine, 6-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-95-0 CAPLUS
CN 4-Quinazolinamine, 6-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-96-1 CAPLUS
 CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-97-2 CAPLUS
 CN 4-Quinazolinamine, 6-[5-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-98-3 CAPLUS
 CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-99-4 CAPLUS

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 202197-00-0 CAPLUS

CN 4-Quinazolinamine, 6-(1-methyl-1H-pyrrol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-01-1 CAPLUS

CN 1H-Pyrrole-2-carboxaldehyde, 1-methyl-5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-02-2 CAPLUS

CN 4-Piperidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-03-3 CAPLUS

CN 2-Pyrrolidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-04-4 CAPLUS


CN 2,4-Imidazolidinedione, 3-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-05-5 CAPLUS
CN 1,2,4-Oxadiazol-5(2H)-one, 3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-06-6 CAPLUS
CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-07-7 CAPLUS
CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-08-8 CAPLUS

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-09-9 CAPLUS

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-10-2 CAPLUS


CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-11-3 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-12-4 CAPLUS
CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-13-5 CAPLUS
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-14-6 CAPLUS
CN 4-Quinazolinamine, N-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 202197-15-7 CAPLUS
CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-16-8 CAPLUS
CN 4-Quinazolinamine, 7-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-17-9 CAPLUS

CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 202197-18-0 CAPLUS

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-
1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-
quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-20-4 CAPLUS


CN 4-Quinazolinamine, 7-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202197-21-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202197-22-6 CAPLUS

CN 4-Quinazolinamine, 6-(3-methyl-4-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-23-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-1-methyl-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-24-8 CAPLUS

CN 1H-Imidazole-5-carboxaldehyde, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-80-6 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-81-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 202197-82-8 CAPLUS


CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-83-9 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazoliny]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-84-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazoliny]-2-furanyl]methyl]-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 202197-85-1 CAPLUS


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 202197-86-2 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-87-3 CAPLUS
CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-88-4 CAPLUS
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-89-5 CAPLUS


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-90-8 CAPLUS


CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-91-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-92-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-93-1 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-94-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-95-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-96-4 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-97-5 CAPLUS

CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-98-6 CAPLUS
CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 202197-99-7 CAPLUS
CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-00-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-01-4 CAPLUS
CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-02-5 CAPLUS
CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-03-6 CAPLUS
CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-04-7 CAPLUS

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-05-8 CAPLUS

CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

CM 1


CRN 202196-82-5

CMF C27 H23 N4 O . Cl




● Cl⁻

RN 202198-06-9 CAPLUS
CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-07-0 CAPLUS
CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-08-1 CAPLUS
 CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 202198-09-2 CAPLUS
 CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-10-5 CAPLUS
 CN 2-Furancarboxamide, N-[2-(methylsulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 202198-11-6 CAPLUS
 CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-12-7 CAPLUS


CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methoxysulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-13-8 CAPLUS


CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-14-9 CAPLUS


CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 CAPLUS

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 202197-65-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)

RN 202197-65-7 CAPLUS

CN 4-Quinazolinamine, 6-[5-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:265828 CAPLUS

DOCUMENT NUMBER: 128:294788

TITLE: 4-Aminoquinazoline derivatives for treatment of hyperproliferative disorders or conditions in mammals

INVENTOR(S): Arnold, Lee Daniel; Sobolov-Jaynes, Susan Beth

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English



Searched by Barb O'Bryen, STIC 308-4291

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 837063	A1	19980422	EP 1997-307724	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2218945	AA	19980417	CA 1997-2218945	19971015
JP 10152477	A2	19980609	JP 1997-284872	19971017
JP 3457164	B2	20031014		
BR 9705088	A	19990720	BR 1997-5088	19971017
PRIORITY APPLN. INFO.:			US 1996-28881P	P 19961017
OTHER SOURCE(S):	MARPAT 128:294788			

GI




AB The title compds. I [R1 = CF3, halo, OH, etc.; Q1 = ArYX; Ar = monocyclic or bicyclic aryl or heteroaryl ring; X = C2 alkene, C2 alkyne or absent; Y = (CH2)p, wherein one or two of the CH2 groups may be replaced by either O, S, SO2, CO, NH or NMe; Z = NR3R4; R3 = H; R4 = Q2, Ph substituted by R5q, or NR3R4 = II, wherein the dotted line represents an optional double bond; m = 1, 2; n = 0, 1, 2, 3; o = 0, 1, 2; p = 0-5; q = 0-3 integer] and their pharmaceutically acceptable salts are prepd. Thus, heating (1H-indol-5-yl)-(6-iodo-7-methoxyquinazolin-4-yl)amine with 4-vinylpyridine, Pd acetate and NEt3 in MeCN gave (1H-indol-5-yl)-[7-methoxy-6-(2-pyridin-4-yl-vinyl)quinazolin-4-yl]amine.

IT 206190-55-8P 206190-63-8P 206190-65-0P
 206190-67-2P 206190-70-7P 206190-72-9P
 206190-74-1P 206190-91-2P 206190-95-6P
 206190-96-7P 206190-99-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (aminoquinazoline derivs. for treatment of hyperproliferative diseases)

RN 206190-55-8 CAPLUS


CN 4-Quinazolinamine, N-(3-bromophenyl)-7-methoxy-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-63-8 CAPLUS
CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 206190-65-0 CAPLUS
CN 4-Quinazolinamine, N-[3-(5-oxazolyl)phenyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-67-2 CAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-70-7 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-72-9 CAPLUS

CN 4-Quinazolinamine, N-(3-ethynylphenyl)-7-methoxy-6-(3-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 206190-74-1 CAPLUS


CN 4-Quinazolinamine, N-1H-indol-5-yl-7-methoxy-6-(3-pyridinyl)- (9CI) (CA
INDEX NAME)




RN 206190-91-2 CAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 206190-95-6 CAPLUS
CN 7-Quinazolinol, 4-(1H-indol-5-ylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 206190-96-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indol-5-yl-7-(2-methoxyethoxy)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 206190-99-0 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-7-methoxy-6-(6-methoxy-3-pyridinyl)-
(9CI) (CA INDEX NAME)REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:696745 CAPLUS

DOCUMENT NUMBER: 128:3695

TITLE: Preparation of N-quinazolinylacrylamides and analogs
as tyrosine kinase inhibitorsINVENTOR(S): Bridges, Alexander James; Denny, William Alexander;
Dobrusin, Ellen Myra; Doherty, Annette Marian; Fry,
David W.; Mcnamara, Dennis Joseph; Showalter, Howard
Daniel Hollis; Smaill, Jeffrey B.; Zhou, Hairong; et
al.PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Bridges, Alexander James;
Denny, William Alexander; Dobrusin, Ellen Myra;
Doherty, Annette Marian; Fry, David W.; Mcnamara,
Dennis Joseph; Showalter, Howard Daniel Hollis;
Smaill, Jeffrey B.; Zhou, Hairong

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738983	A1	19971023	WO 1997-US5778	19970408
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,				

ML, MR, NE, SN, TD, TG



CA 2249446	AA	19971023	CA 1997-2249446	19970408
AU 9724463	A1	19971107	AU 1997-24463	19970408
AU 725533	B2	20001012		
EP 892789	A1	19990127	EP 1997-920213	19970408
EP 892789	B1	20020227		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI

CN 1218456	A	19990602	CN 1997-194458	19970408
BR 9708640	A	19990803	BR 1997-8640	19970408
JP 2000508657	T2	20000711	JP 1997-537173	19970408
JP 3370340	B2	20030127		
AT 213730	E	20020315	AT 1997-920213	19970408
ES 2174250	T3	20021101	ES 1997-920213	19970408
ZA 9703060	A	19971104	ZA 1997-3060	19970410
BG 63160	B1	20010531	BG 1998-102811	19981001
NO 9804718	A	19981209	NO 1998-4718	19981009
KR 2000005364	A	20000125	KR 1998-708086	19981010
US 6344459	B1	20020205	US 1999-155501	19990608
US 6602863	B1	20030805	US 2000-671559	20000927

PRIORITY APPLN. INFO.: US 1996-15351P P 19960412
WO 1997-US5778 W 19970408
US 1999-155501 A3 19990608

OTHER SOURCE(S): MARPAT 128:3695
GI




AB Title compds. [I; R = (CHR6)pR9; R1R2 = CH:CR7CR8:CH, CH:CR7CR8:N, CH:CR7N:CH, etc.; R6 = H or alkyl; 1 of R7,R8 = Z1Z2R10 and the other = OR4, SR4, NHR3; R3,R4 = (un)substituted alkyl, heterocyclylalkyl, etc.; R9 = (un)substituted Ph; R10 = CR11:CHR5, C.tplbond.CR5, CR11:C:CHR5; R5 = H, halo, alkyl, Ph, etc.; R11 = H, halo, alkyl; Z1 = bond, O, (alkyl)imino, CH2, etc.; Z2 = CO, SO, P(O)(OH), etc.; p = 0 or 1] were prepd. Thus, I (R = C6H4Br-3, R1R2 = CH:NCR8:CH, R8 = F) was condensed with 3-morpholinopropanamine and the product acylated by CH2:CHCOCl to give title compd. II. Data for biol. activity of I were given.

IT 198960-38-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)


RN 198960-38-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[4-[(3-bromophenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)



L41 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:568104 CAPLUS
DOCUMENT NUMBER: 127:220671
TITLE: Preparation of 4-anilino-7-heteroarylquinazolines as
tyrosine kinase inhibitors.
INVENTOR(S): Barker, Andrew John; Johnstone, Craig
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730044	A1	19970821	WO 1997-GB345	19970210
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9716127	A1	19970902	AU 1997-16127	19970210
EP 880517	A1	19981202	EP 1997-902497	19970210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2000505441	T2	20000509	JP 1997-529074	19970210
AT 212022	E	20020215	AT 1997-902497	19970210
ES 2171884	T3	20020916	ES 1997-902497	19970210
US 5814630	A	19980929	US 1997-800830	19970213
PRIORITY APPLN. INFO.:			GB 1996-3097	A 19960214
			WO 1997-GB345	W 19970210
OTHER SOURCE(S):	MARPAT 127:220671			
GI				




AB Title compds. [I; Q1 = (substituted) (benzo-fused) 5-6 membered heteroaryl; m = 1, 2; R1 = H, halo, CF3, OH, amino, NO2, cyano, CO2H, carbamoyl, alkoxycarbamoyl, alkyl, alkoxy, etc.; Q2 = (substituted) Ph], having antiproliferative activity, were prepd. Thus, 7-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride reacted with diisopropyl 5-morpholinomethylthien-3-ylboronate to give 4-(3-chloro-4-fluoroanilino)-7-(5-morpholinomethylthien-3-yl)quinazoline. The latter inhibited EGF-stimulated growth of KB cells with IC50 = 0.12 .mu.M.

IT 194851-13-3P 194851-14-4P 194851-15-5P
194851-21-3P 194851-22-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-anilino-7-heteroarylquinazolines as tyrosine kinase inhibitors)


RN 194851-13-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 194851-14-4 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 194851-15-5 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 194851-21-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 194851-22-4 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



L41 ANSWER 26 OF 52ⁿ CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1997:568090 CAPLUS
 DOCUMENT NUMBER: 127:248122
 TITLE: Quinazoline derivatives as **antitumor** agents
 INVENTOR(S): Barker, Andrew John; Johnstone, Craig
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730034	A1	19970821	WO 1997-GB344	19970210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2242102	AA	19970821	CA 1997-2242102	19970210
AU 9716126	A1	19970902	AU 1997-16126	19970210
AU 707339	B2	19990708		
EP 880507	A1	19981202	EP 1997-902496	19970210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1211240	A	19990317	CN 1997-192242	19970210
JP 2000504713	T2	20000418	JP 1997-529073	19970210
NZ 330816	A	20000526	NZ 1997-330816	19970210
ZA 9701231	A	19970814	ZA 1997-1231	19970213
US 5866572	A	19990202	US 1997-796483	19970213
NO 9803707	A	19981013	NO 1998-3707	19980813
US 6399602	B1	20020604	US 1998-152070	19980911
US 2003018029	A1	20030123	US 2002-136276	20020502
PRIORITY APPLN. INFO.:			GB 1996-3095	A 19960214
			WO 1997-GB344	W 19970210
			US 1997-796483	A3 19970213
			US 1998-152070	A1 19980911
OTHER SOURCE(S):		MARPAT 127:248122		
GI				




AB The invention concerns quinazoline derivs. I [X1 = bond, CO, C(R2)2, CH(OR2), S, C.tplbond.C, O, S, etc.; Q1 = Ph, naphthyl, or 5- or 6-membered heteroaryl optionally bearing 1-3 substituents; m = 1 or 2; R1 = H, halo, CF3, OH, NH2, cyano, etc.; R2 = H, alkyl; Q2 = Ph or 9- or 10-membered bicyclic heterocycle optionally bearing 1-3 substituents] and their pharmaceutically acceptable salts. Also disclosed are processes for prepn. of I and salts, pharmaceutical compns. contg. them, and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative diseases such as **cancer**. Examples include syntheses of 40 compds. and various intermediates. For instance, Pd(PPh3)4-catalyzed coupling of 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline-HCl with di-iso-Pr [5-(2-morpholinoethyl)thien-2-yl]boronate (prepn. given) gave 27% title compd. II. At 50 mg/kg/day in athymic nude mice with human vulval epidermoid carcinoma xenografts (cell line A-431), II gave 64% inhibition of **tumor** vol. (vs. control) after 13 days.

IT **195457-16-0P**, 4-(3-Chloro-4-fluoroanilino)-6-(3-furyl)quinazoline
195457-17-1P, 4-(3-Chloro-4-fluoroanilino)-6-(2-furyl)quinazoline
195457-18-2P, 4-(3-Chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline **195457-19-3P**, 4-(3-Chloro-4-fluoroanilino)-6-(3-thienyl)quinazoline **195457-20-6P**, 4-(3-Chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline
195457-21-7P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(morpholinomethyl)thien-3-yl]quinazoline **195457-22-8P**, 4-(3-Chloro-4-fluoroanilino)-6-(4-imidazolyl)quinazoline
195457-23-9P, 4-(3-Chloro-4-fluoroanilino)-6-(2-pyridyl)quinazoline **195457-24-0P**, 4-(3-Chloro-4-fluoroanilino)-6-(3-pyridyl)quinazoline **195457-50-2P**, 4-[3-Methyl-4-(2-pyridylmethoxy)anilino]-6-(2-thienyl)quinazoline **195457-51-3P**, 6-(3-Furyl)-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline
195457-52-4P, 4-(3-Chloro-4-fluoroanilino)-6-(4-oxazolyl)quinazoline


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of quinazoline derivs. as **antitumor** agents and antiproliferatives)

RN 195457-16-0 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-17-1 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-furanyl)- (9CI) (CA
INDEX NAME)



RN 195457-18-2 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-thienyl)- (9CI) (CA
INDEX NAME)




RN 195457-19-3 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-thienyl)- (9CI) (CA
INDEX NAME)




RN 195457-20-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-[2-(4-morpholinyl)ethyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-21-7 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-22-8 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 195457-23-9 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-pyridinyl)- (9CI) (CA
INDEX NAME)



RN 195457-24-0 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-pyridinyl)- (9CI) (CA
INDEX NAME)




RN 195457-50-2 CAPLUS
CN 4-Quinazolinamine, N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-6-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 195457-51-3 CAPLUS

CN 4-Quinazolinamine, 6-(3-furanyl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 195457-52-4 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-oxazolyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:476843 CAPLUS
DOCUMENT NUMBER: 125:142761
TITLE: Quinazoline derivatives
INVENTOR(S): Barker, Andrew John
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616960	A1	19960606	WO 1995-GB2768	19951128
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9539330	A1	19960619	AU 1995-39330	19951128
EP 794953	A1	19970917	EP 1995-937126	19951128
EP 794953	B1	19990506		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 10509972	T2	19980929	JP 1995-518417	19951128
AT 179708	E	19990515	AT 1995-937126	19951128
US 5955464	A	19990921	US 1997-860088	19970522
PRIORITY APPLN. INFO.:			GB 1994-24233	19941130
			WO 1995-GB2768	19951128
OTHER SOURCE(S):	MARPAT 125:142761			
GI				



AB The invention concerns quinazoline derivs. I (m = 1, 2; R1 = H, halo, alkyl, alkoxy; n = 1-3; R2 = H, OH, halo, alkyl; R = 5- or 9-membered nitrogen-linked heteroaryl moiety contg. up to four nitrogen heteroatoms, or R = a 5-, 6-, 9- or 10-membered nitrogen-linked unsatd. heterocyclic moiety contg. up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo) and the use of the receptor tyrosine kinase inhibitory properties of the compds. in the treatment of proliferative diseases such as **cancer**. Among the approx. 15 title compds. prepd., 4-(3-methylanilino)-, 4-(3-chloro-4-fluoroanilino)-, 4-(4-benzoyl-3-chloroanilino)-, and 4-[3-methyl-4-(2-pyridylmethoxy)anilino]-6-(1-imidazolyl)quinazolines were claimed.


IT **179552-59-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)

RN 179552-59-1 CAPLUS

CN 4-Quinazolinamine, 6-(1H-imidazol-1-yl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




IT **179552-76-2**

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)

RN 179552-76-2 CAPLUS

CN 2H-Imidazole-2-thione, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




IT 179552-62-6P 179552-64-8P 179552-65-9P
 179552-66-0P 179552-67-1P 179552-71-7P
 179552-77-3P 179552-78-4P 179552-80-8P
 179552-81-9P 179552-83-1P 179552-84-2P
 179552-88-6P 179552-91-1P 179552-93-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of tyrosine kinase inhibiting imidazolylquinazolines)


RN 179552-62-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-1-yl)- (9CI)
 (CA INDEX NAME)




RN 179552-64-8 CAPLUS

CN 2(1H)-Pyridinone, 1-[4-[(3,4-dichlorophenyl)amino]-6-quinazolinyl]- (9CI)
 (CA INDEX NAME)




RN 179552-65-9 CAPLUS

CN 4-Quinazolinamine, N-(2,4-difluorophenyl)-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-66-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-difluorophenyl)-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-67-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 179552-71-7 CAPLUS


CN 2H-Imidazole-2-thione, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 179552-77-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-1-yl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 179552-78-4 CAPLUS

CN 4-Quinazolinamine, N-[2-fluoro-4-(2-pyridinylmethoxy)phenyl]-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-80-8 CAPLUS

CN 4-Quinazolinamine, 6-(1H-imidazol-1-yl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 179552-81-9 CAPLUS


CN Methanone, [2-chloro-4-[[6-(1H-imidazol-1-yl)-4-quinazolinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 179552-83-1 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-phenylacetylphenyl)-6-(4-chloro-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 179552-84-2 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-88-6 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-1,2,4-triazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179552-91-1 CAPLUS
CN 4-Quinazolinamine, N-(2,4-difluorophenyl)-6-(1H-1,2,4-triazol-1-yl)- (9CI)
(CA INDEX NAME)




RN 179552-93-3 CAPLUS
CN 4-Quinazolinamine, 6-(1H-benzimidazol-1-yl)-N-(3-methylphenyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:468620 CAPLUS
DOCUMENT NUMBER: 122:214099
TITLE: Preparation of 4-anilinoquinazolines as
anticancer agents

INVENTOR(S): Barker, Andrew John
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 635498	A1	19950125	EP 1994-305195	19940715
EP 635498	B1	20010418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
IL 110164	A1	20000928	IL 1994-110164	19940629
ZA 9405156	A	19950119	ZA 1994-5156	19940714
AT 200667	E	20010515	AT 1994-305195	19940715
ES 2156137	T3	20010616	ES 1994-305195	19940715
WO 9503283	A1	19950202	WO 1994-GB1544	19940718
W: AU, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KR, LT, LV, MD, NO, NZ, PL, RO, RU, SK, UA				
AU 9471916	A1	19950220	AU 1994-71916	19940718
JP 09500636	T2	19970121	JP 1995-504996	19940718
US 5475001	A	19951212	US 1994-272390	19940719
PRIORITY APPLN. INFO.:			GB 1993-14893	A 19930719
			WO 1994-GB1544	W 19940718
OTHER SOURCE(S):		MARPAT 122:214099		
GI				




AB Title compds. [I; R1 = OH, NH2, alkoxy, heterocyclyl, etc.; R2 = (un)substituted Ph; R3 = halo] were prepd. Thus, I (R1 = OMe, R2 = 3,4-ClFC6H3, R3 = F) (multistep prepn. from Me 4-fluoro-3-methoxybenzoate given) had ED50 of <12.5mg/kg orally for inhibition of growth facto TGF.alpha.-induced liver hepatocyte proliferation in rats.


IT **162012-42-2P 162012-59-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-anilinoquinazolines as **anticancer** agents)

RN 162012-42-2 CAPLUS

CN 2-Pyrrolidinone, 1-[7-fluoro-4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 162012-59-1 CAPLUS
CN 2-Pyrrolidinone, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-quinazolinyl]- (9CI) (CA INDEX NAME)




L41 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:23238 CAPLUS
DOCUMENT NUMBER: 122:31545
TITLE: Preparation of aminoquinazolines useful in the treatment of **cancer**
INVENTOR(S): Barker, Andrew John; Brown, Dearg Sutherland
PATENT ASSIGNEE(S): Zeneca, UK
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602851	A1	19940622	EP 1993-309680	19931203
EP 602851	B1	19961009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9350728	A1	19940623	AU 1993-50728	19931116
AU 664496	B2	19951116		
ZA 9308594	A	19940610	ZA 1993-8594	19931117
CA 2103383	AA	19940611	CA 1993-2103383	19931118
IL 107678	A1	19990312	IL 1993-107678	19931119
HU 65622	A2	19940728	HU 1993-3328	19931124
FI 9305431	A	19940611	FI 1993-5431	19931203
AT 143956	E	19961015	AT 1993-309680	19931203

ES 2093367	T3	19961216	ES 1993-309680	19931203
CZ 283612	B6	19980513	CZ 1993-2651	19931206
NO 9304504	A	19940613	NO 1993-4504	19931209
JP 06336481	A2	19941206	JP 1993-309184	19931209
JP 3330706	B2	20020930		
CN 1094043	A	19941026	CN 1993-120872	19931210
US 5580870	A	19961203	US 1993-164725	19931210

PRIORITY APPLN. INFO.: GB 1992-25765 A 19921210
GB 1993-10248 A 19930518

OTHER SOURCE(S): MARPAT 122:31545
GI



I


AB The title compds. [I; Q = 9- or 10-membered bicyclic heterocyclic moiety contg. 1-2 N atoms; R1 = OH, NH₂, ureido, hydroxyamino, trifluoromethoxy, (un)substituted C1-4 alkyl, C1-4 alkoxy, pyrrolidin-1-yl, piperidino, etc.; m = 1-3], useful in the treatment of **cancer** (no data), are prepd. and I-contg. formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was reacted with 5-aminoquinoline, producing 6,7-dimethoxy-4-(5-quinolylamino)quinazoline, m.p. > 240.degree., in 35% yield.

IT 159737-70-9P 159768-36-2P 159768-39-5P
159768-45-3P 159768-55-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **anticancer** agent)

RN 159737-70-9 CAPLUS


CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(1-piperidinyl)-, hydrochloride
(10:9) (9CI) (CA INDEX NAME)



●9/10 HCl


RN 159768-36-2 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-6-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 159768-39-5 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 159768-45-3 CAPLUS
CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 159768-55-5 CAPLUS
CN 2-Pyrrolidinone, 1-[4-(1H-indol-5-ylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:217715 CAPLUS
DOCUMENT NUMBER: 120:217715
TITLE: Quinazoline tyrosine kinase-inhibiting
anticancer agents

INVENTOR(S): Barker, Andrew J.
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: Can. Pat. Appl., 99 pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086968	AA	19930721	CA 1993-2086968	19930108
CA 2086968	C	19980623		
ZA 9300015	A	19930720	ZA 1993-15	19930104
AU 9331010	A1	19930722	AU 1993-31010	19930104
AU 661533	B2	19950727		
HU 63153	A2	19930728	HU 1993-94	19930115
EP 566226	A1	19931020	EP 1993-300270	19930115
EP 566226	B1	19951108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 130000	E	19951115	AT 1993-300270	19930115
ES 2078798	T3	19951216	ES 1993-300270	19930115
CZ 282038	B6	19970416	CZ 1993-43	19930118
NO 9300178	A	19930721	NO 1993-178	19930119
RU 2127263	C1	19990310	RU 1993-4423	19930119
SK 281551	B6	20010510	SK 1993-16	19930119
IL 104479	A1	19991222	IL 1993-104479	19930121
JP 06073025	A2	19940315	JP 1993-26577	19930216
JP 2994165	B2	19991227		
US 5457105	A	19951010	US 1994-284293	19940802
US 5616582	A	19970401	US 1995-490666	19950615

PRIORITY APPLN. INFO.:

GB 1992-1095	A	19920120
GB 1992-13572	A	19920626
GB 1992-23735	A	19921112
US 1993-5280	B1	19930119
US 1994-284293	A1	19940802


OTHER SOURCE(S): MARPAT 120:217715
GI




AB The title compds. I [R1 = HO, (un)substituted amino, carboxy, carbamoyl, ureido, etc.; R2 = H, HO, halogen, CF3, NH2, NO2, CN, (un)substituted C1-4 alkyl, etc.; m = 1-3; n = 1, 2], useful as tyrosine kinase-inhibiting **anticancer** agents (no data), are prepd. and I-contg. formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was condensed with 3-MeC6H4NH2, producing 6,7-dimethoxy-4-(3'-methylanilino)quinazoline hydrochloride, m.p. 248-249.degree..

IT **153437-62-8P 153437-64-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of, as intermediate in prepn. of quinazoline tyrosine kinase-inhibiting **anticancer** agents)

RN 153437-62-8 CAPLUS
 CN 4,6-Quinazolinodiamine, N4-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-64-0 CAPLUS
 CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)-6-nitro- (9CI)
 (CA INDEX NAME)




IT **153437-27-5P 153437-42-4P 153437-49-1P**
153437-57-1P 153437-63-9P 153437-68-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of, as tyrosine kinase-inhibiting **anticancer** agent)


RN 153437-27-5 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 153437-42-4 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 153437-49-1 CAPLUS

CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153437-57-1 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-(1-piperidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 153437-63-9 CAPLUS

CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX
NAME)

RN 153437-68-4 CAPLUS

CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(1-piperidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

L41 ANSWER 31 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:251662 USPATFULL
TITLE: Heterocyclic compounds
INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176451	A1	20030918
APPLICATION INFO.:	US 2003-342810	A1	20030115 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398	

NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 3892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1##

comprising the steps:

(a) reacting a compound of formula (II) ##STR2##

wherein L and L' are suitable leaving groups, with a compound of formula (III)

UNH.sub.2 (III)

to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 202196-42-7P 202196-46-1P 202196-53-0P
202197-19-1P 202197-80-6P 202197-83-9P
202198-15-0P 231278-28-7P 231278-29-8P
231278-30-1P 231278-31-2P 231278-32-3P
231278-33-4P 231278-34-5P 231278-35-6P
231278-36-7P 231278-37-8P 231278-38-9P
231278-39-0P 231278-40-3P 231278-41-4P
231278-42-5P 231278-43-6P 231278-44-7P
231278-45-8P 231278-46-9P 231278-62-9P
231278-63-0P

(intermediate; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 202196-42-7 USPATFULL


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-

(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-80-6 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-83-9 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 USPATFULL


CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-28-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-29-8 USPATFULL


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 231278-30-1 USPATFULL


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-

(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-31-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-32-3 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-33-4 USPATFULL


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-34-5 USPATFULL
CN 2-Thiazolecarboxaldehyde, 4-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]-
(9CI) (CA INDEX NAME)



RN 231278-35-6 USPATFULL
CN 4-Thiazolecarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]-
(9CI) (CA INDEX NAME)




RN 231278-36-7 USPATFULL
CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-37-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-38-9 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinoliny]- (9CI) (CA INDEX NAME)



RN 231278-39-0 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-40-3 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-41-4 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-42-5 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-43-6 USPATFULL

CN 4-Quinolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231278-44-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 231278-45-8 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-46-9 USPATFULL


CN 4-Quinazolinamine, 6-[5-[[[2-(methylthio)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-62-9 USPATFULL

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-63-0 USPATFULL

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 231278-85-6 231278-86-7

(metabolite; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231278-85-6 USPATFULL

CN 4-Quinazolinamine, 6-[5-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-86-7 USPATFULL

CN 4-Quinazolinamine, 6-[4-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 231278-71-0 231278-72-1 231278-73-2
231278-75-4 231278-76-5 231278-77-6
231278-78-7 231278-80-1 231278-82-3
231278-83-4 231278-84-5

(starting material; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231278-71-0 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 231278-72-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-73-2 USPATFULL

CN 3-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-75-4 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-76-5 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-77-6 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(3-bromophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-78-7 USPATFULL

CN 3-Furancarboxaldehyde, 2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-80-1 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-82-3 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-83-4 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-84-5 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 231277-68-2P 231278-05-0P

(target compd., metab.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231277-68-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-05-0 USPATFULL
 CN 4-Quinazolinamine, 6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 231277-70-6P 231277-71-7P 231277-72-8P
 231277-73-9P 231277-74-0P 231277-75-1P
 231277-76-2P 231277-77-3P 231277-78-4P
 231277-79-5P 231277-80-8P 231277-81-9P
 231277-82-0P 231277-83-1P 231277-84-2P
 231277-85-3P 231277-86-4P 231277-87-5P
 231277-88-6P 231277-89-7P 231277-90-0P
 231277-91-1P 231277-92-2P 231277-93-3P
 231277-94-4P 231277-95-5P 231277-96-6P
 231277-97-7P 231277-98-8P 231277-99-9P
 231278-00-5P 231278-07-2P

(target compd.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231277-70-6 USPATFULL
 CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 231277-71-7 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

● 2 HCl

RN 231277-72-8 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)




RN 231277-73-9 USPATFULL
 CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 231277-74-0 USPATFULL
 CN 4-Quinazolinamine, 6-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-75-1 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-76-2 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231277-77-3 USPATFULL
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-78-4 USPATFULL
CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-79-5 USPATFULL

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-80-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 231277-81-9 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-82-0 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 231277-83-1 USPATFULL


CN 4-Quinazolinamine, 6-[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-84-2 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 231277-85-3 USPATFULL


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 231277-86-4 USPATFULL


CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231277-87-5 USPATFULL

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 231277-88-6 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-89-7 USPATFULL

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-90-0 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-91-1 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-93-3 USPATFULL

CN 4-Quinolinamine, 7-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-94-4 USPATFULL

CN 4-Quinolinamine, 7-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-5-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-95-5 USPATFULL

CN 4-Quinolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-96-6 USPATFULL

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-97-7 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-98-8 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-99-9 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-00-5 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-07-2 USPATFULL

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 32 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:214419 USPATFULL

TITLE: Use of tyrosine kinase inhibitors for the treatment of inflammatory processes

INVENTOR(S): Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
Pueschner, Hubert, Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149062	A1	20030807
APPLICATION INFO.:	US 2003-353616	A1	20030129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-DE10204462	20020205
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	

NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:

(a) quinazolines of general formula ##STR1##

wherein A, B, C, D, X, R^{sup.a}, R^{sup.b}, R^{sup.c} and n are as defined herein,

(b) the compounds

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,

(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and

(3) 4-[[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino]-6-(5-[[2-methanesulphonyl-ethyl]amino]methyl)-furan-2-yl]quinazoline or

(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and

(f) EGFR-antisense.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 33 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:79122 USPATFULL

TITLE: Heteroaromatic bicyclic derivatives useful as
anticancer agentsINVENTOR(S): Kath, John Charles, Waterford, CT, UNITED STATES
Tom, Norma Jacqueline, Waterford, CT, UNITED STATES
Cox, Eric David, Mystic, CT, UNITED STATES
Bhattacharya, Samit Kumar, Groton, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055049	A1	20030320
APPLICATION INFO.:	US 2002-226255	A1	20020822 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-488378, filed on 20 Jan 2000, GRANTED, Pat. No. US 6465449		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117341P	19990127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1694	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula 1 ##STR1##

and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R.sup.1, R.sup.3 and R.sup.4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 289037-01-0P 289037-43-0P 289037-44-1P

289037-45-2P 289037-46-3P 289037-47-4P

(prepn. of aminoquinazolines and related compds. as **anticancer**
drugs)


RN 289037-01-0 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(
(phenylmethyl)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI)
(CA INDEX NAME)




RN 289037-43-0 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[(4-phenoxymethyl)amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-44-1 USPATFULL

CN 1H-Indol-5-amine, N-[6-[6-[[6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]methyl]-3-pyridinyl]-4-quinazolinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 289037-45-2 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-46-3 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI)
(CA INDEX NAME)



RN 289037-47-4 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 34 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:24186 USPATFULL
TITLE: Quinazoline derivatives
INVENTOR(S): Barker, Andrew John, Cheshire, UNITED KINGDOM
Johnstone, Craig, Cheshire, UNITED KINGDOM
PATENT ASSIGNEE(S): ZENECA LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018029	A1	20030123
APPLICATION INFO.:	US 2002-136276	A1	20020502 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-152070, filed on 11 Sep 1998, GRANTED, Pat. No. US 6399602 Division of Ser. No. US 1997-796483, filed on 13 Feb 1997, GRANTED, Pat. No. US 5866572		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-3095	19960214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2620	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I
##STR1##

wherein X^{sup.1} is a direct link or a group such as CO, C(R^{sup.2}).sub.2 and CH(OR^{sup.2});

wherein Q^{sup.1} is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q^{sup.1} optionally bears up to 3 substituents;

wherein m is 1 or 2 and each R^{sup.1} may be a group such as hydrogen, halogeno and trifluoromethyl; and

wherein Q^{sup.2} may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q^{sup.2} optionally bears up to 3 substituents;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 195457-16-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-furyl)quinazoline
195457-17-1P, 4-(3-Chloro-4-fluoroanilino)-6-(2-furyl)quinazoline
195457-18-2P, 4-(3-Chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline 195457-19-3P, 4-(3-Chloro-4-fluoroanilino)-6-(3-thienyl)quinazoline 195457-20-6P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline
195457-21-7P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(morpholinomethyl)thien-3-yl]quinazoline 195457-22-8P, 4-(3-Chloro-4-fluoroanilino)-6-(4-imidazolyl)quinazoline
195457-23-9P, 4-(3-Chloro-4-fluoroanilino)-6-(2-pyridyl)quinazoline 195457-24-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-pyridyl)quinazoline 195457-50-2P, 4-[3-Methyl-4-(2-pyridylmethoxy)anilino]-6-(2-thienyl)quinazoline 195457-51-3P, 6-(3-Furyl)-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline

195457-52-4P, 4-(3-Chloro-4-fluoroanilino)-6-(4-oxazolyl)quinazoline

(prepn. of quinazoline derivs. as **antitumor** agents and antiproliferatives)


RN 195457-16-0 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-17-1 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-18-2 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-19-3 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-20-6 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-{2-(4-morpholinyl)ethyl}-2-thienyl]- (9CI) (CA INDEX NAME)



RN 195457-21-7 USPATFULL


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 195457-22-8 USPATFULL


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-4-yl)- (9CI)

(CA INDEX NAME)




RN 195457-23-9 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 195457-24-0 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 195457-50-2 USPATFULL

CN 4-Quinazolinamine, N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-51-3 USPATFULL

CN 4-Quinazolinamine, 6-(3-furanyl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 195457-52-4 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-oxazolyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 35 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:210030 USPATFULL
TITLE: Irreversible inhibitors of tyrosine kinases
INVENTOR(S): Bridges, Alexander James, Saline, MI, United States
Denny, William Alexander, Auckland, NEW ZEALAND
Dobrusin, Ellen Myra, Ann Arbor, MI, United States
Doherty, Annette Marian, Paris, FRANCE
Fry, David William, Ypsilanti, MI, United States
McNamara, Dennis Joseph, Ann Arbor, MI, United States
Showalter, Howard Daniel Hollis, Ann Arbor, MI, United States
Smaill, Jeffrey B., Auckland, NEW ZEALAND
Zhou, Hairong, Ann Arbor, MI, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6602863	B1	20030805
APPLICATION INFO.:	US 2000-671559		20000927 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 155501		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15351P	19960412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Vag, Linda A., Harvey, Suzanne M., Goodman, Rosanne	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	4294	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating **cancer**, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 198960-38-2P

(prepn. of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

RN 198960-38-2 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[4-[(3-bromophenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)



L41 ANSWER 36 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:266335 USPATFULL
TITLE: Heterocyclic compounds
INVENTOR(S): Cockerill, George Stuart, Bedford, UNITED KINGDOM
Carter, Malcolm Clive, Ware, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147214	A1	20021010
APPLICATION INFO.:	US 2002-62647	A1	20020131 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-214267, filed on 31 Dec 1998, GRANTED, Pat. No. US 6391874 A 371 of International Ser. No. WO 1998-EP9703672, filed on 31 Dec 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-14755	19960713
	GB 1996-25458	19961207
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, DURHAM, NC, 27709-3398	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3611	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of **cancer** and psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 202196-33-6P 202196-36-9P 202196-38-1P
202196-41-6P 202196-42-7P 202196-43-8P
202196-44-9P 202196-45-0P 202196-46-1P
202196-47-2P 202196-48-3P 202196-49-4P
202196-50-7P 202196-51-8P 202196-52-9P
202196-53-0P 202196-54-1P 202196-55-2P

202196-56-3P 202196-57-4P 202196-58-5P
202196-59-6P 202196-60-9P 202196-61-0P
202196-62-1P 202196-63-2P 202196-64-3P
202196-65-4P 202196-66-5P 202196-67-6P
202196-68-7P 202196-69-8P 202196-70-1P
202196-71-2P 202196-72-3P 202196-73-4P
202196-74-5P 202196-75-6P 202196-76-7P
202196-77-8P 202196-78-9P 202196-79-0P
202196-80-3P 202196-81-4P 202196-82-5P
202196-83-6P 202196-84-7P 202196-85-8P
202196-86-9P 202196-87-0P 202196-88-1P
202196-89-2P 202196-90-5P 202196-91-6P
202196-92-7P 202196-93-8P 202196-94-9P
202196-95-0P 202196-96-1P 202196-97-2P
202196-98-3P 202196-99-4P 202197-00-0P
202197-01-1P 202197-02-2P 202197-03-3P
202197-04-4P 202197-05-5P 202197-06-6P
202197-07-7P 202197-08-8P 202197-09-9P
202197-10-2P 202197-11-3P 202197-12-4P
202197-13-5P 202197-14-6P 202197-15-7P
202197-16-8P 202197-17-9P 202197-18-0P
202197-19-1P 202197-20-4P 202197-21-5P
202197-22-6P 202197-23-7P 202197-24-8P
202197-80-6P 202197-81-7P 202197-82-8P
202197-83-9P 202197-84-0P 202197-85-1P
202197-86-2P 202197-87-3P 202197-88-4P
202197-89-5P 202197-90-8P 202197-91-9P
202197-92-0P 202197-93-1P 202197-94-2P
202197-95-3P 202197-96-4P 202197-97-5P
202197-98-6P 202197-99-7P 202198-00-3P
202198-01-4P 202198-02-5P 202198-03-6P
202198-04-7P 202198-05-8P 202198-06-9P
202198-07-0P 202198-08-1P 202198-09-2P
202198-10-5P 202198-11-6P 202198-12-7P
202198-13-8P 202198-14-9P 202198-15-0P

(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)


RN 202196-33-6 USPATFULL

CN 4-Quinazolinamine, 6-(2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-36-9 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 202196-38-1 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 202196-41-6 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 202196-42-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-43-8 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-44-9 USPATFULL

CN 4-Quinazolinamine, 6-(4,5-dihydro-2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-45-0 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-1,2,3-triazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-47-2 USPATFULL


CN 4-Quinazolinamine, 6-[5-[(4-methyl-1-piperazinyl)methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-48-3 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-49-4 USPATFULL

CN 1,2-Propanediamine, N1,N1-dimethyl-N2-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI)
(CA INDEX NAME)




RN 202196-50-7 USPATFULL

CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI)
(CA INDEX NAME)




RN 202196-51-8 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[(3-pyridinylamino)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-52-9 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-54-1 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-55-2 USPTFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-56-3 USPTFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-57-4 USPTFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 202196-58-5 USPATFULL

CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-59-6 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-60-9 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-61-0 USPATFULL

CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-62-1 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-63-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-64-3 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-65-4 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-66-5 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-67-6 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-68-7 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-69-8 USPATFULL

CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-70-1 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-71-2 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-72-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-73-4 USPATFULL

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-74-5 USPATFULL

CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-75-6 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-76-7 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-2-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-77-8 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 202196-78-9 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-79-0 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1H-1,2,4-triazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-80-3 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[[1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-1H-imidazol-5-yl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-81-4 USPATFULL

CN 4-Quinazolinamine, 6-[5-[(methanesulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-82-5 USPATFULL


CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 202196-83-6 USPATFULL

CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-84-7 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)




RN 202196-85-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[methyl[2-(methanesulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-86-9 USPATFULL

CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 202196-87-0 USPATFULL

CN Ethanesulfonamide, 2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 202196-88-1 USPATFULL

CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 202196-89-2 USPATFULL

CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-90-5 USPATFULL

CN 2-Furancarboxamide, N-[2-(methysulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]- (9CI) (CA INDEX NAME)




RN 202196-91-6 USPATFULL

CN Ethanesulfonamide, N-methyl-2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 202196-92-7 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-93-8 USPTFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-94-9 USPTFULL

CN 4-Quinazolinamine, 6-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-95-0 USPTFULL

CN 4-Quinazolinamine, 6-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-96-1 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-97-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-98-3 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-99-4 USPATFULL

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 202197-00-0 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-pyrrol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-01-1 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 1-methyl-5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-02-2 USPATFULL

CN 4-Piperidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-03-3 USPATFULL

CN 2-Pyrrolidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-04-4 USPATFULL

CN 2,4-Imidazolidinedione, 3-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-05-5 USPATFULL

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-06-6 USPATFULL

CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-07-7 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-08-8 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-09-9 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-10-2 USPATFULL


CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-11-3 USPTAFULL
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 202197-12-4 USPTAFULL
CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-13-5 USPTAFULL
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-14-6 USPATFULL

CN 4-Quinazolinamine, N-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-15-7 USPATFULL

CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-16-8 USPATFULL

CN 4-Quinazolinamine, 7-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-17-9 USPATFULL

CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 202197-18-0 USPATFULL

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-20-4 USPATFULL


CN 4-Quinazolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202197-21-5 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202197-22-6 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-4-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-23-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-1-methyl-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-24-8 USPATFULL

CN 1H-Imidazole-5-carboxaldehyde, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-80-6 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-81-7 USPATFULL

CN 2-Pyrrolidinecarboxamide, 1-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 202197-82-8 USPATFULL


CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-83-9 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-84-0 USPATFULL

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 202197-85-1 USPATFULL


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, dihydrochloride (9CI)
(CA INDEX NAME)



●2 HCl

RN 202197-86-2 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-87-3 USPATFULL


CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-88-4 USPATFULL


CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-89-5 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-90-8 USPATFULL


CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-91-9 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-92-0 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202197-93-1 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-94-2 USPATFULL


CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-95-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-96-4 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202197-97-5 USPATFULL


CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-98-6 USPATFULL


CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-99-7 USPATFULL


CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-00-3 USPTAFULL
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-01-4 USPTAFULL
CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-02-5 USPATFULL

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-03-6 USPATFULL

CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-04-7 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202198-05-8 USPATFULL

CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 202196-82-5


CMF C27 H23 N4 O . Cl



● Cl⁻

RN 202198-06-9 USPATFULL


CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-07-0 USPATFULL


CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-08-1 USPATFULL


CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 202198-09-2 USPATFULL


CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-10-5 USPATFULL


CN 2-Furancarboxamide, N-[2-(methylsulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 202198-11-6 USPATFULL


CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-12-7 USPATFULL


CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-13-8 USPATFULL


CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-14-9 USPATFULL


CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 USPATFULL

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-
1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 202197-65-7P

(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)

RN 202197-65-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 37 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:266326 USPATFULL

TITLE: Heterocyclic compounds

INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM

Cockerill, George Stuart, Bedford, UNITED KINGDOM

Guntrip, Stephen Barry, Hertford, UNITED KINGDOM

Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES

Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147205	A1	20021010
APPLICATION INFO.:	US 2002-71358	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30		

Searched by Barb O'Bryen, STIC 308-4291

Jun 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
	WO 1999-EP48	19990108
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, DURHAM, NC, 27709-3398	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3860	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202196-42-7P 202196-46-1P 202196-53-0P
202197-19-1P 202197-80-6P 202197-83-9P
202198-15-0P 231278-28-7P 231278-29-8P
231278-30-1P 231278-31-2P 231278-32-3P
231278-33-4P 231278-34-5P 231278-35-6P
231278-36-7P 231278-37-8P 231278-38-9P
231278-39-0P 231278-40-3P 231278-41-4P
231278-42-5P 231278-43-6P 231278-44-7P
231278-45-8P 231278-46-9P 231278-62-9P
231278-63-0P

(intermediate; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 202196-42-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-80-6 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-83-9 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 USPATFULL


CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-28-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-29-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231278-30-1 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-fluoro-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-31-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-32-3 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-33-4 USPATFULL


CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-34-5 USPATFULL


CN 2-Thiazolecarboxaldehyde, 4-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]-
(9CI) (CA INDEX NAME)

RN 231278-35-6 USPATFULL

CN 4-Thiazolecarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]-
(9CI) (CA INDEX NAME)

RN 231278-36-7 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylmethoxy)phenyl]amino]-6-
quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-37-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-38-9 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[(4-phenoxyphenyl)amino]-7-quinolinyl]- (9CI)
(CA INDEX NAME)



RN 231278-39-0 USPATFULL

CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[4-(phenylsulfonyl)phenyl]amino]-6-


quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-40-3 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-41-4 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-42-5 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 231278-43-6 USPATFULL

CN 4-Quinolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231278-44-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-7-methoxy-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 231278-45-8 USPATFULL


CN 2-Furancarboxaldehyde, 5-[7-methoxy-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 231278-46-9 USPATFULL


CN 4-Quinazolinamine, 6-[5-[[[2-(methylthio)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-62-9 USPATFULL

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-63-0 USPATFULL

CN 2-Furancarboxaldehyde, 5-[7-fluoro-4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 231278-85-6 231278-86-7

(metabolite; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231278-85-6 USPATFULL

CN 4-Quinazolinamine, 6-[5-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-86-7 USPATFULL

CN 4-Quinazolinamine, 6-[4-(aminomethyl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 231278-71-0 231278-72-1 231278-73-2
231278-75-4 231278-76-5 231278-77-6
231278-78-7 231278-80-1 231278-82-3
231278-83-4 231278-84-5

(starting material; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231278-71-0 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 231278-72-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-73-2 USPATFULL

CN 3-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-75-4 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-76-5 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-77-6 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-[(3-bromophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-78-7 USPATFULL

CN 3-Furancarboxaldehyde, 2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 231278-80-1 USPATEFULL


CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylsulfonyl)phenyl]amino]-6-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-82-3 USPATEFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-fluoro-4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 231278-83-4 USPATEFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]- (9CI) (CA INDEX NAME)



RN 231278-84-5 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazoliny]- (9CI) (CA INDEX NAME)




IT 231277-68-2P 231278-05-0P

(target compd., metab.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231277-68-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 231278-05-0 USPATFULL
 CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 231277-70-6P 231277-71-7P 231277-72-8P
 231277-73-9P 231277-74-0P 231277-75-1P
 231277-76-2P 231277-77-3P 231277-78-4P
 231277-79-5P 231277-80-8P 231277-81-9P
 231277-82-0P 231277-83-1P 231277-84-2P
 231277-85-3P 231277-86-4P 231277-87-5P
 231277-88-6P 231277-89-7P 231277-90-0P
 231277-91-1P 231277-92-2P 231277-93-3P
 231277-94-4P 231277-95-5P 231277-96-6P
 231277-97-7P 231277-98-8P 231277-99-9P
 231278-00-5P 231278-07-2P

(target compd.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)


RN 231277-70-6 USPATFULL
 CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 231277-71-7 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

● 2 HCl

RN 231277-72-8 USPATFULL
 CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-73-9 USPATFULL
 CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-74-0 USPATFULL
 CN 4-Quinazolinamine, 6-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-75-1 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-76-2 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-77-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-78-4 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-79-5 USPATFULL

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-80-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 231277-81-9 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-82-0 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 231277-83-1 USPATFULL


CN 4-Quinazolinamine, 6-[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-84-2 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 231277-85-3 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-86-4 USPATFULL
CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 231277-87-5 USPATFULL
CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-[[[3-(trifluoromethyl)phenyl]methoxy]phenyl]]-, (9CI) (CA INDEX NAME)




RN 231277-88-6 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 231277-89-7 USPATFULL

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-90-0 USPATFULL

CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-91-1 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-(phenylmethoxy)phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 231277-93-3 USPATFULL

CN 4-Quinolinamine, 7-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-94-4 USPATFULL

CN 4-Quinolinamine, 7-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]-5-thiazolyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-95-5 USPATFULL

CN 4-Quinolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 231277-96-6 USPATFULL

CN 4-Quinazolinamine, 7-methoxy-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-97-7 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 231277-98-8 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 231277-99-9 USPATFULL

CN 4-Quinazolinamine, 7-fluoro-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 231278-00-5 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 231278-07-2 USPATFULL

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 38 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:268748 USPATFULL

TITLE: Heteroaromatic bicyclic derivatives useful as anticancer agents

INVENTOR(S): Kath, John Charles, Waterford, CT, United States
Tom, Norma Jacqueline, Waterford, CT, United States
Cox, Eric David, Mystic, CT, United States
Bhattacharya, Samit Kumar, Groton, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6465449	B1	20021015
APPLICATION INFO.:	US 2000-488378		20000120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117341P	19990127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	

ASSISTANT EXAMINER: Patel, Sudhaker B.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Looney, Adrian G.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of the formula 1 ##STR1##

and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R^{sup.1}, R^{sup.3} and R^{sup.4} are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 289037-01-0P 289037-43-0P 289037-44-1P

289037-45-2P 289037-46-3P 289037-47-4P

(prepn. of aminoquinazolines and related compds. as **anticancer** drugs)


RN 289037-01-0 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(phenylmethyl)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI)
(CA INDEX NAME)




RN 289037-43-0 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[(4-phenoxyphenyl)amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-44-1 USPATFULL

CN 1H-Indol-5-amine, N-[6-[6-[[6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl)methyl]-3-pyridinyl]-4-quinazolinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 289037-45-2 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 289037-46-3 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 289037-47-4 USPATFULL

CN 3-Azabicyclo[3.1.0]hexane-6-methanol, 3-[[5-[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-6-quinazolinyl]-2-pyridinyl]methyl]-
(9CI) (CA INDEX NAME)



L41 ANSWER 39 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:129961 USPATFULL

TITLE: Quinazoline derivatives

INVENTOR(S): Barker, Andrew John, Macclesfield, UNITED KINGDOM

Johnstone, Craig, Macclesfield, UNITED KINGDOM

PATENT ASSIGNEE(S): Zeneca Limited, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399602	B1	20020604
APPLICATION INFO.:	US 1998-152070		19980911 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-796483, filed on 13 Feb 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-3095	19960214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
ASSISTANT EXAMINER:	Liu, Hong	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2935	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I
##STR1##

wherein X^{sup.1} is a direct link or a group such as CO, C(R^{sup.2}).sub.2 and CH(OR^{sup.2});

wherein Q^{sup.1} is phenyl, naphthyl or a 5- or 6-membered heteroaryl

moiety and Q.sup.1 optionally bears up to 3 substituents;

wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; and

wherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents;

or a pharmaceutically-acceptable salt thereof;


processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 195457-16-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-furyl)quinazoline
195457-17-1P, 4-(3-Chloro-4-fluoroanilino)-6-(2-furyl)quinazoline
195457-18-2P, 4-(3-Chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline 195457-19-3P, 4-(3-Chloro-4-fluoroanilino)-6-(3-thienyl)quinazoline 195457-20-6P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline 195457-21-7P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(morpholinomethyl)thien-3-yl]quinazoline 195457-22-8P, 4-(3-Chloro-4-fluoroanilino)-6-(4-imidazolyl)quinazoline 195457-23-9P, 4-(3-Chloro-4-fluoroanilino)-6-(2-pyridyl)quinazoline 195457-24-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-pyridyl)quinazoline 195457-50-2P, 4-[3-Methyl-4-(2-pyridylmethoxy)anilino]-6-(2-thienyl)quinazoline 195457-51-3P, 6-(3-Furyl)-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline 195457-52-4P, 4-(3-Chloro-4-fluoroanilino)-6-(4-oxazolyl)quinazoline
(prepn. of quinazoline derivs. as **antitumor** agents and antiproliferatives)


RN 195457-16-0 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-17-1 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-18-2 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-19-3 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-20-6 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-[2-(4-morpholinyl)ethyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-21-7 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-22-8' USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 195457-23-9 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 195457-24-0 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 195457-50-2 USPATFULL

CN 4-Quinazolinamine, N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 195457-51-3 USPATFULL

CN 4-Quinazolinamine, 6-(3-furanyl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 195457-52-4 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-oxazolyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 40 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:116269 USPATFULL

TITLE: Fused heterocyclic compounds as protein tyrosine kinase inhibitors

INVENTOR(S): Cockerill, George Stuart, Herts, UNITED KINGDOM
Carter, Malcolm Clive, Herts, UNITED KINGDOM
Guntrip, Stephen Barry, Herts, UNITED KINGDOM

PATENT ASSIGNEE(S): Smith, Kathryn Jane, Herts, UNITED KINGDOM
SmithKline Beecham Corporation, Philadelphia, PA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391874	B1	20020521
	WO 9802434		19980122
APPLICATION INFO.:	US 1998-214267		19981231 (9)
	WO 1997-EP3672		19970711

Searched by Barb O'Bryen, STIC 308-4291

19981231 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-14755	19960713
	GB 1996-25458	19961207
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Solola, T. A.	
LEGAL REPRESENTATIVE:	Lemanowicz, John L.	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3913	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of **cancer** and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH₂), (CH₂)W, or W, in which W is O, S(O)_m wherein m is 0, 1 or 2, or NR^a wherein R^a is hydrogen or a C₁₋₈ alkyl group; R¹ represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)_m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)_m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R¹ being optionally substituted by one or more R³ groups; P=0 to 3; U, R², R³ are as defined in the application. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 202196-33-6P 202196-36-9P 202196-38-1P
202196-41-6P 202196-42-7P 202196-43-8P
202196-44-9P 202196-45-0P 202196-46-1P
202196-47-2P 202196-48-3P 202196-49-4P
202196-50-7P 202196-51-8P 202196-52-9P
202196-53-0P 202196-54-1P 202196-55-2P
202196-56-3P 202196-57-4P 202196-58-5P
202196-59-6P 202196-60-9P 202196-61-0P
202196-62-1P 202196-63-2P 202196-64-3P
202196-65-4P 202196-66-5P 202196-67-6P
202196-68-7P 202196-69-8P 202196-70-1P
202196-71-2P 202196-72-3P 202196-73-4P
202196-74-5P 202196-75-6P 202196-76-7P
202196-77-8P 202196-78-9P 202196-79-0P
202196-80-3P 202196-81-4P 202196-82-5P
202196-83-6P 202196-84-7P 202196-85-8P
202196-86-9P 202196-87-0P 202196-88-1P
202196-89-2P 202196-90-5P 202196-91-6P
202196-92-7P 202196-93-8P 202196-94-9P
202196-95-0P 202196-96-1P 202196-97-2P
202196-98-3P 202196-99-4P 202197-00-0P
202197-01-1P 202197-02-2P 202197-03-3P
202197-04-4P 202197-05-5P 202197-06-6P
202197-07-7P 202197-08-8P 202197-09-9P
202197-10-2P 202197-11-3P 202197-12-4P
202197-13-5P 202197-14-6P 202197-15-7P
202197-16-8P 202197-17-9P 202197-18-0P
202197-19-1P 202197-20-4P 202197-21-5P
202197-22-6P 202197-23-7P 202197-24-8P
202197-80-6P 202197-81-7P 202197-82-8P

202197-83-9P 202197-84-0P 202197-85-1P
202197-86-2P 202197-87-3P 202197-88-4P
202197-89-5P 202197-90-8P 202197-91-9P
202197-92-0P 202197-93-1P 202197-94-2P
202197-95-3P 202197-96-4P 202197-97-5P
202197-98-6P 202197-99-7P 202198-00-3P
202198-01-4P 202198-02-5P 202198-03-6P
202198-04-7P 202198-05-8P 202198-06-9P
202198-07-0P 202198-08-1P 202198-09-2P
202198-10-5P 202198-11-6P 202198-12-7P
202198-13-8P 202198-14-9P 202198-15-0P

(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)


RN 202196-33-6 USPATFULL

CN 4-Quinazolinamine, 6-(2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-36-9 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 202196-38-1 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 202196-41-6 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(2-pyrimidinyl)- (9CI)
(CA INDEX NAME)




RN 202196-42-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-43-8 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-44-9 USPATFULL

CN 4-Quinazolinamine, 6-(4,5-dihydro-2-furanyl)-N-[4-(phenylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)




RN 202196-45-0 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-1,2,3-triazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-46-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-47-2 USPATFULL


CN 4-Quinazolinamine, 6-[5-[(4-methyl-1-piperazinyl)methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-48-3 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-49-4 USPATFULL

CN 1,2-Propanediamine, N1,N1-dimethyl-N2-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 202196-50-7 USPATFULL

CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazoliny]]-2-furanyl]methyl]- (9CI)
(CA INDEX NAME)




RN 202196-51-8 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[(3-pyridinylamino)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-52-9 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)




RN 202196-53-0 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-54-1 USPATFULL


CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-55-2 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-56-3 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-57-4 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 202196-58-5 USPATFULL

CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-59-6 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-60-9 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-61-0 USPATFULL

CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-62-1 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-63-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-64-3 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-65-4 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-66-5 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-67-6 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-68-7 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-69-8 USPATFULL

CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-70-1 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-71-2 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-72-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-73-4 USPATFULL

CN 4-Quinazolinamine, N-[1-(phenylmethoxy)-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 202196-74-5 USPATFULL

CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202196-75-6 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-76-7 USPATFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-imidazol-2-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-77-8 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 202196-78-9 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-79-0 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1H-1,2,4-triazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-80-3 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[[1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-1H-imidazol-5-yl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202196-81-4 USPATFULL

CN 4-Quinazolinamine, 6-[5-[(methanesulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-N-[1-(phenylmethoxy)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202196-82-5 USPATFULL


CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 202196-83-6 USPATFULL

CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-84-7 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-85-8 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[methyl[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-86-9 USPATFULL

CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 202196-87-0 USPATFULL

CN Ethanesulfonamide, 2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 202196-88-1 USPATFULL

CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 202196-89-2 USPATFULL

CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-90-5 USPATFULL

CN 2-Furancarboxamide, N-[2-(methoxymethyl)phenyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202196-91-6 USPATFULL

CN Ethanesulfonamide, N-methyl-2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 202196-92-7 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethoxy)phenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-93-8 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-94-9 USPATFULL

CN 4-Quinazolinamine, 6-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-95-0 USPATFULL

CN 4-Quinazolinamine, 6-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202196-96-1 USPATFULL

CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-97-2 USPATFULL

CN 4-Quinazolinamine, 6-[5-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-3-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-98-3 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202196-99-4 USPTFULL

CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 202197-00-0 USPTFULL

CN 4-Quinazolinamine, 6-(1-methyl-1H-pyrrol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-01-1 USPTFULL

CN 1H-Pyrrole-2-carboxaldehyde, 1-methyl-5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-02-2 USPATFULL

CN 4-Piperidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-03-3 USPATFULL

CN 2-Pyrrolidinone, 1-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-04-4 USPATFULL

CN 2,4-Imidazolidinedione, 3-[[3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 202197-05-5 USPATFULL

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 202197-06-6 USPATFULL

CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-07-7 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-08-8 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-5-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-09-9 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-10-2 USPATFULL

CN 4-Quinazolinamine, 6-[1-[3-(dimethylamino)propyl]-1H-imidazol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-11-3 USPATFULL

CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-12-4 USPATFULL

CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-13-5 USPATFULL

CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-14-6 USPATFULL

CN 4-Quinazolinamine, N-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 202197-15-7 USPATFULL

CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-16-8 USPATFULL

CN 4-Quinazolinamine, 7-(1-methyl-1H-imidazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-17-9 USPATFULL

CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 202197-18-0 USPATFULL

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-
1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 202197-19-1 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-
quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-20-4 USPATFULL


CN 4-Quinazolinamine, 7-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 202197-21-5 USPATFULL


CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-7-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202197-22-6 USPATFULL

CN 4-Quinazolinamine, 6-(3-methyl-4-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-23-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-1-methyl-1H-imidazol-2-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 202197-24-8 USPATFULL

CN 1H-Imidazole-5-carboxaldehyde, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202197-80-6 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-81-7 USPATFULL

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 202197-82-8 USPATFULL


CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-83-9 USPATFULL

CN 2-Furancarboxaldehyde, 5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-84-0 USPATFULL

CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 202197-85-1 USPATFULL


CN 4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, dihydrochloride (9CI)
(CA INDEX NAME)



● 2 HCl


RN 202197-86-2 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202197-87-3 USPATFULL
CN 4-Quinazolinamine, N-[1-[(2-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-88-4 USPATFULL
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-89-5 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-90-8 USPATFULL


CN 4-Quinazolinamine, N-[1-[(2,3-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-91-9 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-92-0 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202197-93-1 USPATFULL


CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-94-2 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-95-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202197-96-4 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(phenylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202197-97-5 USPATFULL


CN 4-Quinazolinamine, N-[1-[(3,5-difluorophenyl)methyl]-1H-indazol-5-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-98-6 USPATFULL


CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 202197-99-7 USPATFULL

CN 4-Quinazolinamine, N-[4-[(2-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-00-3 USPATFULL

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-01-4 USPATFULL


CN 4-Quinazolinamine, N-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-02-5 USPATFULL
CN 4-Quinazolinamine, N-[1-(phenylmethyl)-1H-indazol-5-yl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-03-6 USPATFULL
CN 4-Quinazolinamine, N-[4-(3-pyridinylmethoxy)phenyl]-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 202198-04-7 USPATFULL

CN 4-Quinazolinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethoxy)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 202198-05-8 USPATFULL

CN Pyridinium, 1-methyl-2-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 202196-82-5


CMF C27 H23 N4 O . Cl



● Cl⁻

RN 202198-06-9 USPATFULL


CN 4-Quinazolinamine, 6-(1,2-dimethyl-1H-imidazol-5-yl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-07-0 USPATFULL


CN 4-Quinazolinamine, 6-(3-methyl-5-isoxazolyl)-N-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-08-1 USPATFULL


CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 202198-09-2 USPATFULL

CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202198-10-5 USPATFULL
 CN 2-Furancarboxamide, N-[2-(methylsulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 202198-11-6 USPATFULL
 CN 4-Quinazolinamine, 6-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-12-7 USPATFULL


CN 4-Quinazolinamine, 6-[1-methyl-5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-pyrrol-2-yl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-13-8 USPATFULL


CN 4-Quinazolinamine, 7-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-14-9 USPATFULL


CN 4-Quinazolinamine, 7-(2-furanyl)-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-15-0 USPATFULL

CN 4-Quinazolinamine, 7-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[1-(phenylmethyl)-1H-indazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 202197-65-7P

(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)

RN 202197-65-7 USPATFULL

CN 4-Quinazolinamine, 6-[5-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 41 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:24288 USPATFULL

TITLE: Irreversible inhibitors of tyrosine kinases

INVENTOR(S): Bridges, Alexander James, Saline, MI, United States

Denny, William Alexander, Auckland, NEW ZEALAND

Dobrusin, Ellen Myra, Ann Arbor, MI, United States

Doherty, Annette Marian, Paris, FRANCE

Fry, David William, Ypsilanti, MI, United States

McNamara, Dennis Joseph, Ann Arbor, MI, United States

Showalter, Howard Daniel Hollis, Ann Arbor, MI, United States

Smaill, Jeffrey B., Auckland, NEW ZEALAND

Zhou, Hairong, Ann Arbor, MI, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

Searched by Barb O'Bryen, STIC 308-4291

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6344459	B1	20020205
	WO 9738983		19971023
APPLICATION INFO.:	US 1999-155501		19990608 (9)
	WO 1997-US5778		19970408
			19990608 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15351P	19960412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Crissey, Todd M, Vag, Linda A., Harvey, Suzanne M.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	4084	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating **cancer**, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 198960-38-2P

(prepn. of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors)

RN 198960-38-2 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[4-[(3-bromophenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)



L41 ANSWER 42 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:157421 USPATFULL

TITLE: Pyridopyrimidine analogs and related compounds and methods for treating inflammatory conditions

INVENTOR(S): Palanki, Moorthy S. S., Encinitas, CA, United States
Suto, Mark J., La Jolla, CA, United States

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6150372 20001121
APPLICATION INFO.: US 1999-340557 19990628 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1997-886198, filed on 1 Jul
1997, now patented, Pat. No. US 5939421
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1052

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219774-04-6P

(prepn. of quinazoline analogs and related compds. for treating inflammatory conditions)

RN 219774-04-6 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(1-piperidinyl)-2-(trifluoromethyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



L41 ANSWER 43 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:113750 USPATFULL

TITLE: 4-anilinoquinazoline derivatives bearing a heteroaryl substituted at the 6-position and possessing anti-cell-proliferation properties

INVENTOR(S): Barker, Andrew John, Macclesfield, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955464		19990921
	WO 9616960		19960606
APPLICATION INFO.:	US 1997-860088		19970522 (8)
	WO 1995-GB2768		19951128
			19970522 PCT 371 date
			19970522 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-24233	19941130
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Truong, Tamthom N.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1768	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns 4-anilinoquinazoline derivatives of the formula I
##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno,
(1-4C)alkyl and (1-4C)alkoxy;

n is 1, 2 or 3;

each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and
Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up
to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered
nitrogen-linked unsaturated heterocyclic moiety containing up to three
nitrogen heteroatoms which bears one or two substituents selected from
oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation, pharmaceutical compositions containing
them, and the use of the receptor tyrosine kinase inhibitory properties
of the compounds in the treatment of proliferative disease such as
cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179552-59-1P

(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)

RN 179552-59-1 USPATFULL

CN 4-Quinazolinamine, 6-(1H-imidazol-1-yl)-N-(3-methylphenyl)- (9CI) (CA
INDEX NAME)




IT 179552-76-2

(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)

RN 179552-76-2 USPATFULL

CN 2H-Imidazole-2-thione, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



IT 179552-62-6P 179552-64-8P 179552-65-9P

179552-66-0P 179552-67-1P 179552-71-7P

179552-77-3P 179552-78-4P 179552-80-8P


179552-81-9P 179552-83-1P 179552-84-2P

179552-88-6P 179552-91-1P 179552-93-3P

(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)


RN 179552-62-6 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-1-yl)- (9CI)
(CA INDEX NAME)




RN 179552-64-8 USPATFULL

CN 2(1H)-Pyridinone, 1-[4-[(3,4-dichlorophenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)




RN 179552-65-9 USPATFULL

CN 4-Quinazolinamine, N-(2,4-difluorophenyl)-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-66-0 USPATFULL

CN 4-Quinazolinamine, N-(3,4-difluorophenyl)-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-67-1 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-71-7 USPATFULL

CN 2H-Imidazole-2-thione, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 179552-77-3 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-1-yl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 179552-78-4 USPATFULL
CN 4-Quinazolinamine, N-[2-fluoro-4-(2-pyridinylmethoxy)phenyl]-6-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-80-8 USPATFULL

CN 4-Quinazolinamine, 6-(1H-imidazol-1-yl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 179552-81-9 USPATFULL

CN Methanone, [2-chloro-4-[[6-(1H-imidazol-1-yl)-4-quinazolinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 179552-83-1 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-chloro-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 179552-84-2 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-pyrazol-1-yl)- (9CI)
(CA INDEX NAME)



RN 179552-88-6 USPATFULL


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-1,2,4-triazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 179552-91-1 USPATFULL

CN 4-Quinazolinamine, N-(2,4-difluorophenyl)-6-(1H-1,2,4-triazol-1-yl)- (9CI)
(CA INDEX NAME)



RN 179552-93-3 USPATFULL

CN 4-Quinazolinamine, 6-(1H-benzimidazol-1-yl)-N-(3-methylphenyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 44 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:96372 USPATFULL

TITLE: Quinazoline analogs and related compounds and methods
for treating inflammatory conditions

INVENTOR(S): Palanki, Moorthy S. S., Encinitas, CA, United States

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Suto, Mark J., La Jolla, CA, United States
Signal Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939421		19990817
APPLICATION INFO.:	US 1997-886198		19970701 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1076		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219774-04-6P

(prepn. of quinazoline analogs and related compds. for treating inflammatory conditions)

RN 219774-04-6 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(1-piperidiny1)-2-(trifluoromethyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



L41 ANSWER 45 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:15926 USPATFULL

TITLE: Quinazoline derivatives

INVENTOR(S): Barker, Andrew John, Macclesfield, United Kingdom
Johnstone, Craig, Macclesfield, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5866572		19990202
APPLICATION INFO.:	US 1997-796483		19970213 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-3095	19960214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2526	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein X.sup.1 is a direct link or a group such as CO, C(R.sup.2).sub.2 and CH(OR.sup.2);

wherein Q.sup.1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;

wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; and

wherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 195457-16-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-furyl)quinazoline
195457-17-1P, 4-(3-Chloro-4-fluoroanilino)-6-(2-furyl)quinazoline
195457-18-2P, 4-(3-Chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline 195457-19-3P, 4-(3-Chloro-4-fluoroanilino)-6-(3-thienyl)quinazoline 195457-20-6P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline 195457-21-7P, 4-(3-Chloro-4-fluoroanilino)-6-[5-(morpholinomethyl)thien-3-yl]quinazoline 195457-22-8P, 4-(3-Chloro-4-fluoroanilino)-6-(4-imidazolyl)quinazoline 195457-23-9P, 4-(3-Chloro-4-fluoroanilino)-6-(2-pyridyl)quinazoline 195457-24-0P, 4-(3-Chloro-4-fluoroanilino)-6-(3-pyridyl)quinazoline 195457-50-2P, 4-[3-Methyl-4-(2-pyridylmethoxy)anilino]-6-(2-thienyl)quinazoline 195457-51-3P, 6-(3-Furyl)-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline 195457-52-4P, 4-(3-Chloro-4-fluoroanilino)-6-(4-oxazolyl)quinazoline

(prepn. of quinazoline derivs. as **antitumor** agents and antiproliferatives)


RN 195457-16-0 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 195457-17-1 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-furanyl)- (9CI) (CA
INDEX NAME)




RN 195457-18-2 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-thienyl)- (9CI) (CA
INDEX NAME)




RN 195457-19-3 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-thienyl)- (9CI) (CA
INDEX NAME)




RN 195457-20-6 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-[2-(4-morpholinyl)ethyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-21-7 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 195457-22-8 USPATFULL


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 195457-23-9 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(2-pyridinyl)- (9CI) (CA
INDEX NAME)



RN 195457-24-0 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(3-pyridinyl)- (9CI) (CA
INDEX NAME)




RN 195457-50-2 USPATFULL
CN 4-Quinazolinamine, N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-6-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 195457-51-3 USPATFULL

CN 4-Quinazolinamine, 6-(3-furanyl)-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 195457-52-4 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-oxazolyl)- (9CI) (CA
INDEX NAME)



L41 ANSWER 46 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:119145 USPATFULL

TITLE: Quinazoline compounds

INVENTOR(S): Barker, Andrew John, Macclesfield, United Kingdom
Johnstone, Craig, Macclesfield, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814630		19980929
APPLICATION INFO.:	US 8008302		19970213 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 9603097	19960214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1342	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline compounds of the formula I ##STR1## wherein Q.sup.1 is a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;

wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl;

and wherein Q.sup.2 is phenyl which optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof;

processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194851-13-3P 194851-14-4P 194851-15-5P


194851-21-3P 194851-22-4P

(prepn. of 4-anilino-7-heteroarylquinazolines as tyrosine kinase inhibitors)

RN 194851-13-3 USPATFULL


CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-furanyl)- (9CI) (CA

INDEX NAME)




RN 194851-14-4 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 194851-15-5 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)




RN 194851-21-3 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 194851-22-4 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-(1H-imidazol-1-yl)- (9CI)
(CA INDEX NAME)

L41 ANSWER 47 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:27169 USPATFULL

TITLE: Quinazoline derivatives as anti-proliferative agents

INVENTOR(S): Barker, Andrew J., Macclesfield, England

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616582		19970401
APPLICATION INFO.:	US 1995-490666		19950615 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-284293, filed on 2 Aug 1994, now patented, Pat. No. US 5457105 which is a continuation of Ser. No. US 1993-5280, filed on 19 Jan 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-1095	19920120
	GB 1992-13572	19920626
	GB 1992-23735	19921112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	12	

EXEMPLARY CLAIM: 1

LINE COUNT: 3508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R^{sup.1} includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;

n is 1 or 2 and each R^{sup.2} includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof;

processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 153437-62-8P 153437-64-0P

(prepn. of, as intermediate in prepn. of quinazoline tyrosine kinase-inhibiting **anticancer** agents)


RN 153437-62-8 USPATFULL

CN 4,6-Quinazolinodiamine, N4-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-64-0 USPATFULL

CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)-6-nitro- (9CI) (CA INDEX NAME)



IT 153437-27-5P 153437-42-4P 153437-49-1P


153437-57-1P 153437-63-9P 153437-68-4P

(prepn. of, as tyrosine kinase-inhibiting **anticancer** agent)


RN 153437-27-5 USPATFULL

CN 2-Pyrrolidinone, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI) (CA


INDEX NAME)



RN 153437-42-4 USPATFULL

CN 2,5-Pyrrolidinedione, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)


RN 153437-49-1 USPATFULL

CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(4-morpholinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 153437-57-1 USPATFULL

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-(1-piperidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153437-63-9 USPATFULL
CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-68-4 USPATFULL
CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(1-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L41 ANSWER 48 OF 52 USPATFULL on STN
ACCESSION NUMBER: 96:111459 USPATFULL
TITLE: Quinazoline derivatives

Searched by Barb O'Bryen, STIC 308-4291

INVENTOR(S): Barker, Andrew J., Macclesfield, United Kingdom
Brown, Dearg S., Wilmslow, United Kingdom
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5580870		19961203
APPLICATION INFO.:	US 1993-164725		19931210 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-25765	19921210
	GB 1993-10248	19930518

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Cushman Darby & Cushman, L.L.P.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 2124

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R.sup.1 includes hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy; and Q is a 9- or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, or Q is a 9- or 10-membered bicyclic aryl moiety which heterocyclic or aryl moiety may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 159737-70-9P 159768-36-2P 159768-39-5P
159768-45-3P 159768-55-5P

(prepn. of, as **anticancer** agent)

RN 159737-70-9 USPATFULL


CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(1-piperidinyl)-, hydrochloride
(10:9) (9CI) (CA INDEX NAME)



● 9/10 HCl

RN 159768-36-2 USPATFULL


CN 4-Quinazolinamine, N-1H-indazol-5-yl-6-(1-pyrrolidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 159768-39-5 USPATFULL

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 159768-45-3 USPATFULL


CN 4-Quinazolinamine, N-1H-indol-5-yl-6-(1-pyrrolidinyl)-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 159768-55-5 USPATFULL

CN 2-Pyrrolidinone, 1-[4-(1H-indol-5-ylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 49 OF 52 USPATFULL on STN
ACCESSION NUMBER: 95:110449 USPATFULL
TITLE: Quinazoline derivatives
INVENTOR(S): Barker, Andrew J., Macclesfield, United Kingdom
PATENT ASSIGNEE(S): Zeneca Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5475001		19951212
APPLICATION INFO.:	US 1994-272390		19940719 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-14893	19930719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1327	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1##
wherein R.sup.1 includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy,
(1-4C)alkylamino and di-[(1-4C)alkyl]amino;

R.sup.3 is halogeno;

n is 1, 2 or 3 and R.sup.2 includes hydrogen, hydroxy, halogeno and
(1-4C)alkyl;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation; pharmaceutical compositions containing
them; and the use of the receptor tyrosine kinase inhibitory properties
of the compounds in the treatment of **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 162012-42-2P 162012-59-1P

(prepn. of 4-anilinoquinazolines as **anticancer** agents)


RN 162012-42-2 USPATFULL

CN 2-Pyrrolidinone, 1-[7-fluoro-4-[(3-methylphenyl)amino]-6-quinazolinyl]-
(9CI) (CA INDEX NAME)



RN 162012-59-1 USPATFULL

CN 2-Pyrrolidinone, 1-[4-[(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-quinazolinyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 50 OF 52 USPATFULL on STN

ACCESSION NUMBER: 95:90529 USPATFULL

TITLE: Quinazoline derivatives useful for treatment of
neoplastic disease

INVENTOR(S): Barker, Andrew J., Macclesfield, England

PATENT ASSIGNEE(S): Zeneca Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5457105		19951010
APPLICATION INFO.:	US 1994-284293		19940802 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-5280, filed on 19 Jan 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-1095	19920120
	GB 1992-13572	19920626
	GB 1992-23735	19921112

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Cushman Darby & Cushman
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 3702

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R^{sup.1} includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;

n is 1 or 2 and each R^{sup.2} includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 153437-62-8P 153437-64-0P

(prepn. of, as intermediate in prepn. of quinazoline tyrosine kinase-inhibiting **anticancer** agents)


RN 153437-62-8 USPATFULL

CN 4,6-Quinazolinodiamine, N4-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-64-0 USPATFULL

CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)-6-nitro- (9CI) (CA INDEX NAME)




IT 153437-27-5P 153437-42-4P 153437-49-1P

153437-57-1P 153437-63-9P 153437-68-4P


(prepn. of, as tyrosine kinase-inhibiting **anticancer** agent)

RN 153437-27-5 USPATFULL


CN 2-Pyrrolidinone, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 153437-42-4 USPATFULL
CN 2,5-Pyrrolidinedione, 1-[4-[(3-methylphenyl)amino]-6-quinazolinyl]- (9CI)
(CA INDEX NAME)




RN 153437-49-1 USPATFULL
CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(4-morpholinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153437-57-1 USPATFULL
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-(1-piperidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153437-63-9 USPATFULL
CN 4-Quinazolinamine, N-(3-methylphenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 153437-68-4 USPATFULL
CN 4-Quinazolinamine, N-(3-methylphenyl)-6-(1-piperidiny)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L41 ANSWER 51 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:258630 BIOSIS
DOCUMENT NUMBER: PREV200300258630
TITLE: Effect of GW572016 on ERBB-2 signaling, cell growth, and apoptosis in rat biliary cancer cells.
AUTHOR(S): Lai, Guan-Hua [Reprint Author]; Sirica, Alphonse E.
CORPORATE SOURCE: Pathology, Virginia Commonwealth University, 1101 East Marshall Street, Richmond, VA, 23298-0297, USA
ghlai@hsc.vcu.edu; asirica@hsc.vcu.edu
SOURCE: FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 163.10. <http://www.fasebj.org/>. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. San Diego, CA, USA. April 11-15, 2003. FASEB.
ISSN: 0892-6638 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Jun 2003
Last Updated on STN: 1 Aug 2003
ABSTRACT: Overexpression of ErbB-2 has been linked to cholangiocarcinogenesis in both experimental rodents and in the human. We have now investigated the effects of GW572016 (GlaxoSmithKline), a potent new small molecule inhibitor of epidermal growth factor receptor (ErbB-1) and of ErbB-2 tyrosine kinase activity, for its ability to suppress growth and induce apoptosis in a novel rat biliary cancer cell line (C611B ChC) constitutively overexpressing activated ErbB-2. ErbB1 was only weakly expressed in C611B ChC cells and they did not express ErbB-4. ErbB-3 was detected by Western Blotting in C611B ChC cells, but at a lower amount than ErbB-2, and evidence was obtained for ErbB-2/ErbB-3 heterodimer formation in these cells. GW572016 produced significant dose-dependent suppression of cell growth and induced prominent apoptosis in cultured C611B ChC cells. These effects correlated with a selective suppression of ErbB-2 tyrosine phosphorylation, and downstream, with inhibition of both the Akt and ERK 1/2 signaling pathways. Apoptosis induced by GW572016 in cultured C611B ChC cells involved activation of caspase-3 and associated cleavage of polyADP-ribose polymerase. These data strongly suggest GW572016 targeting of ErbB-2 overexpressed in biliary cancer cells may provide a novel therapeutic strategy for the treatment of a cancer for which there is currently no effective therapy.
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - General 02502
Cytology - Animal 02506
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Digestive system - Physiology and biochemistry 14004
Digestive system - Pathology 14006
Endocrine - General 17002
Neoplasms - Pathology, clinical aspects and systemic effects 24004
INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Cell Biology; Digestive System (Ingestion and Assimilation); Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
biliary cancer cells
INDEX TERMS: Diseases
biliary cancer: digestive system disease, neoplastic disease

INDEX TERMS: Biliary Tract Neoplasms (MeSH)
Chemicals & Biochemicals
GW572016; ErbB-2: epidermal growth factor receptor;
ErbB-1: epidermal growth factor receptor; ErbB-2
tyrosine kinase; caspase-3

INDEX TERMS: Miscellaneous Descriptors
ERBB-2 signaling; cell growth; apoptosis

ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
C611B ChC cell line (cell line): rat biliary cancer cell
line
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates,
Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: 231277-92-2 (GW572016) *Structure printed at end of this section*
137632-09-8 (ErbB-2 tyrosine kinase)
169592-56-7 (caspase-3)

L41 ANSWER 52 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:82208 BIOSIS
DOCUMENT NUMBER: PREV200300082208
TITLE: GW572016, a novel dual EGFR/Her-2 small molecule, tyrosine
kinase inhibitor induces regression and significant growth
delay in tamoxifen-resistant, MCF-7 derived tumors.

AUTHOR(S): Blackwell, K. [Reprint Author]; Spector, N.; Snyder, S.;
Marks, J.; Xia, W.; Liu, L.-H.; Broadwater, G.; McDonnell,
D.; Dewhirst, M.

CORPORATE SOURCE: Duke University, Durham, NC, USA
SOURCE: Breast Cancer Research and Treatment, (December 2002) Vol.
76, No. Supplement 1, pp. S130. print.
Meeting Info.: 25th Annual San Antonio Breast Cancer
Symposium. San Antonio, TX, USA. December 11-14, 2002.
ISSN: 0167-6806 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 6 Feb 2003
Last Updated on STN: 6 Feb 2003

CONCEPT CODE: General biology - Symposia, transactions and proceedings
00520
Biochemistry studies - General 10060
Pathology - Therapy 12512
Reproductive system - Physiology and biochemistry 16504
Reproductive system - Pathology 16506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic
effects 24004
Neoplasms - Therapeutic agents and therapy 24008

INDEX TERMS: Major Concepts
Pharmacology; Reproductive System (Reproduction); Tumor
Biology

INDEX TERMS: Diseases
breast cancer: neoplastic disease, reproductive system
disease/female
Breast Neoplasms (MeSH)

INDEX TERMS: Chemicals & Biochemicals
GW572016: antineoplastic-drug, tyrosine kinase
inhibitor, epidermal growth factor receptor/Her-2 small

INDEX TERMS: molecule; tamoxifen: antineoplastic-drug; EGFR/Her-2
[epidermal growth factor receptor/Her-2]: drug target
Miscellaneous Descriptors
tamoxifen resistant tumor xenograft: regression, growth
delay

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
MCF-7 cell line (cell line): human breast cancer cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates,
Vertebrates

ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common): nude
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates,
Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: ~~231277-92-2~~ (GW572016)
10540-29-1 (tamoxifen)

=> fil reg; s 231277-92-2

~~FILE IN REGISTRY~~ ENTERED AT 10:35:50 ON 21 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2003 HIGHEST RN 607332-91-2

DICTIONARY FILE UPDATES: 20 OCT 2003 HIGHEST RN 607332-91-2

TSCA INFORMATION.NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L42 1 231277-92-2
(231277-92-2/RN)

=> d ide


L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN

RN ~~231277-92-2~~ REGISTRY

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN GW 572016
FS 3D CONCORD
MF C29 H26 Cl F N4 O4 S
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, SYNTHLINE, TOXCENTER, USPATFULL



*Structure
for Biosis hit RN*

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil medl; d que 127

FILE--'MEDLINE' ENTERED AT 10:36:17 ON 21 OCT 2003

FILE LAST UPDATED: 18 OCT 2003 (20031018/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 1462317 SEA FILE=MEDLINE ABB=ON C4./CT = *Neoplasms*
L21 18675 SEA FILE=MEDLINE ABB=ON PROTEIN-TYROSINE KINASE/CT
L26 524 SEA FILE=MEDLINE ABB=ON (KINASE# (L)ACTIVIT?(L)ASSOCIAT?)/TI
L27 13 SEA FILE=MEDLINE ABB=ON L19/MAJ AND L21/MAJ AND L26

=> d iall 127 1,3,5,10,11,13

L27 ANSWER 1 OF 13 MEDLINE on STN
ACCESSION NUMBER: 2003402758 MEDLINE
DOCUMENT NUMBER: 22822099 PubMed ID: 12941830
TITLE: C-SRC tyrosine **kinase activity** is
associated with tumor colonization in bone and lung
in an animal model of human breast cancer metastasis.
AUTHOR: Myoui Akira; Nishimura Riko; Williams Paul J; Hiraga Toru;
Tamura Daisuke; Michigami Toshimi; Mundy Gregory R; Yoneda
Toshiyuki
CORPORATE SOURCE: Osaka University, Graduate School of Medicine, Department
of Orthopaedics, Suita, Osaka 565-0871, Japan.
CONTRACT NUMBER: P01-CA40035 (NCI)
R01-AR28149 (NIAMS)
R01-DK45229 (NIDDK)
SOURCE: CANCER RESEARCH, (2003 Aug 15) 63 (16) 5028-33.
Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030828
Last Updated on STN: 20030925
Entered Medline: 20030924

ABSTRACT:

The proto-oncogene, c-src, has been implicated in the tumorigenesis in breast cancer. However, the relationship of c-src with distant metastasis is unclear. Moreover, the role of c-src in organ-preferential metastasis of breast cancer is unknown. Because breast cancer has a strong predilection for metastasizing to bone, we examined the role of c-src in bone metastases using an animal model in which inoculation of the MDA-231 human breast cancer cells into the left cardiac ventricle preferentially developed osteolytic bone metastases in female nude mice. A clone of the MDA-231 with the increased capacity of bone metastasis exhibited elevated c-src tyrosine kinase (TK) activity compared with parental cells. MDAsrc527 cells caused significantly increased size of the osteolytic bone metastases with increased number of osteoclasts and mitotic cancer cells compared with MDA-231EV or MDAsrcWT. In contrast, MDAsrc295 cells caused impaired metastases to bone. Of note, mice inoculated with MDAsrc295 cells via tail vein developed reduced lung metastases and prolonged survival

compared with mice with MDA-231EV cells, suggesting that c-src TK is unlikely to play a specific role in bone metastases. The growth in vitro and in vivo and production of parathyroid hormone-related protein, a key cytokine in the pathogenesis of osteolytic bone metastases in breast cancer, were promoted in MDAsrc527 and diminished in MDAsrc295. These results suggest that c-src TK is associated with the capacity of breast cancer to metastasize to bone through regulating cell growth and parathyroid hormone-related protein production. Our results together with the fact that c-src is an essential molecule for bone resorption by osteoclasts, which are central players in osteolytic bone metastases, support the notion that c-src TK is a potential target molecule for designing novel therapeutic interventions, especially for bone metastases in breast cancer.

CONTROLLED TERM: Check Tags: Animal; Female; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Bone Neoplasms: PA, pathology

*Bone Neoplasms: SC, secondary

Bone Resorption: ET, etiology

Breast Neoplasms: EN, enzymology

*Breast Neoplasms: PA, pathology

Cell Division

Lung Neoplasms: PA, pathology

*Lung Neoplasms: SC, secondary

Mice

Osteoclasts: PH, physiology

Peptide Hormones: BI, biosynthesis

Peptide Hormones: GE, genetics

*Protein-Tyrosine Kinase: PH, physiology

Transfection

CHEMICAL NAME: 0 (Peptide Hormones); 0 (parathyroid hormone-related protein); EC 2.7.1.- (protein-tyrosine kinase c-src); EC 2.7.1.112 (Protein-Tyrosine Kinase)

L27 ANSWER 3 OF 13

MEDLINE on STN

ACCESSION NUMBER: 96239091 MEDLINE

DOCUMENT NUMBER: 96239091 PubMed ID: 8670046

TITLE: A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine **kinase activity** associated with multiple endocrine neoplasia type 2A and 2B.

AUTHOR: Cosma M P; Panariello L; Quadro L; Dathan N A; Fattoruso O; Colantuoni V

CORPORATE SOURCE: Dipartimento di Biochimica e Biotecnologie Mediche, CEINGE, Centro de Ingegneria Genetica, Universita degli Studi di Napoli 'Federico II', Naples, Italy.

SOURCE: BIOCHEMICAL JOURNAL, (1996 Mar 1) 314 (Pt 2) 397-400.

Journal code: 2984726R. ISSN: 0264-6021.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199608

ENTRY DATE: Entered STN: 19960819

Last Updated on STN: 20000303

Entered Medline: 19960805

ABSTRACT:

We demonstrate that a Hirschsprung (HSCR) mutation in the tyrosine kinase domain of the RET proto-oncogene abolishes in cis the tyrosine-phosphorylation associated with the activating mutation in multiple endocrine neoplasia type 2A (MEN2A) in transiently transfected Cos cells. Yet the double mutant RET2AHS retains the ability to form stable dimers, thus dissociating the dimerization from the phosphorylation potential. Co-transfection experiments with single and double mutants carrying plasmids RET2A and RET2AHS in different ratios drastically reduced the phosphorylation levels of the RET2A protein, suggesting

a dominant-negative effect of the HSCR mutation. Also, the phosphorylation associated with the multiple endocrine neoplasia type 2B (MEN2B) allele was affected in experiments with single and double mutants carrying plasmids co-transfected under the same conditions. Finally, analysis of the enzymic activity of MEN2A and MEN2B tumours confirmed the relative levels of tyrosine phosphorylation observed in Cos cells, indicating that this condition, in vivo, may account for the RET transforming potential.

CONTROLLED TERM: Check Tags: Animal; Support, Non-U.S. Gov't

Base Sequence

Cell Line

Enzyme Activation

*Hirschsprung Disease: GE, genetics

Molecular Sequence Data

*Multiple Endocrine Neoplasia Type 2a: EN, enzymology

Multiple Endocrine Neoplasia Type 2a: GE, genetics

*Multiple Endocrine Neoplasia Type 2b: EN, enzymology

Multiple Endocrine Neoplasia Type 2b: GE, genetics

Mutation

Oligodeoxyribonucleotides

Phosphorylation

*Protein-Tyrosine Kinase: ME, metabolism

*Proto-Oncogene Proteins: GE, genetics

*Receptor Protein-Tyrosine Kinases: GE, genetics

CHEMICAL NAME: 0 (Oligodeoxyribonucleotides); 0 (Proto-Oncogene Proteins); 0 (proto-oncogene proteins ret); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor Protein-Tyrosine Kinases); EC 2.7.1.112 (Ret oncogene protein, Drosophila)

L27 ANSWER 5 OF 13

MEDLINE on STN

ACCESSION NUMBER: 92138090 MEDLINE

DOCUMENT NUMBER: 92138090 PubMed ID: 1310491

TITLE: Enhanced insulin-receptor tyrosine kinase activity associated with chromosomal

translocation (1;19) in a pre-B-cell leukemia line.

AUTHOR: Newman J D; Harrison L C; Eckardt G S; Jack I

CORPORATE SOURCE: Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Victoria; Australia.

SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1992 Feb 1) 50 (3) 500-4. Journal code: 0042124. ISSN: 0020-7136.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199203

ENTRY DATE: Entered STN: 19920329

Last Updated on STN: 20000303

Entered Medline: 19920306

ABSTRACT:

The gene for the insulin receptor has been assigned to chromosome 19 near the breakpoint of the translocation t(1;19) which occurs in 25% of pre-B-cell leukemias. Insulin receptors in a pre-B-cell leukemia cell line (ACV) with t(1;19) were found to have 2-fold higher affinity for insulin, 5-fold higher basal and insulin-stimulated beta sub-unit autophosphorylation, and 2-fold higher basal and 4-fold higher insulin-stimulated beta sub-unit kinase activity on the synthetic peptide poly(Glu,Tyr), compared to receptors in a B-cell line (ADD) with normal karyotype from the same patient. ACV cells had a novel 13-kb receptor mRNA species and expressed a DNA polymorphism localized to the tyrosine kinase domain of the receptor gene. These findings suggest that t(1;19) in the ACV cell may result in rearrangement of the insulin receptor

gene and translation of a receptor with enhanced tyrosine kinase activity.

CONTROLLED TERM: Check Tags: Human; In Vitro; Support, Non-U.S. Gov't
Blotting, Northern
Blotting, Southern
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 19
DNA, Neoplasm: GE, genetics
Gene Expression
Insulin: ME, metabolism
*Leukemia, Pre-B-Cell: GE, genetics
*Protein-Tyrosine Kinase: GE, genetics
Protein-Tyrosine Kinase: ME, metabolism
RNA, Messenger: GE, genetics
RNA, Neoplasm: GE, genetics
Receptor, Insulin: ME, metabolism
Translocation (Genetics)
Tumor Cells, Cultured
CAS REGISTRY NO.: 11061-68-0 (Insulin)
CHEMICAL NAME: 0 (DNA, Neoplasm); 0 (RNA, Messenger); 0 (RNA, Neoplasm);
EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112
(Receptor, Insulin)

L27 ANSWER 10 OF 13 MEDLINE on STN
ACCESSION NUMBER: 88139522 MEDLINE
DOCUMENT NUMBER: 88139522 PubMed ID: 3343288
TITLE: Identification and characterization of tyrosine
kinase activity associated with
mitochondrial outer membrane in sarcoma 180 cells.
AUTHOR: Piedimonte G; Chamaret S; Dauguet C; Borghetti A F;
Montagnier L
CORPORATE SOURCE: Istituto di Patologia Generale, Universita di Parma, Italy.
SOURCE: JOURNAL OF CELLULAR BIOCHEMISTRY, (1988 Jan) 36 (1) 91-102.
Journal code: 8205768. ISSN: 0730-2312.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198804
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19880406

ABSTRACT:

Tyrosine protein kinase activity has been detected in the mitochondrial fraction purified from sarcoma 180 tumor cells. Following hypotonic disruption of mitochondria, tyrosine kinase activity appeared to cosediment with monamine oxidase, marker enzyme of mitochondrial outer membrane; meanwhile, serine and threonine kinases were found to be associated with the inner membrane and matrix of mitochondria. Mitochondrial tyrosine kinase(s) showed thermosensitivity and Mn²⁺ dependence, useful properties for its characterization and separation from tyrosine kinases associated with other particulate fraction and from serine and threonine kinases associated with mitochondria. Following in vitro incubation of mitochondria with labelled ATP as substrate and analysis by PAGE, a complex pattern of phosphotyrosine containing proteins with a major band of 50-55 kilodaltons resulted.

CONTROLLED TERM: Check Tags: Animal; Female; Support, Non-U.S. Gov't
Kinetics
Manganese: PD, pharmacology
Mice
Mice, Inbred BALB C
*Mitochondria: EN, enzymology
Molecular Weight
Protein Kinases: AN, analysis
*Protein-Tyrosine Kinase: IP, isolation &

purification***Sarcoma 180: EN, enzymology**

Temperature

Vanadates: PD, pharmacology

CAS REGISTRY NO.: 7439-96-5 (Manganese)

CHEMICAL NAME: 0 (Vanadates); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.37 (Protein Kinases)

L27 ANSWER 11 OF 13

MEDLINE on STN

ACCESSION NUMBER: 87289689 MEDLINE

DOCUMENT NUMBER: 87289689 PubMed ID: 3112775

TITLE: Reduced tyrosine **kinase** specific **activity** is **associated** with hypophosphorylation of pp60c-src in cells infected with avian erythroblastosis virus.

AUTHOR: McCarley D J; Parsons S J

CONTRACT NUMBER: CA29243 (NCI)

CA39438 (NCI)

SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1987 Aug) 84 (16) 5793-7.
Journal code: 7505876. ISSN: 0027-8424.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198709

ENTRY DATE: Entered STN: 19900305

Last Updated on STN: 20000303

Entered Medline: 19870918

ABSTRACT:

Avian erythroblastosis virus (AEV) is a replication-defective retrovirus that causes erythroblastosis and sarcomas in chickens and transforms immature erythroid cells and fibroblasts in culture. AEV encodes two oncogenes, v-erbA and v-erbB, whose products are closely related to the thyroxine receptor and the epidermal growth factor receptor, respectively. Since tyrosine protein kinases have been implicated in the process of normal growth signal transduction, we wished to study the possible consequences of the expression of these mutated, growth-regulating receptor genes on the activity of the cellular tyrosine kinase pp60c-src. A continuous cell line from AEV-infected quail embryo fibroblasts was derived that exhibited a typical transformed phenotype and expressed the viral oncogene products, p75gag-erbA and gp66-68erbB. Using an immune-complex kinase assay, we found that the specific activity of pp60c-src in AEV-transformed quail cells was decreased by a factor of 6-30 relative to that found in uninfected quail cells. A concomitant 50-80% reduction of ³²Pi incorporation into the pp60c-src protein from radiolabeled, transformed cells was also observed, indicating a relationship between hypophosphorylation and diminished enzyme activity. Partial proteolytic phosphopeptide analysis revealed a decrease in phosphorylation of both serine- and tyrosine-containing peptides, suggesting an activation of specific phosphatases or inhibition of specific kinases in the AEV-transformed quail cells. Similar results were found in pp60c-src precipitated from AEV-transformed chicken and rat cells.

CONTROLLED TERM: Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

***Avian Leukosis: EN, enzymology**

Chickens

Coturnix

Erythroblastosis Virus, Avian

Gene Expression Regulation

Oncogene Protein pp60(v-src)

Oncogenes

Peptide Mapping

Phosphorylation

*Protein-Tyrosine Kinase: ME, metabolism
Rats
*Retroviridae Proteins: ME, metabolism
Serine: AN, analysis
Tyrosine: AN, analysis
CAS REGISTRY NO.: 55520-40-6 (Tyrosine); 56-45-1 (Serine)
CHEMICAL NAME: 0 (Retroviridae Proteins); EC 2.7.1.112 (Oncogene Protein
pp60(v-src)); EC 2.7.1.112 (Protein-Tyrosine Kinase)

L27 ANSWER 13 OF 13 MEDLINE on STN
ACCESSION NUMBER: 86042648 MEDLINE
DOCUMENT NUMBER: 86042648 PubMed ID: 2414774
TITLE: Increased pp60c-src tyrosyl kinase
activity in human neuroblastomas is
associated with amino-terminal tyrosine
phosphorylation of the src gene product.
AUTHOR: Bolen J B; Rosen N; Israel M A
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE
UNITED STATES OF AMERICA, (1985 Nov) 82 (21) 7275-9.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198512
ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19851205

ABSTRACT:

We have observed a 20- to 40-fold increase in pp60c-src tyrosyl kinase activity in human neuroblastoma cell lines over that found in either human glioblastoma cells or human fibroblasts. The level of c-src gene transcripts and pp60c-src protein synthesis in the neuroblastoma cells was not significantly increased when compared to the levels found in glioblastoma cells. Approximately one-half of the pp60c-src molecules synthesized during a 4-hr [35S]methionine or [32P]orthophosphate labeling period in neuroblastoma cells were found to migrate more slowly on NaDodSO4/polyacrylamide gels than pp60c-src molecules labeled in glioblastoma cells. Peptide and phosphoamino acid analysis of the in vivo phosphorylated c-src molecules from these two cell types revealed that pp60c-src molecules from the neuroblastoma cells possess in the amino-terminal portion of the protein at least one unique tyrosine phosphorylation site not found in pp60c-src derived from glioblastoma cells.

CONTROLLED TERM: Check Tags: Comparative Study; Human
Cell Line
Fibroblasts: EN, enzymology
Glioma: EN, enzymology
*Neoplasm Proteins: ME, metabolism
*Neuroblastoma: EN, enzymology
Phosphorylation
Phosphotyrosine
*Protein-Tyrosine Kinase: ME, metabolism
Proto-Oncogene Protein pp60(c-src)
*Proto-Oncogene Proteins: ME, metabolism
Transcription, Genetic
Tyrosine: AA, analogs & derivatives
Tyrosine: AN, analysis
CAS REGISTRY NO.: 21820-51-9 (Phosphotyrosine); 55520-40-6 (Tyrosine)
CHEMICAL NAME: 0 (Neoplasm Proteins); 0 (Proto-Oncogene Proteins); EC
2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112
(Proto-Oncogene Protein pp60(c-src))

=> d que 132

L19 1462317 SEA FILE=MEDLINE ABB=ON C4./CT
L21 18675 SEA FILE=MEDLINE ABB=ON PROTEIN-TYROSINE KINASE/CT
L22 1348 SEA FILE=MEDLINE ABB=ON L21/MAJ AND L19/MAJ
L23 36242 SEA FILE=MEDLINE ABB=ON L19(L)EN/CT
L30 967070 SEA FILE=MEDLINE ABB=ON GENERAL REVIEW/DT
L31 171 SEA FILE=MEDLINE ABB=ON L22 AND L30
L32 38 SEA FILE=MEDLINE ABB=ON L23 AND L31

=> d iall 132 38,4,7,11,16,18,21,22,24,27,29,30,32

L32 ANSWER 38 OF 38 MEDLINE on STN
ACCESSION NUMBER: 87228416 MEDLINE
DOCUMENT NUMBER: 87228416 PubMed ID: 3035350
TITLE: Leukaemogenesis: a postulated mechanism involving tyrosine
protein kinase and DNA topoisomerase.
AUTHOR: Francis G E
SOURCE: MEDICAL HYPOTHESES, (1987 Mar) 22 (3) 223-35. Ref: 66
Journal code: 7505668. ISSN: 0306-9877.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198707
ENTRY DATE: Entered STN: 19900305
Last Updated on STN: 19900305
Entered Medline: 19870708

ABSTRACT:

The weight of available evidence suggests that leukaemogenesis is a multi-step, complex process. Since there are different types of leukaemia, it seems likely that a variety of distinct molecular mechanisms are involved, arising from different combinations of genetic defects. It is not therefore surprising that studies at genetic, karyotypic, biochemical, cellular and clinical levels all reveal considerable heterogeneity of abnormalities. An attempt to define associations between abnormalities at these different levels in the myeloid leukaemias, led to a new hypothesis which provides a link between activation of the tyrosine kinase group of oncogenes and two components of multi-step leukaemogenesis: reduced differentiation and the tendency for acquisition of further genetic changes.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
Cell Transformation, Neoplastic
DNA: ME, metabolism
*DNA Topoisomerases, Type I: ME, metabolism
***Leukemia, Myeloid: EN, enzymology**
Leukemia, Myeloid: ET, etiology
Oncogenes
***Protein-Tyrosine Kinase: ME, metabolism**
Proto-Oncogenes
CAS REGISTRY NO.: 9007-49-2 (DNA)
CHEMICAL NAME: EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 5.99.1.2 (DNA
Topoisomerases, Type I)

L32 ANSWER 4 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2003021773 MEDLINE
DOCUMENT NUMBER: 22416102 PubMed ID: 12528768
TITLE: Tyrosine kinases as targets for cancer therapy.
AUTHOR: Levitzki Alexander
CORPORATE SOURCE: Unit of Cellular Signaling, Department of Biological
Chemistry, The Silverman Institute for Life Sciences, The
Hebrew University of Jerusalem, Jerusalem 91904, Israel..
levitzki@vms.huji.ac.il
SOURCE: EUROPEAN JOURNAL OF CANCER, (2002 Sep) 38 Suppl 5 S11-8.

Ref: 52

Journal code: 9005373. ISSN: 0959-8049.

PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200302

ENTRY DATE: Entered STN: 20030117

Last Updated on STN: 20030228

Entered Medline: 20030227

ABSTRACT:

Enhanced protein tyrosine kinase (PTK) activity correlates with the development of cancer and other proliferative diseases. The hypothesis that PTK inhibitors may be of value in the treatment of cancer led to the systematic synthesis of selective tyrosine phosphorylation inhibitors (tyrphostins) that show in vitro and in vivo anticancer activity. This review will provide an overview of research efforts in the development of tyrphostins such as AG 957, AG 1112, and AG 1318. Other tyrphostins discussed are AG 1478 and RG 13022, which are both epidermal growth factor receptor kinase inhibitors; AG 490, a Jak-2 kinase inhibitor; AG 1296, a PDGFR kinase inhibitor; and STI 571 (imatinib, Glivec/Gleevec; Novartis Pharma AG, Basel, Switzerland). STI 571 is now approved for the treatment of chronic myeloid leukemia and shows activity against gastrointestinal stromal tumors. The chemistry, kinetics, biological activity, and clinical potential of these compounds will be discussed.

CONTROLLED TERM: Check Tags: Human

Antineoplastic Agents: CH, chemistry

Antineoplastic Agents: PK, pharmacokinetics

*Antineoplastic Agents: TU, therapeutic use

Drug Design

Enzyme Inhibitors: CH, chemistry

Enzyme Inhibitors: PK, pharmacokinetics

*Enzyme Inhibitors: TU, therapeutic use

*Neoplasm Proteins: AI, antagonists & inhibitors

*Neoplasms: DT, drug therapy

Neoplasms: EN, enzymology

*Protein-Tyrosine Kinase: AI, antagonists & inhibitors

Tyrphostins: CH, chemistry

Tyrphostins: PK, pharmacokinetics

*Tyrphostins: TU, therapeutic use

CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); 0 (Neoplasm Proteins); 0 (Tyrphostins); EC 2.7.1.112 (Protein-Tyrosine Kinase)

L32 ANSWER 7 OF 38

MEDLINE on STN

ACCESSION NUMBER: 2002656459 MEDLINE

DOCUMENT NUMBER: 22303793 PubMed ID: 12415815

TITLE: Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.

AUTHOR: Van Zandwijk Nico; Baas Paul

CORPORATE SOURCE: Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

SOURCE: Suppl Tumori, (2002 Jul-Aug) 1 (4) S37-8. Ref: 13
Journal code: 101153052.

PUB. COUNTRY: Italy

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200211
ENTRY DATE: Entered STN: 20021106
Last Updated on STN: 20021211
Entered Medline: 20021121
CONTROLLED TERM: Check Tags: Female; Human; Male
Adult
Aged
*Antineoplastic Agents: TU, therapeutic use
*Carcinoma, Non-Small-Cell Lung: DT, drug therapy
Carcinoma, Non-Small-Cell Lung: EN, enzymology
Clinical Trials
*Enzyme Inhibitors: TU, therapeutic use
*Epidermal Growth Factor: AI, antagonists & inhibitors
*Lung Neoplasms: DT, drug therapy
Lung Neoplasms: EN, enzymology
Maximum Tolerated Dose
Middle Age
*Protein-Tyrosine Kinase: AI, antagonists & inhibitors
Quinazolines: TU, therapeutic use
Receptor, erbB-2: AI, antagonists & inhibitors
CAS REGISTRY NO.: 184475-35-2 (Gefitinib); 62229-50-9 (Epidermal Growth Factor)
CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); 0 (Quinazolines); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, erbB-2)

L32 ANSWER 11 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2002344067 MEDLINE
DOCUMENT NUMBER: 22081535 PubMed ID: 12086869
TITLE: Smart drugs: tyrosine kinase inhibitors in cancer therapy.
AUTHOR: Shawver Laura K; Slamon Dennis; Ullrich Axel
CORPORATE SOURCE: SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080, USA.
SOURCE: Cancer Cell, (2002 Mar) 1 (2) 117-23. Ref: 61
Journal code: 101130617. ISSN: 1535-6108.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200208
ENTRY DATE: Entered STN: 20020628
Last Updated on STN: 20020814
Entered Medline: 20020813

ABSTRACT:

Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development.

CONTROLLED TERM: Check Tags: Animal; Human
Angiogenesis Inhibitors: AD, administration & dosage
Angiogenesis Inhibitors: TU, therapeutic use

Antineoplastic Agents: AD, administration & dosage
*Antineoplastic Agents: TU, therapeutic use
Drug Delivery Systems
Enzyme Inhibitors: AD, administration & dosage
*Enzyme Inhibitors: TU, therapeutic use
Neoplasms: BS, blood supply
*Neoplasms: DT, drug therapy
*Neoplasms: EN, enzymology
Neovascularization, Pathologic
*Protein-Tyrosine Kinase: AI, antagonists & inhibitors
Protein-Tyrosine Kinase: ME, metabolism
Receptor Protein-Tyrosine Kinases: AI, antagonists & inhibitors
Receptor Protein-Tyrosine Kinases: ME, metabolism
Receptor, Epidermal Growth Factor: AI, antagonists & inhibitors
Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, erbB-2: AI, antagonists & inhibitors
Receptor, erbB-2: ME, metabolism
Receptors, Growth Factor: AI, antagonists & inhibitors
Receptors, Growth Factor: ME, metabolism
Receptors, Vascular Endothelial Growth Factor
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); 0 (Receptors, Growth Factor); EC 2.7.1.- (Bcr-Abl tyrosine kinase); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor Protein-Tyrosine Kinases); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptors, Vascular Endothelial Growth Factor)

L32 ANSWER 16 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2002064879 MEDLINE
DOCUMENT NUMBER: 21650420 PubMed ID: 11790564
TITLE: Rational therapeutic intervention in cancer: kinases as drug targets.
AUTHOR: Sawyers Charles L
CORPORATE SOURCE: 11-934 Factor Building, University of California, Los Angeles Division of Hematology and Oncology, 10833 Le Conte Avenue, Los Angeles, California 90095-1678, USA..
csawyers@mednet.ucla.edu
SOURCE: CURRENT OPINION IN GENETICS AND DEVELOPMENT, (2002 Feb) 12 (1) 111-5. Ref: 37
Journal code: 9111375. ISSN: 0959-437X.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200204
ENTRY DATE: Entered STN: 20020125
Last Updated on STN: 20020412
Entered Medline: 20020411

ABSTRACT:
Landmark clinical studies of new drugs developed to target specific forms of cancer were reported in 2001. Herceptin, a monoclonal antibody against the Her2/neu receptor tyrosine kinase, prolonged the survival of women with Her-2/neu positive metastatic breast cancer, when combined with chemotherapy. STI-571, a small molecule inhibitor of the Bcr-Abl, c-kit and platelet derived growth factor receptor tyrosine kinases, produced dramatic clinical responses in patients with Bcr-Abl positive chronic myeloid leukemia and c-kit positive

gastrointestinal stromal tumors. These examples have galvanized the cancer research community to extend kinase-inhibitor therapy to other cancers.

CONTROLLED TERM: Check Tags: Animal; Female; Human
Antibodies, Monoclonal: TU, therapeutic use
*Antineoplastic Agents: TU, therapeutic use
Breast Neoplasms: DT, drug therapy
Clinical Trials
Drug Delivery Systems
Enzyme Inhibitors: TU, therapeutic use
Mutation
*Neoplasms: DT, drug therapy
Neoplasms: EN, enzymology
Neoplasms: GE, genetics
*Protein-Tyrosine Kinase: AI, antagonists & inhibitors
Receptor, erbB-2: AI, antagonists & inhibitors
CHEMICAL NAME: 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, erbB-2)

L32 ANSWER 18 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2001289792 MEDLINE
DOCUMENT NUMBER: 21256220 PubMed ID: 11357143
TITLE: Oncogenic kinase signalling.
AUTHOR: Blume-Jensen P; Hunter T
CORPORATE SOURCE: The Salk Institute, Molecular and Cell Biology Laboratory, 10010 North Torrey Pines Road, La Jolla, California 92037, USA.. blume@salk.edu
SOURCE: NATURE, (2001 May 17) 411 (6835) 355-65. Ref: 93
Journal code: 0410462. ISSN: 0028-0836.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200106
ENTRY DATE: Entered STN: 20010625
Last Updated on STN: 20010625
Entered Medline: 20010621

ABSTRACT:

Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans. Their activity is normally tightly controlled and regulated. Perturbation of PTK signalling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation. The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signalling. This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signalling in human malignancies.

CONTROLLED TERM: Check Tags: Animal; Human; Support, Non-U.S. Gov't
1-Phosphatidylinositol 3-Kinase: GE, genetics
1-Phosphatidylinositol 3-Kinase: ME, metabolism
Mutation: GE, genetics
*Neoplasms: EN, enzymology
Neoplasms: GE, genetics
Neoplasms: ME, metabolism
Neoplasms: PA, pathology
Oncogene Proteins: AI, antagonists & inhibitors

Oncogene Proteins: GE, genetics
*Oncogene Proteins: ME, metabolism
Oncogenes: GE, genetics
Protein-Tyrosine Kinase: AI, antagonists & inhibitors
Protein-Tyrosine Kinase: GE, genetics
*Protein-Tyrosine Kinase: ME, metabolism
Receptor Protein-Tyrosine Kinases: GE, genetics
Receptor Protein-Tyrosine Kinases: ME, metabolism
Retroviridae Proteins, Oncogenic: GE, genetics
Retroviridae Proteins, Oncogenic: ME, metabolism
Ribosomal Protein S6 Kinases: GE, genetics
Ribosomal Protein S6 Kinases: ME, metabolism
*Signal Transduction
CHEMICAL NAME: 0 (Oncogene Proteins); 0 (Retroviridae Proteins, Oncogenic); 0 (oncogene protein akt); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor Protein-Tyrosine Kinases); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.1.37 (Ribosomal Protein S6 Kinases)

L32 ANSWER 21 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2001143495 MEDLINE
DOCUMENT NUMBER: 20544509 PubMed ID: 11095400
TITLE: Protein tyrosine kinases in malignant melanoma.
AUTHOR: Easty D J; Bennett D C
CORPORATE SOURCE: Department of Pathology, University College Dublin, Ireland.. david.easty@ucd.ie
SOURCE: MELANOMA RESEARCH, (2000 Oct) 10 (5) 401-11. Ref: 123
Journal code: 9109623. ISSN: 0960-8931.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200103
ENTRY DATE: Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010308

ABSTRACT:

Protein tyrosyl phosphorylation is an essential component in intracellular signalling, with diverse and crucial functions including mediation of cell proliferation, survival, death, differentiation, migration and attachment. It is regulated by the balance between the activities of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases. A number of PTKs are encoded by proto-oncogenes or viral oncogenes, and are thus strongly implicated in cancer. While a role for PTKs in human melanoma is less firmly established, human melanomas or melanoma cells have been reported to contain more tyrosine phosphate than normal melanocytes, and some receptor PTKs (EPH-A2/ ECK and EPH-B3) are overexpressed in over 90% of melanoma cell lines. Other specific PTKs are also frequently overexpressed, including KDR and fibroblast growth factor receptor-4 (FGF-R4), while, interestingly, yet others, such as KIT and FES, are consistently downregulated in melanoma cell lines. All of these differentially expressed PTKs are candidates for gene products important in melanoma development. In addition, PTKs expressed in significant amounts in both benign and malignant melanocytes, such as insulin-like growth factor-1 receptor (IGF1-R), FGF-R1, HER2/NEU and FAK, are likely to play a role in melanoma genesis and progression.

CONTROLLED TERM: Check Tags: Animal; Human; Support, Non-U.S. Gov't
Melanocytes: EN, enzymology
*Melanoma: EN, enzymology
Melanoma: GE, genetics

Oncogenes

Protein-Tyrosine Kinase: GE, genetics***Protein-Tyrosine Kinase: ME, metabolism**

Protein-Tyrosine-Phosphatase: ME, metabolism

Proto-Oncogenes

Tumor Cells, Cultured

CHEMICAL NAME: EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 3.1.3.48
(Protein-Tyrosine-Phosphatase)

L32 ANSWER 22 OF 38 MEDLINE on STN
ACCESSION NUMBER: 2001078169 MEDLINE
DOCUMENT NUMBER: 20567288 PubMed ID: 11114748
TITLE: Tyrosine kinases and gastric cancer.
AUTHOR: Lin W; Kao H W; Robinson D; Kung H J; Wu C W; Chen H C
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica, Taipei
115, Taiwan, Republic of China.
SOURCE: ONCOGENE, (2000 Nov 20) 19 (49) 5680-9. Ref: 163
Journal code: 8711562. ISSN: 0950-9232.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010111

ABSTRACT:

Carcinoma of the stomach is one of the most prevalent cancer types in the world today. Two major forms of gastric cancer are distinguished according to their morphological and clinicopathological classifications (well differentiated/intestinal type and poorly differentiated/diffuse type), characteristics that could also be attributed to the altered expression of different types of oncogenes or tumor suppressor genes. Significant differences exist for gastric cancer incidence comparing people of different ethnic origins, implicating various genetic and epigenetic factors for gastric oncogenesis. There are only a limited number of molecular markers available for gastric cancer detection and prognostic evaluation, among which are tyrosine kinases. There is convincing evidence that tyrosine kinases are involved in oncogenesis and disease progression for many human cancers. Amplifications of certain tyrosine kinases (c-met, k-sam and erbB2/neu) have been associated with human gastric cancer progression. Alternatively spliced transcripts and enhanced protein-expression levels for some of these tyrosine kinases are correlated with clinical outcomes for gastric cancer patients. With advent of high throughput techniques, it is now possible to detect nearly all expressed tyrosine kinases in a single screen. This increases the chance to identify additional tyrosine kinases as predictive markers for gastric cancers. In this article, we will first review the literature data concerning certain tyrosine kinases implicated in gastric carcinogenesis and then summarize more recent work which provide comprehensive tyrosine kinase profiles for gastric cancer specimens and cell lines. Two new gastric cancer molecular markers (tie-1 and mkk4) have been identified through the use of these profiles and demonstrated effective as clinical prognostic indicators.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Protein-Tyrosine Kinase: ME, metabolism**Stomach Neoplasms: EN, enzymology****Stomach Neoplasms: GE, genetics**

CHEMICAL NAME: EC 2.7.1.112 (Protein-Tyrosine Kinase)

L32 ANSWER 24 OF 38 MEDLINE on STN
ACCESSION NUMBER: 1999214938 MEDLINE

DOCUMENT NUMBER: 99214938 PubMed ID: 10198725
TITLE: Tyrosine kinase inhibitors in chronic myeloid leukemia.
AUTHOR: Sawyers C L; Druker B
CORPORATE SOURCE: Department of Medicine and Molecular Biology Institute,
University of California Los Angeles, USA.
SOURCE: CANCER JOURNAL FROM SCIENTIFIC AMERICAN, (1999 Mar-Apr) 5
(2) 63-9. Ref: 66
Journal code: 9513568. ISSN: 1081-4442.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199906
ENTRY DATE: Entered STN: 19990614
Last Updated on STN: 19990614
Entered Medline: 19990603

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
Antineoplastic Agents: TU, therapeutic use
Bone Marrow Transplantation
Clinical Trials
*Enzyme Inhibitors: TU, therapeutic use
Interferons: TU, therapeutic use
*Leukemia, Myeloid, Chronic: DT, drug therapy
*Leukemia, Myeloid, Chronic: EN, enzymology
Leukemia, Myeloid, Chronic: TH, therapy
*Protein-Tyrosine Kinase: AI, antagonists &
inhibitors

CAS REGISTRY NO.: 9008-11-1 (Interferons)
CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); EC
2.7.1.112 (Protein-Tyrosine Kinase)

L32 ANSWER 27 OF 38 MEDLINE on STN
ACCESSION NUMBER: 1998324442 MEDLINE
DOCUMENT NUMBER: 98324442 PubMed ID: 9662065
TITLE: Molecular profiling of tyrosine kinases in normal and
cancer cells.
AUTHOR: Kung H J; Chen H C; Robinson D
CORPORATE SOURCE: Molecular and Genomic Medicine Division, National Health
Research Institutes, Taipei, Taiwan, ROC.
CONTRACT NUMBER: CA 39207 (NCI)
CA 57179 (NCI)
DK 52659 (NIDDK)
SOURCE: JOURNAL OF BIOMEDICAL SCIENCE, (1998) 5 (2) 74-8. Ref: 25
Journal code: 9421567. ISSN: 1021-7770.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199809
ENTRY DATE: Entered STN: 19980925
Last Updated on STN: 19980925
Entered Medline: 19980916

ABSTRACT:

As the post-genome era is approaching, with vast amount of sequence information available and new technology developed, scientists are presented with opportunities to explore in simple analysis the structure and expression pattern of not just a single gene, but of an entire family of genes, if not the entire genome. The concept of 'molecular profiling' or 'expression array' has thus emerged. The need to simultaneously 'see' all genes in the same family is

obvious under the precept of the combinatorial process being an underlying principle of complex biological systems: no gene exists in isolation, for virtually every molecule participates in intermolecular interactions. The activation of receptor tyrosine kinases through homo or hetero-dimerization is the prototypic example. In this review, a tyrosine kinase profile technique and its application to studying the expression of tyrosine kinases and the identification of novel kinases will be discussed. This serves as an introduction to the several interesting papers published in this special 'kinase' issue of the Journal of Biomedical Sciences, using this technique. A new simplified approach, kinase display, which is an extension of the profiling method and requires only restriction digestion and gel analysis will also be introduced.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Gene Expression

Genetic Techniques

***Neoplasms: EN, enzymology**

***Neoplasms: GE, genetics**

Polymerase Chain Reaction

***Protein-Tyrosine Kinase: GE, genetics**

Protein-Tyrosine Kinase: PH, physiology

Signal Transduction

CHEMICAL NAME: EC 2.7.1.112 (Protein-Tyrosine Kinase)

L32 ANSWER 29 OF 38 MEDLINE on STN

ACCESSION NUMBER: 1998086174 MEDLINE

DOCUMENT NUMBER: 98086174 PubMed ID: 9426205

TITLE: Protein tyrosine kinases and cancer.

AUTHOR: Kolibaba K.S; Druker B J

CORPORATE SOURCE: Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA.

SOURCE: BIOCHIMICA ET BIOPHYSICA ACTA, (1997 Dec 9) 1333 (3)

F217-48. Ref: 410

Journal code: 0217513. ISSN: 0006-3002.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199801

ENTRY DATE: Entered STN: 19980130

Last Updated on STN: 20000303

Entered Medline: 19980122

CONTROLLED TERM: Check Tags: Animal; Human

Autocrine Communication

***Cell Transformation, Neoplastic**

DNA-Binding Proteins: PH, physiology

Dimerization

Enzyme Activation

Multiple Endocrine Neoplasia: PP, physiopathology
Mutation

Neoplasms: BS, blood supply

***Neoplasms: EN, enzymology**

Phosphorylation

***Protein-Tyrosine Kinase: PH, physiology**

Proto-Oncogene Proteins: PH, physiology

Proto-Oncogene Proteins c-abl: PH, physiology

Receptor Protein-Tyrosine Kinases: PH, physiology

Receptor, Epidermal Growth Factor: PH, physiology

Receptors, Growth Factor: PH, physiology

Receptors, Platelet-Derived Growth Factor: PH, physiology

Receptors, Vascular Endothelial Growth Factor

Signal Transduction

CHEMICAL NAME: Transcription Factors: PH, physiology
0 (DNA-Binding Proteins); 0 (Proto-Oncogene Proteins); 0
(Receptors, Growth Factor); 0 (Transcription Factors); 0
(proto-oncogene protein bcr); 0 (proto-oncogene proteins
ret); 0 (tel protein); EC 2.7.1.- (anaplastic lymphoma
kinase); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC
2.7.1.112 (Proto-Oncogene Proteins c-abl); EC 2.7.1.112
(Receptor Protein-Tyrosine Kinases); EC 2.7.1.112
(Receptor, Epidermal Growth Factor); EC 2.7.1.112
(Receptors, Platelet-Derived Growth Factor); EC 2.7.1.112
(Receptors, Vascular Endothelial Growth Factor); EC
2.7.1.112 (Ret oncogene protein, Drosophila)

L32 ANSWER 30 OF 38 MEDLINE on STN
ACCESSION NUMBER: 95154546 MEDLINE
DOCUMENT NUMBER: 95154546 PubMed ID: 7851627
TITLE: Tyrosine protein kinase inhibition and cancer.
AUTHOR: Boutin J A
CORPORATE SOURCE: Institut de Recherches SERVIER, Departement de Chimie des
Peptides, Suresnes, France.
SOURCE: INTERNATIONAL JOURNAL OF BIOCHEMISTRY, (1994 Oct-Nov) 26
(10-11) 1203-26. Ref: 216
Journal code: 0250365. ISSN: 0020-711X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199503
ENTRY DATE: Entered STN: 19950322
Last Updated on STN: 19950322
Entered Medline: 19950310

ABSTRACT:

The various aspects of the research on tyrosine protein kinase inhibition and its connections with cancer are presented. The emphasis was made on the theoretical low toxic side effects of specific tyrosine protein kinase inhibitors. Particularly, the strategy of finding peptidic substrate-derived inhibitors or modulators is discussed, with an almost complete compendium of the tyrosine protein kinase peptidic substrates published so far. A series of data has been gathered that may serve as a basis for the discovery of selective and specific tyrosine protein kinase inhibitors by screening on molecular and cellular models. The potential of SH2 domain-interfering agents are also presented as a promising route to new anticancer compounds.

CONTROLLED TERM: Amino Acid Sequence
Molecular Sequence Data
Neoplasms: DT, drug therapy
***Neoplasms: EN, enzymology**
Protease Inhibitors: ME, metabolism
Protease Inhibitors: TU, therapeutic use
***Protein-Tyrosine Kinase: AI, antagonists & inhibitors**
Protein-Tyrosine Kinase: ME, metabolism
Substrate Specificity
CHEMICAL NAME: 0 (Protease Inhibitors); EC 2.7.1.112 (Protein-Tyrosine Kinase)

L32 ANSWER 32 OF 38 MEDLINE on STN
ACCESSION NUMBER: 93279724 MEDLINE
DOCUMENT NUMBER: 93279724 PubMed ID: 8505055
TITLE: Protein-tyrosine kinases, oncogenes, and cancer.
AUTHOR: Parsons J T; Parsons S J

SOURCE: IMPORTANT ADVANCES IN ONCOLOGY, (1993) 3-17. Ref: 149
Journal code: 8505229. ISSN: 0883-5896.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199307

ENTRY DATE: Entered STN: 19930716
Last Updated on STN: 19970203
Entered Medline: 19930708

CONTROLLED TERM: Check Tags: Animal; Human; Support, Non-U.S. Gov't;
Support, U.S. Gov't, P.H.S.
***Neoplasms: EN, enzymology**
***Neoplasms: GE, genetics**
***Oncogenes**
***Protein-Tyrosine Kinase**
Signal Transduction

CHEMICAL NAME: EC 2.7.1.112 (Protein-Tyrosine Kinase)

=> fil.medl; d que 134

FILE 'MEDLINE' ENTERED AT 10:37:01 ON 21 OCT 2003

FILE LAST UPDATED: 18 OCT 2003 (20031018/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 1462317 SEA FILE=MEDLINE ABB=ON C4./CT - *Neoplasms*
L21 18675 SEA FILE=MEDLINE ABB=ON PROTEIN-TYROSINE KINASE/CT
L22 1348 SEA FILE=MEDLINE ABB=ON L21/MAJ AND L19/MAJ
L23 36242 SEA FILE=MEDLINE ABB=ON L19(L)EN/CT *EN = enzymology*
L33 634 SEA FILE=MEDLINE ABB=ON (CERB OR C ERB) (W) B2 OR CERBB2 OR C
ERBB2
L34 4 SEA FILE=MEDLINE ABB=ON L23 AND L22 AND L33

=> diall-134-1-4

L34 ANSWER 1 OF 4 MEDLINE on STN
ACCESSION NUMBER: 97337286 MEDLINE
DOCUMENT NUMBER: 97337286 PubMed ID: 9194028
TITLE: Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells.
AUTHOR: Imaizumi M; Nishimura M; Takeuchi S; Murase M; Hamaguchi M
CORPORATE SOURCE: Department of Thoracic Surgery, Nagoya University School of Medicine, Japan.
SOURCE: LUNG CANCER, (1997 May) 17 (1) 69-84.
Journal code: 8800805. ISSN: 0169-5002.
PUB. COUNTRY: Ireland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199709
ENTRY DATE: Entered STN: 19970922
Last Updated on STN: 20000303
Entered Medline: 19970905

ABSTRACT:

To clarify the role of tyrosine phosphorylation of cellular proteins in human lung cancer cells, phosphotyrosine (PTYR)-containing proteins in lung cancer cell lines and in paired tissues resected from cancerous and normal lungs were studied by immunoblotting with an anti-PTYR antibody. We found that the profiles of protein phosphorylation were very similar among those cell lines which had different histological features. The major PTYR-containing proteins (180-190 KDa, 120-130 KD, and 95-100 KDa) were detected in lung cancer cell lines. The expression of EGF receptor (EGF-r) (p185) and o-erb B2 protein, and tyrosine phosphorylation of p125FAK were examined in cancerous lung tissues and normal lung tissues. In surgical specimens, approximately half of the samples of lung cancer tissues showed clear elevation of tyrosine phosphorylation. In these cancerous tissues, no clear amplification of EGF-r and c-
erb B2 protein expression was observed. However, elevation of tyrosine phosphorylation of p125FAK was observed in cancerous lung tissues but not in normal lung tissues, and its phosphorylation was closely correlated with the nodal involvement of cancer and disease-free survival time. These

results suggested that the intracellular signaling pathway via tyrosine phosphorylation plays a role in the generation and immortalization of lung cancer, and assessment of tyrosine phosphorylation of cellular proteins.

especially p125FAK, may be available clinically as a prognostic factor.

CONTROLLED TERM: Check Tags: Female; Human; Male; Support, Non-U.S. Gov't

Adult

Aged

*Cell Adhesion Molecules: PH, physiology

Epidermal Growth Factor: PD, pharmacology

Fluorescent Antibody Technique, Indirect

Immunohistochemistry

Lung: CH, chemistry

Lung: PA, pathology

Lung Neoplasms: CH, chemistry

Lung Neoplasms: EN, enzymology

*Lung Neoplasms: PA, pathology

Middle Age

Phosphorylation: DE, drug effects

Phosphotyrosine: AN, analysis

*Protein-Tyrosine Kinase: PH, physiology

Proteins: CH, chemistry

*Proteins: PH, physiology

*Receptor, Epidermal Growth Factor: PH, physiology

Receptor, erbB-2: BI, biosynthesis

Survival Rate

Tumor Cells, Cultured

CAS REGISTRY NO.: 21820-51-9 (Phosphotyrosine); 62229-50-9 (Epidermal Growth Factor)

CHEMICAL NAME: 0 (Cell Adhesion Molecules); 0 (Proteins); EC 2.7.1.- (endogenous substrate p120); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2)

L34 ANSWER 2 OF 4

MEDLINE on STN

ACCESSION NUMBER: 94088574 MEDLINE

DOCUMENT NUMBER: 94088574 PubMed ID: 7903421

TITLE: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.

AUTHOR: Muthuswamy S K; Siegel P M; Dankort D L; Webster M A; Muller W J

CORPORATE SOURCE: Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Ontario, Canada.

SOURCE: MOLECULAR AND CELLULAR BIOLOGY, (1994 Jan) 14 (1) 735-43. Journal code: 8109087. ISSN: 0270-7306.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199401

ENTRY DATE: Entered STN: 19940209

Last Updated on STN: 20000303

Entered Medline: 19940121

ABSTRACT:

Amplification and overexpression of the neu (c-erbB2) proto-oncogene has been implicated in the pathogenesis of 20 to 30% of human breast cancers. Although the activation of Neu receptor tyrosine kinase appears to be a pivotal step during mammary tumorigenesis, the mechanism by which Neu signals cell proliferation is unclear. Molecules bearing a domain shared by the c-Src proto-oncogene (Src homology 2) are thought to be involved in signal transduction from activated receptor tyrosine kinases such as Neu. To test whether c-Src was implicated in Neu-mediated signal transduction, we measured the activity of the c-Src tyrosine kinase in tissue extracts from either mammary tumors or adjacent mammary epithelium derived from transgenic

mice expressing a mouse mammary tumor virus promoter/enhancer/unactivated neu fusion gene. The Neu-induced mammary tumors possessed six- to eightfold-higher c-Src kinase activity than the adjacent epithelium. The increase in c-Src tyrosine kinase activity was not due to an increase in the levels of c-Src but rather was a result of the elevation of its specific activity. Moreover, activation of c-Src was correlated with its ability to complex tyrosine-phosphorylated Neu both in vitro and in vivo. Together, these observations suggest that activation of the c-Src tyrosine kinase during mammary tumorigenesis may occur through a direct interaction with activated Neu.

CONTROLLED TERM: Check Tags: Animal; Female; Human; Support, Non-U.S. Gov't

Breast Neoplasms: EN, enzymology

Breast Neoplasms: ET, etiology

Breast Neoplasms: GE, genetics

Enzyme Activation: GE, genetics

Gene Expression

Genes, myc

*Mammary Neoplasms, Experimental: EN, enzymology

Mammary Neoplasms, Experimental: ET, etiology

*Mammary Neoplasms, Experimental: GE, genetics

Mammary Tumor Virus, Mouse: GE, genetics

Mice

Mice, Transgenic

*Protein-Tyrosine Kinase: GE, genetics

Proto-Oncogene Proteins: GE, genetics

Proto-Oncogene Proteins c-myc: GE, genetics

*Proto-Oncogenes

Receptor, Epidermal Growth Factor: GE, genetics

Receptor, erbB-2

Signal Transduction: GE, genetics

Signal Transduction: PH, physiology

CHEMICAL NAME: 0 (Proto-Oncogene Proteins); 0 (Proto-Oncogene Proteins c-myc); EC 2.7.1.- (protein-tyrosine kinase c-src); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2)

GENE NAME: c-Myc; c-Src; neu

L34 ANSWER 3 OF 4 MEDLINE on STN

ACCESSION NUMBER: 93081195 MEDLINE

DOCUMENT NUMBER: 93081195 PubMed ID: 1360230

TITLE: c-erbB2 amplification and overexpression in human tumors.

AUTHOR: Lofts F J; Gullick W J

SOURCE: CANCER TREATMENT AND RESEARCH, (1992) 61 161-79. Ref: 128

Journal code: 8008541. ISSN: 0927-3042.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199301

ENTRY DATE: Entered STN: 19930129

Last Updated on STN: 20000303

Entered Medline: 19930106

ABSTRACT:

There is no evidence for activation of c-erbB2 by mutation in human cancer. Gene rearrangements are observed at low frequency, but there are a proportion of human cancers that are associated with c-***erbB2*** gene amplification and membrane protein overexpression. The human cancers so affected are adenocarcinomas of the breast, ovary, stomach, and bladder, with up to 20% of primary lesions exhibiting either increased gene

copy number and/or excess membrane staining. The **c-erbB2** protein on these tumors could be used as a therapeutic target, as in monoclonal antibody targetted therapy already being assessed in **c-erbB2** positive breast cancer. Other possible therapeutic strategies include the development of tyrosine kinase inhibitors or ligand antagonists.

CONTROLLED TERM: Check Tags: Animal; Human

Adenocarcinoma: EN, enzymology

Adenocarcinoma: GE, genetics

Cell Transformation, Neoplastic: GE, genetics

Enzyme Induction

Gene Amplification

*Gene Expression Regulation, Neoplastic

Neoplasm Proteins: BI, biosynthesis

*Neoplasm Proteins: GE, genetics

*Neoplasms: EN, enzymology

Neoplasms: GE, genetics

Oncogenes

Organ Specificity

Phosphorylation

Protein Processing, Post-Translational

Protein-Tyrosine Kinase: BI, biosynthesis

*Protein-Tyrosine Kinase: GE, genetics

Proto-Oncogene Proteins: BI, biosynthesis

*Proto-Oncogene Proteins: GE, genetics

*Proto-Oncogenes

Rats

Receptor, erbB-2

CHEMICAL NAME: 0 (Neoplasm Proteins); 0 (Proto-Oncogene Proteins); EC

2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112

(Receptor, erbB-2)

GENE NAME: HER2/neu; **c-erbB2**; neu

L34 ANSWER 4 OF 4 MEDLINE on STN

ACCESSION NUMBER: 93081194 MEDLINE

DOCUMENT NUMBER: 93081194 PubMed ID: 1360229

TITLE: Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia.

AUTHOR: Di Fiore P P; Kraus M H

SOURCE: CANCER TREATMENT AND RESEARCH, (1992) 61 139-60. Ref: 69
Journal code: 8008541. ISSN: 0927-3042.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199301

ENTRY DATE: Entered STN: 19930129

Last Updated on STN: 20000303

Entered Medline: 19930106

CONTROLLED TERM: Check Tags: Animal; Human

Cell Transformation, Neoplastic: GE, genetics

Enzyme Induction

Gene Amplification

Genes, Structural

Mice

Mitosis

*Multigene Family

Neoplasm Proteins: BI, biosynthesis

Neoplasm Proteins: GE, genetics

*Neoplasm Proteins: PH, physiology

*Neoplasms: EN, enzymology

Neoplasms: GE, genetics

Neoplasms, Experimental: GE, genetics

Oncogene Proteins v-erbB

Oncogenes

Protein-Tyrosine Kinase: BI, biosynthesis**Protein-Tyrosine Kinase: GE, genetics*****Protein-Tyrosine Kinase: PH, physiology**

Proto-Oncogene Proteins: BI, biosynthesis

Proto-Oncogene Proteins: GE, genetics

***Proto-Oncogene Proteins: PH, physiology**

Proto-Oncogenes

Rats

Receptor, Epidermal Growth Factor: BI, biosynthesis

Receptor, Epidermal Growth Factor: GE, genetics

***Receptor, Epidermal Growth Factor: PH, physiology**

Receptor, erbB-2

Receptor, erbB-3

Recombinant Fusion Proteins: BI, biosynthesis

Retroviridae Proteins, Oncogenic: BI, biosynthesis

Retroviridae Proteins, Oncogenic: GE, genetics

Retroviridae Proteins, Oncogenic: PH, physiology

Sequence Homology, Amino Acid

Transforming Growth Factor alpha: PH, physiology

CHEMICAL NAME:

0 (Neoplasm Proteins); 0 (Oncogene Proteins v-erbB); 0
(Proto-Oncogene Proteins); 0 (Recombinant Fusion Proteins);
0 (Retroviridae Proteins, Oncogenic); 0 (Transforming
Growth Factor alpha); EC 2.7.1.112 (Protein-Tyrosine
Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor);
EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor,
erbB-3)

GENE NAME:

EGFR; HER-2; HER-3; c-erbB; **c-erbB2**; c-fms; erbB;
erbB2; erbB3; neu; ras; v-erbB; v-fms

=> fil medl; d que 137

FILE 'MEDLINE' ENTERED AT 10:37:15 ON 21 OCT 2003

FILE LAST UPDATED: 18 OCT 2003 (20031018/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 1462317 SEA FILE=MEDLINE ABB=ON C4./CT -*Neoplasms*
L36 12 SEA FILE=MEDLINE ABB=ON (CERB OR C ERB) (W) B4 OR CERBB4 OR C
ERBB4
L37 6 SEA FILE=MEDLINE ABB=ON L36 AND L19

=> d iall 137 1-6

L37 ANSWER 1 OF 6 MEDLINE on STN
ACCESSION NUMBER: 1999111199 MEDLINE
DOCUMENT NUMBER: 99111199 PubMed ID: 9815641
TITLE: Altered gene expression in drug-resistant human breast cancer cells.
AUTHOR: Wosikowski K; Schuurhuis D; Kops G J; Saceda M; Bates S E
CORPORATE SOURCE: Medicine Branch, Division of Clinical Science, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
SOURCE: CLINICAL CANCER RESEARCH, (1997 Dec) 3 (12 Pt 1) 2405-14.
Journal code: 9502500. ISSN: 1078-0432.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199903
ENTRY DATE: Entered STN: 19990316
Last Updated on STN: 20000303
Entered Medline: 19990303

ABSTRACT:

It is increasingly recognized that drug-resistant cells undergo transitions not directly linked to "classical" drug resistance. We examined the expression of growth factors, growth factor receptors, and the estrogen receptor in 17 drug-resistant and 2 revertant human breast cancer sublines to provide an understanding of the phenotypic changes that occur and how these changes could affect the biology of the cell. These sublines were derived from five parental human breast cancer cell lines (MCF-7, ZR75B, T47D, MDA-MB-231, and MDA-MB-453). The expression of estrogen receptor was absent or decreased in 6 of the 15 resistant MCF-7, ZR75B, and T47D sublines. Increases of as much as 49-fold compared to parental levels were observed in transforming growth factor alpha, epidermal growth factor receptor, c-erbB2, and/or c-erbB3 mRNA expression in 14 of the 17 resistant sublines. Altered amphiregulin and insulin-like growth factor-I receptor expression was observed in nine and four drug-resistant sublines, respectively. No major alterations were observed in epidermal growth factor and **c-erbB4** expression. Few alterations were observed in two sublines derived from estrogen receptor-negative cells. Higher levels of phosphotyrosine residues were detected in a subset of the resistant sublines, indicating an increased tyrosine kinase activity in these cells. Interestingly, decreased growth rates were observed in all of the sublines, despite up-regulated growth

factor-related gene expression. Taken together, these data suggest that loss of estrogen receptor, increased expression of growth factor pathway genes, and decreased growth rate regularly occur in drug-resistant breast cancer cells. Although we do not know whether the altered expression of growth factor pathway genes is linked as a cause or a consequence of the reduced growth rate, it is well established that decreased growth rate confers drug resistance. These phenotypic changes in drug-resistant human breast cancer cells could serve to initiate, support, or extend the drug resistance.

CONTROLLED TERM: Check Tags: Female; Human
*Antineoplastic Agents: TO, toxicity
*Breast Neoplasms: GE, genetics
Cell Division: DE, drug effects
DNA Topoisomerases, Type II: BI, biosynthesis
DNA Topoisomerases, Type II: GE, genetics
*Drug Resistance, Multiple: GE, genetics
*Gene Expression Regulation, Neoplastic
*Genes, erbB-2
*Proto-Oncogene Proteins: GE, genetics
Proto-Oncogenes
RNA, Messenger: GE, genetics
*Receptor, Epidermal Growth Factor: GE, genetics
Receptor, erbB-2: GE, genetics
Receptor, erbB-3
Receptors, Estrogen: AN, analysis
Receptors, Estrogen: GE, genetics
Transcription, Genetic
Tumor Cells, Cultured

CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Proto-Oncogene Proteins); 0 (RNA, Messenger); 0 (Receptors, Estrogen); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor, erbB-3); EC 5.99.1.3 (DNA Topoisomerases, Type II)

L37 ANSWER 2 OF 6 MEDLINE on STN
ACCESSION NUMBER: 1999002487 MEDLINE
DOCUMENT NUMBER: 99002487 PubMed ID: 9788438
TITLE: c-erbB3 and **c-erbB4** expression is a feature of the endocrine responsive phenotype in clinical breast cancer.
AUTHOR: Knowlden J M; Gee J M; Seery L T; Farrow L; Gullick W J; Ellis I O; Blamey R W; Robertson J F; Nicholson R I
CORPORATE SOURCE: Tenovus Cancer Research Centre, University of Wales College of Medicine, Heath Park, Cardiff, UK.
SOURCE: ONCOGENE, (1998 Oct 15) 17 (15) 1949-57.
Journal code: 8711562. ISSN: 0950-9232.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 19990106
Last Updated on STN: 20000303
Entered Medline: 19981106

ABSTRACT:

We examined c-erbB3 and **c-erbB4** mRNA expression in 47 primary breast cancer samples by simultaneous RT-PCR and have investigated correlations between these parameters and the expression of both ER and EGFR mRNA and protein as measured by RT-PCR and ICA and with Ki67 immunostaining. A direct association was found between c-erbB3 and **c-erbB4** mRNA and ER marker status measured by either RT-PCR (c-erbB3 P = 0.0003; ***c*** **-erbB4** P = 0.02) or ICA (c-erbB-3 P = 0.002; **c-erbB4***** P = 0.01). Inverse associations were seen between c-erbB3 and ***c*** **-erbB4** mRNA marker status and EGFR membrane protein

(c-erbB3: P = 0.003; **cerbB4**: P = 0.003) and mRNA (**c-***erbB4***** : P = 0.009) status. These associations were reinforced by Spearman Rank Correlation Tests. A significant relationship was seen between Ki67 and **c-erbB4** mRNA status and level. Measurements of c-erbB3 protein levels in tumour samples removed from a further 89 patients of known response to endocrine therapy: (i) confirmed the relationship between c-erbB3 and ER and (ii) identified that patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to benefit from endocrine measures. A non-significant trend was recorded between c-erbB3 levels and Ki67 immunostaining. These results clearly demonstrate that increased c-erbB3 and *****c*** -erbB4** expression appears to be associated with the prognostically-favourable ER phenotype.

CONTROLLED TERM: Check Tags: Female; Human; Support, Non-U.S. Gov't
*Antineoplastic Agents, Hormonal: TU, therapeutic use
Base Sequence
*Breast Neoplasms: DT, drug therapy
*Breast Neoplasms: GE, genetics
DNA Primers
Phenotype
Postmenopause
*Proto-Oncogene Proteins: GE, genetics
Proto-Oncogene Proteins: ME, metabolism
RNA, Messenger: GE, genetics
RNA, Messenger: ME, metabolism
*Receptor, Epidermal Growth Factor: GE, genetics
Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, erbB-3
Reverse Transcriptase Polymerase Chain Reaction
*Tamoxifen: TU, therapeutic use
CAS REGISTRY NO.: 10540-29-1 (Tamoxifen)
CHEMICAL NAME: 0 (Antineoplastic Agents, Hormonal); 0 (DNA Primers); 0 (Proto-Oncogene Proteins); 0 (RNA, Messenger); EC 2.7.1.- (HER4 protein); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-3)

L37 ANSWER 3 OF 6 MEDLINE on STN
ACCESSION NUMBER: 1998228743 MEDLINE
DOCUMENT NUMBER: 98228743 PubMed ID: 9580484
TITLE: [Growth hormones and oncogenes in mammary adenocarcinomas induced by medroxyprogesterone acetate in BALB/c mice]. Factores de crecimiento y oncogenes en adenocarcinomas mamarios inducidos por acetato de medroxyprogesterona en ratones BALB/c.
AUTHOR: Elizalde P V; Balana M E; Charreau E H
CORPORATE SOURCE: Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina.
SOURCE: MEDICINA, (1997) 57 Suppl 2 70-4.
Journal code: 0204271. ISSN: 0025-7680.
PUB. COUNTRY: Argentina
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Spanish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 19980723
Last Updated on STN: 20000303
Entered Medline: 19980716

ABSTRACT:

We have studied the involvement of growth factors (GF), their receptors (GF-R) and oncogenes in modulating tumor growth in the medroxyprogesterone acetate (MPA)-induced mammary tumor model in BALB/c mice. We demonstrated the presence of both ligands of the insulin-like growth factor family (IGF-I, IGF-II) and the two types of receptors (IGF-RI, IGF-RII). MPA upregulated IGF-II mRNA and protein levels in hormone-dependent lines (MPA-D). The progression to a

hormone-independent phenotype was accompanied by a high constitutive expression of IGF-II and by a significant decrease in IGF-IIR number. An antisense strategy used to evaluate the role of IGF in the MPA-induced growth of epithelial MPA-D cells showed that IGF mediate progestin-induced mammary tumor growth by autocrine/intracrine pathways. We also studied the role of heregulins (HRG), the recently identified ligands for the c-erbB3 and c-erbB4 oncogenes. HRG mRNA expression was restricted to tumors of ductal origin. MPA induced an in vivo up-regulation of HRG expression. Finally, we also found that MPA may be exerting its proliferative effect on MPA-D lines by inhibiting the expression of transforming growth factor beta 1, (TGF-beta 1) and the lack of expression of TGF-beta 1 in hormone-independent tumors may be related to the acquisition of autonomous growth.

CONTROLLED TERM: Check Tags: Animal; Female; Support, Non-U.S. Gov't

Adenocarcinoma: CI, chemically induced

Adenocarcinoma: GE, genetics

***Adenocarcinoma: ME, metabolism**

Cell Transformation, Neoplastic: GE, genetics

***Cell Transformation, Neoplastic: ME, metabolism**

English Abstract

Epidermal Growth Factor: AN, analysis

***Growth Substances: AN, analysis**

Insulin-Like Growth Factor I: AN, analysis

Insulin-Like Growth Factor II: AN, analysis

Mammary Neoplasms, Experimental: CI, chemically induced

Mammary Neoplasms, Experimental: GE, genetics

***Mammary Neoplasms, Experimental: ME, metabolism**

Medroxyprogesterone 17-Acetate

Mice

Mice, Inbred BALB C

***Oncogenes: GE, genetics**

***Receptors, Growth Factor: AN, analysis**

Transforming Growth Factor beta: AN, analysis

CAS REGISTRY NO.: 62229-50-9 (Epidermal Growth Factor); 67763-96-6

(Insulin-Like Growth Factor I); 67763-97-7 (Insulin-Like Growth Factor II); 71-58-9 (Medroxyprogesterone 17-Acetate)

CHEMICAL NAME: 0 (Growth Substances); 0 (Receptors, Growth Factor); 0

(Transforming Growth Factor beta)

L37 ANSWER 4 OF 6 MEDLINE on STN

ACCESSION NUMBER: 1998155669 MEDLINE

DOCUMENT NUMBER: 98155669 PubMed ID: 9494565

TITLE: Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck.

AUTHOR: Ibrahim S O; Vasstrand E N; Liavaag P G; Johannessen A C; Lillehaug J R

CORPORATE SOURCE: Department of Odontology-Oral Pathology and Forensic Odontology, University of Bergen, Norway..
Sosman@gades.uib.no

SOURCE: ANTICANCER RESEARCH, (1997 Nov-Dec) 17 (6D) 4539-46.
Journal code: 8102988. ISSN: 0250-7005.

PUB. COUNTRY: Greece

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199803

ENTRY DATE: Entered STN: 19980407

Last Updated on STN: 20000303

Entered Medline: 19980326

ABSTRACT:

The exact role of oncogenes and proto-oncogenes in the development of squamous cell carcinoma of the head and neck (SCCHN) is still debatable. The expression of the c-erbB-2, c-erbB-3 and c-erbB-4 members of the epidermal growth factor

receptor family was examined in 16 fresh frozen tissue specimens of SCCNH using avidin-biotin complex immunohistochemistry, with monoclonal and/or polyclonal antibodies directed against each. Eight fresh frozen tissue specimens of normal oral mucosa were included as controls. Of the SCCNH examined, mixed membrane/cytoplasmic staining (moderate to intense) of c-erbB-2 was found in 14/16 cases (88%). When present in the specimen, immunopositive staining of c-erbB-2 was seen in some of the oral surface epithelial cell layers (basal, intermediate and/or superficial) as well as the tumour islands. Weak cytoplasmic staining of c-erbB-3 and c-erbB-4 was found in 13/16 (81%) and 11/16 (69%) cases respectively. When present in the specimen, c-erbB-3 and c-erbB-4 immunopositive staining was seen in some of the oral surface epithelial cell layers (basal, intermediate and/or superficial) as well as the tumour islands. For the positive carcinomas for c-erbB-2, c-erbB-3 and c-erbB-4, the epithelium located near the carcinomas showed weak mixed membrane/cytoplasmic staining of c-erbB-2 in 5/14 cases (36%), weak cytoplasmic staining of c-erbB-3 in 7/13 cases (54%) and of c-erbB-4 in 3/11 cases (27%). All the normal control oral mucosa showed the same pattern of staining for c-erbB-2, c-erbB-3 and c-erbB-4 found in the epithelium located near the carcinomas. Only expression of c-erbB-2 was found to correlate with the increase in the tumour stage, while co-expression of c-erbB-2, c-erbB-3 and c-erbB-4 was found to correlate with the patient survival time in 25% of the carcinomas examined. The present study shows that a) expression of c-erbB-2, but not c-erbB-3 and c-erbB-4 correlates with the increase of the tumour stage b) co-expression of c-erbB-2, c-erbB-3 and c-erbB-4 correlates with decreased survival time in some of the cases of SCCNH, but not the majority c) co-expression of the c-erbB family in normal oral mucosa as well as in the carcinoma may question whether the increased tendency for development of the disease is due to co-expression of c-erbB proto-oncogenes in head and neck lesions.

CONTROLLED TERM: Check Tags: Female; Human; Male; Support, Non-U.S. Gov't

Adult

Aged

Aged, 80 and over

*Carcinoma, Squamous Cell: GE, genetics

Carcinoma, Squamous Cell: PA, pathology

*Genes, erbB-2

*Head and Neck Neoplasms: GE, genetics

Head and Neck Neoplasms: PA, pathology

Immunohistochemistry

Middle Age

Mouth Mucosa: PA, pathology

Mouth Neoplasms: GE, genetics

Mouth Neoplasms: PA, pathology

*Multigene Family

Neoplasm Staging

Proto-Oncogene Proteins: BI, biosynthesis

Receptor, Epidermal Growth Factor: BI, biosynthesis

Receptor, erbB-2: BI, biosynthesis

Receptor, erbB-3

CHEMICAL NAME: 0 (Proto-Oncogene Proteins); EC 2.7.1.- (HER4 protein); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor, erbB-3)

L37 ANSWER 5 OF 6

MEDLINE on STN

ACCESSION NUMBER: 97284441 MEDLINE

DOCUMENT NUMBER: 97284441 PubMed ID: 9139855

TITLE: Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells.

AUTHOR: De Boer W I; Houtsmuller A B; Izadifar V; Muscatelli-Groux B; Van der Kwast T H; Chopin D K

CORPORATE SOURCE: GETU-Centre des Recherches Chirurgicales, Universite Paris XII, Creteil, France.. deboer@pathology.medfac.leidenuniv.n

1
SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1997 Apr 10) 71 (2)
284-91.
Journal code: 0042124. ISSN: 0020-7136.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199705
ENTRY DATE: Entered STN: 19970609
Last Updated on STN: 20000303
Entered Medline: 19970523

ABSTRACT:
Studies on epidermal-growth-factor-like-, fibroblast- and transforming growth factors suggested their implication in tumorigenesis involving effects on tumour-cell proliferation and migration. In human transitional-cell carcinomas (TCC), enhanced expression of TGF alpha and EGF receptors correlated with an aggressive phenotype. However, little is known about functions of these growth factors in invasive TCCs. In this study, we performed protein- and RNA-expression studies on a set of growth factors and their receptors on the newly established invasive human TCC cell line designated 1207. The data were correlated with functional proliferation and migration studies. Similar expression patterns of many cellular markers, growth factors and their receptors were noted both in the original TCC tissue and in its derivative cell line, indicating the relevance of this cell line to the investigation of growth factor functions on TCC cells. The proliferation induction by EGF, TGF alpha, amphiregulin, heregulin alpha, FGF-1 and FGF-7 correlated with the presence of EGF receptors, **c-erbB4** and FGFR2 (IIIb), respectively. Amphiregulin and heregulin alpha induced the most proliferation. In conformity with the low expression of TGF beta receptors I and II, TGF beta1, barely inhibited proliferation, while TGF alpha induced invasion of 1207 cells into Matrigel. These data support the notion that notably EGF-like proteins mediate TCC growth and invasion through autocrine pathways which can be reinforced by loss of TGF beta1 regulation.

CONTROLLED TERM: Check Tags: Animal; Female; Human; Support, Non-U.S. Gov't
Biological Markers
*Bladder Neoplasms: ME, metabolism
*Carcinoma, Transitional Cell: ME, metabolism
Cell Division: DE, drug effects
Epidermal Growth Factor: ME, metabolism
Fibroblast Growth Factors: ME, metabolism
Fibroblast Growth Factors: PD, pharmacology
*Growth Substances: ME, metabolism
Immunohistochemistry
Mice
Mice, Nude
Neoplasm Invasiveness
Neoplasm Transplantation
Receptor, Epidermal Growth Factor: ME, metabolism
Receptors, Fibroblast Growth Factor: ME, metabolism
*Receptors, Growth Factor: ME, metabolism
Receptors, Transforming Growth Factor beta: ME, metabolism
Transforming Growth Factor alpha: PD, pharmacology
Transforming Growth Factor beta: ME, metabolism
Tumor Cells, Cultured

CAS REGISTRY NO.: 62031-54-3 (Fibroblast Growth Factors); 62229-50-9
(Epidermal Growth Factor)

CHEMICAL NAME: 0 (Biological Markers); 0 (Growth Substances); 0
(Receptors, Fibroblast Growth Factor); 0 (Receptors, Growth
Factor); 0 (Receptors, Transforming Growth Factor beta); 0
(Transforming Growth Factor alpha); 0 (Transforming Growth
Factor beta); EC 2.7.1.112 (Receptor, Epidermal Growth
Factor)

L37 ANSWER 6 OF 6 MEDLINE on STN
ACCESSION NUMBER: 94289771 MEDLINE
DOCUMENT NUMBER: 94289771 PubMed ID: 7912566
TITLE: The type I growth factor receptors in human breast cancer.
AUTHOR: Rajkumar T; Gullick W J
CORPORATE SOURCE: ICRF Oncology Unit, Hammersmith Hospital, London, U.K.
SOURCE: BREAST CANCER RESEARCH AND TREATMENT, (1994 Jan) 29 (1)
3-9. Ref: 40
Journal code: 8111104. ISSN: 0167-6806.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199407
ENTRY DATE: Entered STN: 19940815
Last Updated on STN: 20000303
Entered Medline: 19940729

ABSTRACT:

The type 1 family of growth factor receptors includes the EGFR, c-erbB2, c-erbB3, and **c-erbB4**. All four members of the family are expressed in breast cancer. The EGFR gene and more frequently the c-erbB2 gene are amplified in a proportion of cases. In addition to increased expression as a result of gene amplification, overexpression of perhaps all of the receptors also appears to occur, probably as a result of increased mRNA transcription. Overexpression may have prognostic value and may predict response to current therapies. Finally these GFR proteins represent targets for new types of chemotherapeutic agents.

CONTROLLED TERM: Check Tags: Animal; Female; Human
Antineoplastic Agents: CS, chemical synthesis
Breast Neoplasms: GE, genetics
***Breast Neoplasms: ME, metabolism**
Drug Design
Gene Amplification
Gene Expression
Prognosis
Proto-Oncogene Proteins: BI, biosynthesis
Proto-Oncogene Proteins: ME, metabolism
RNA, Messenger: BI, biosynthesis
Receptor, Epidermal Growth Factor: BI, biosynthesis
*Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, erbB-2
Receptor, erbB-3
Transcription, Genetic
Tumor Markers, Biological: AN, analysis
CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Proto-Oncogene Proteins); 0 (RNA, Messenger); 0 (Tumor Markers, Biological); EC 2.7.1.- (HER4 protein); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor, erbB-3)

=> fil medl; d que 140

FILE 'MEDLINE' ENTERED AT 10:37:32 ON 21 OCT 2003

FILE LAST UPDATED: 18 OCT 2003 (20031018/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 1462317 SEA FILE=MEDLINE ABB=ON C4./CT - *Neoplasms*
L21 18675 SEA FILE=MEDLINE ABB=ON PROTEIN-TYROSINE KINASE/CT
L22 1348 SEA FILE=MEDLINE ABB=ON L21/MAJ AND L19/MAJ
L23 36242 SEA FILE=MEDLINE ABB=ON L19(L)EN/CT *EN = enzymology*
L39 4110 SEA FILE=MEDLINE ABB=ON ~~EGFR OR EG FR~~
L40 9 SEA FILE=MEDLINE ABB=ON L23 AND L22 AND L39

=> d iall 140 1-9; fil hom

L40 ANSWER 1 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002629352 MEDLINE
DOCUMENT NUMBER: 22261896 PubMed ID: 12374696
TITLE: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
AUTHOR: Bianco Cataldo; Tortora Giampaolo; Bianco Roberto; Caputo Roberta; Veneziani Bianca Maria; Caputo Rosa; Damiano Vincenzo; Troiani Teresa; Fontanini Gabriella; Raben David; Pepe Stefano; Bianco A Raffaele; Ciardiello Fortunato
CORPORATE SOURCE: Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli "Federico II," 80131 Naples, Italy.
SOURCE: CLINICAL CANCER RESEARCH, (2002 Oct) 8 (10) 3250-8.
Journal code: 9502500. ISSN: 1078-0432.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20021022
Last Updated on STN: 20030307
Entered Medline: 20030306

ABSTRACT:

PURPOSE: The epidermal growth factor receptor (EGFR) is expressed in the majority of human epithelial cancers and has been implicated in the development of cancer cell resistance to cytotoxic drugs and to ionizing radiation. Experimental Design: We used ZD1839, a selective small molecule ***EGFR*** tyrosine kinase inhibitor currently in clinical development. We tested the antiproliferative and the proapoptotic activity of ZD1839 in combination with ionizing radiation in human colon (GEO), ovarian (OVCAR-3), non-small cell lung (A549 and Calu-6), and breast (MCF-7 ADR) cancer cell lines. The antitumor activity of this combination was also tested in nude mice bearing established GEO colon cancer xenografts. RESULTS: With ionizing radiation or ZD1839, a dose-dependent growth inhibition was observed in all of the cancer cell lines growing in soft agar. A cooperative antiproliferative and proapoptotic effect was obtained when cancer cells were treated with

ionizing radiation followed by ZD1839. This effect was accompanied by inhibition in the expression of the antiapoptotic proteins bcl-xL and bcl-2, and by a suppression of the activated (phosphorylated) form of akt protein. Treatment of mice bearing established human GEO colon cancer xenografts with radiotherapy (RT) resulted in a dose-dependent tumor growth inhibition that was reversible upon treatment cessation. Long term GEO tumor growth regressions were obtained after RT in combination with ZD1839. This resulted in a significant improvement in survival of these mice as compared with the control group ($P < 0.001$), the RT-treated group ($P < 0.001$), or the ZD1839-treated group ($P < 0.001$). The only mice alive 10 weeks after tumor cell injection were in the RT-plus-ZD1839 group. Furthermore, 10% of mice in this group were alive and tumor-free after 26 weeks. Similar results were obtained in mice bearing established human A549 lung adenocarcinoma xenografts. Finally, the combined treatment with RT plus ZD1839 was accompanied by a significant potentiation in the inhibition of transforming growth factor alpha, vascular epidermal growth factor, and basic fibroblast growth factor expression in cancer cells, which resulted in significant antiangiogenic effects as determined by immunohistochemical count of neovessels within the GEO tumors. CONCLUSION: This study provides a rationale for evaluating in cancer patients the combination of ionizing radiation and selective EGFR tyrosine kinase inhibitors such as ZD1839.

CONTROLLED TERM: Check Tags: Animal; Female; Human; Support, Non-U.S. Gov't

*Antineoplastic Agents: TU, therapeutic use

Blotting, Western

Combined Modality Therapy

Disease Models, Animal

Dose-Response Relationship, Drug

Immunoenzyme Techniques

Mice

Mice, Inbred BALB C

Mice, Nude

Neoplasms, Experimental: DT, drug therapy

Neoplasms, Experimental: EN, enzymology

Neoplasms, Experimental: PA, pathology

Neoplasms, Experimental: PC, prevention & control

*Neoplasms, Experimental: TH, therapy

Phosphorylation

*Protein-Tyrosine Kinase: AI, antagonists & inhibitors

Protein-Tyrosine Kinase: ME, metabolism

Proto-Oncogene Proteins: ME, metabolism

Proto-Oncogene Proteins c-bcl-2: ME, metabolism

*Quinazolines: TU, therapeutic use

Radiation, Ionizing

*Receptor, Epidermal Growth Factor: AI, antagonists & inhibitors

Receptor, Epidermal Growth Factor: ME, metabolism

Survival Rate

Tumor Cells, Cultured: DE, drug effects

Tumor Cells, Cultured: RE, radiation effects

CAS REGISTRY NO.: 184475-35-2 (Gefitinib)

CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Proto-Oncogene Proteins); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (Quinazolines); 0 (bcl-x protein); 0 (proto-oncogene protein akt); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor)

L40 ANSWER 2 OF 9

MEDLINE on STN

ACCESSION NUMBER: 2001374546 MEDLINE

DOCUMENT NUMBER: 21324312 PubMed ID: 11431328

TITLE: Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of

apoptotic glioblastoma cells.
AUTHOR: Jones G; Machado J Jr; Merlo A
CORPORATE SOURCE: Molecular Neuro-Oncology Laboratory, Department of Clinical and Biological Sciences, University of Basel, 4031 Basel, Switzerland.
SOURCE: CANCER RESEARCH, (2001 Jul 1) 61 (13) 4978-81.
Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200107
ENTRY DATE: Entered STN: 20010723
Last Updated on STN: 20010723
Entered Medline: 20010719

ABSTRACT:

In glioblastoma cells, inhibition of focal adhesion kinase (FAK) by the focal adhesion targeting domain attenuated epidermal growth factor receptor (***EGFR***) signaling, inhibiting epidermal growth factor-dependent migration. Although the EGFR-specific antagonist PD153035 increased caspase-3 activity, this was independent of FAK activity. Instead, the increase in apoptosis upon inhibition of FAK induced the aggregation of an NH(2)-terminal FAK fragment normally present in the nucleus. A recombinant NH(2)-terminal FAK construct was also targeted to the nucleus and aggregated in apoptotic cells upon coexpression with the focal adhesion targeting domain. Therefore, loss of FAK from the focal adhesions inhibits EGFR signaling at the cell membrane and transmits a proapoptotic signal to an NH(2)-terminal variant of FAK present in the nucleus.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
*Apoptosis: PH, physiology
*Cell Movement: PH, physiology
Cell Nucleus: EN, enzymology
Glioblastoma: EN, enzymology
*Glioblastoma: PA, pathology
Phosphorylation
Protein-Tyrosine Kinase: ME, metabolism
*Protein-Tyrosine Kinase: PH, physiology
*Receptor, Epidermal Growth Factor: AI, antagonists & inhibitors
Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, Epidermal Growth Factor: PH, physiology
Signal Transduction: PH, physiology
Tumor Cells, Cultured
CHEMICAL NAME: EC 2.7.1.- (endogenous substrate pp120); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor)

L40 ANSWER 3 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1999362592 MEDLINE
DOCUMENT NUMBER: 99362592 PubMed ID: 10432378
TITLE: In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.
AUTHOR: Sweeney W E; Futey L; Frost P; Avner E D
CORPORATE SOURCE: Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio 44106-6003, USA.
CONTRACT NUMBER: DK 44875 (NIDDK)
DK 51068 (NIDDK)
SOURCE: KIDNEY INTERNATIONAL, (1999 Aug) 56 (2) 406-13.
Journal code: 0323470. ISSN: 0085-2538.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 199908
ENTRY DATE: Entered STN: 19990913
Last Updated on STN: 20000303
Entered Medline: 19990830

ABSTRACT:

BACKGROUND: Recessively transmitted polycystic kidney disease (PKD) in many murine models is characterized by the initial formation of proximal tubular cysts (stage 1), followed by growth and enlargement of renal collecting tubule (CT) cysts (stage 2). Previous studies have reported that stage 1 cyst formation and growth could be manipulated in vitro by using embryonic kidney explants and newborn explant microslices in organ culture. **METHODS:** Microslices of postnatal kidneys cultured on Transwell tissue culture inserts allow experimental manipulation of stage 2 CT cyst development and growth. This system was used to test a potential therapeutic compound for treatment of PKD. This compound, EKI-785, modulates altered epidermal growth factor receptor (**EGFR**) expression in CT cysts by inhibition of **EGFR** autophosphorylation. **RESULTS:** These studies demonstrate that: (a) minor modifications of the previously described organ culture system permit successful culture of more mature renal tissue, and (b) cystic explants treated with EGF and EKI-785 demonstrated a marked reduction in CT cystic lesions compared with cystic explants treated with EGF alone. **CONCLUSIONS:** This study suggests that pharmacological strategies can be used to decrease **EGFR** tyrosine kinase activity and CT cyst formation and enlargement in murine PKD.

CONTROLLED TERM: Check Tags: Animal; In Vitro; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Cell Division: DE, drug effects
Cell Survival: DE, drug effects
Disease Models, Animal
*Enzyme Inhibitors: PD, pharmacology
Epidermal Growth Factor: PD, pharmacology
Gene Expression Regulation, Enzymologic: DE, drug effects
Kidney Tubules, Collecting: CY, cytology
Kidney Tubules, Collecting: DE, drug effects
Mice
Mice, Mutant Strains
Nephrons: CY, cytology
Nephrons: DE, drug effects
*Organ Culture: MT, methods
Phosphorylation
*Polycystic Kidney Diseases: DT, drug therapy
Polycystic Kidney Diseases: EN, enzymology
Polycystic Kidney Diseases: GE, genetics
*Protein-Tyrosine Kinase: AI, antagonists & inhibitors
Protein-Tyrosine Kinase: ME, metabolism
*Quinazolines: PD, pharmacology
Receptor, Epidermal Growth Factor: ME, metabolism
CAS REGISTRY NO.: 62229-50-9 (Epidermal Growth Factor)
CHEMICAL NAME: 0 (CL 387785); 0 (Enzyme Inhibitors); 0 (Quinazolines); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor)

L40 ANSWER 4 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1999086969 MEDLINE
DOCUMENT NUMBER: 99086969 PubMed ID: 9870145
TITLE: Type 1 protein tyrosine kinases in benign and malignant breast lesions.
AUTHOR: Suo Z; Emilsen E; Tveit K M; Nesland J M
CORPORATE SOURCE: Department of Pathology, Norwegian Radium Hospital and Institute for Cancer Research, University of Oslo, Norway.
SOURCE: HISTOPATHOLOGY, (1998 Dec) 33 (6) 514-21.
Journal code: 7704136. ISSN: 0309-0167.

PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199903
ENTRY DATE: Entered STN: 19990402
Last Updated on STN: 20000303
Entered Medline: 19990325

ABSTRACT:

AIMS: To determine their significance, we examined the expression pattern of the four epidermal growth factor receptor (**EGFR**) family members as well as the phosphotyrosine kinase activity in breast tumour tissues. **METHODS AND RESULTS:** Fifty-three malignant breast tumours, four breast cancer cell lines, and 10 benign breast tumours were investigated. Fifty-three per cent (28/53) of the malignant tumours expressed **EGFR** protein, and the majority of these positive tumours were strongly positive. Eighty per cent (8/10) of the benign tumours also expressed **EGFR** protein, but all in a lower or moderate level. An association between **EGFR** expression and increasing malignancy grade was found in the group of infiltrating ductal carcinomas. Of the malignant tumours, 35.8% (19/53) expressed c-erbB-2 protein and 17% (9/53) c-erbB-3 protein, while no expression of c-erbB-2 and c-erbB-3 proteins was found in the benign tumours. Contrary to previous reports, we observed c-erbB-4 receptor protein to be less expressed in the malignant breast tumours. The 'normal' breast epithelial cells adjacent to the malignant tumours and the benign tumours demonstrated intensified membrane staining for c-erbB-4, while a number of the malignant tumours demonstrated a weak cytoplasmic staining or were negative. However, several malignant tumours with strong membrane staining for the c-erbB-4 protein were also found. No simple association between the expression of the four receptors and phosphotyrosine kinase activity was found. **CONCLUSION:** Our study has revealed a complex expression pattern of the **EGFR** family members in breast tumour cells. While the data about **EGFR**, c-erbB-2, c-erbB-3 and phosphotyrosine are largely in line with what has been reported, we found the c-erbB-4 protein expression to be decreased in the malignant tumours.

CONTROLLED TERM: Check Tags: Female; Human
Adult
Aged
Breast: EN, enzymology
*Breast Neoplasms: EN, enzymology
*Carcinoma: EN, enzymology
*Fibroadenoma: EN, enzymology
Immunohistochemistry
Middle Age
Phosphotyrosine: ME, metabolism
*Protein-Tyrosine Kinase: ME, metabolism
Proto-Oncogene Proteins: ME, metabolism
Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, erbB-2: ME, metabolism
Receptor, erbB-3
Tumor Cells, Cultured

CAS REGISTRY NO.: 21820-51-9 (Phosphotyrosine)
CHEMICAL NAME: 0 (Proto-Oncogene Proteins); EC 2.7.1.- (HER4 protein); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor, erbB-3)

L40 ANSWER 5 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1998448304 MEDLINE
DOCUMENT NUMBER: 98448304 PubMed ID: 9775178
TITLE: [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
Tyrosine kinase: implications en pathologie tumorale et perspectives therapeutiques.

AUTHOR: Peyrade F; Taillan B; Lebrun C; Baron V; Dujardin P
CORPORATE SOURCE: Service d'hematologie-medecine interne, Hopital de Cimiez,
Nice, France.
SOURCE: REVUE DE MEDECINE INTERNE, (1998 May) 19 (5) 366-72.
Journal code: 8101383. ISSN: 0248-8663.
PUB. COUNTRY: France
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: French
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 19990106
Last Updated on STN: 20000303
Entered Medline: 19981112

ABSTRACT:

The tyrosine kinase family includes growth factor receptor and cytoplasmic enzymes. It plays a key role in normal cell division and abnormal cell proliferation and differentiation. The most common tyrosine kinases are the epidermal-growth factor (EGFR) and platelet-derived growth factor (PDGF) receptors, and a chromosome Philadelphia product, the Bcr-abl oncogene. Many studies have attempted to correlate clinical evolution of tumors with tyrosine kinase expression. However, clinical application of these new prognostic factors has not yet been demonstrated. More recently, tyrosine-phosphorylation inhibitors (tryphostin) have been developed in phase I studies. Results that were obtained show some objective responses in patients with glioblastoma and polymetastatic cancer. Another approach to block tyrosine kinase expression is the use of monoclonal antibodies. Trials using such antibodies have shown interesting preliminary results.

CONTROLLED TERM: Check Tags: Human
Antibodies, Monoclonal: TU, therapeutic use
Antineoplastic Agents: TU, therapeutic use
Cell Differentiation: PH, physiology
Cell Division: PH, physiology
Clinical Trials, Phase I
Cytoplasm: EN, enzymology
English Abstract
Enzyme Inhibitors: TU, therapeutic use
Fusion Proteins, bcr-abl: PH, physiology
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Glioblastoma: DT, drug therapy
Neoplasms: DT, drug therapy
*Neoplasms: EN, enzymology
Philadelphia Chromosome
Phosphorylation
Prognosis
Protein-Tyrosine Kinase: AI, antagonists &
inhibitors
Protein-Tyrosine Kinase: GE, genetics
*Protein-Tyrosine Kinase: PH, physiology
Protein-Tyrosine Kinase: TU, therapeutic use
Receptor, Epidermal Growth Factor: PH, physiology
Receptors, Growth Factor: PH, physiology
Receptors, Platelet-Derived Growth Factor: PH, physiology
CHEMICAL NAME: 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0
(Enzyme Inhibitors); 0 (Fusion Proteins, bcr-abl); 0
(Receptors, Growth Factor); EC 2.7.1.112 (Protein-Tyrosine
Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor);
EC 2.7.1.112 (Receptors, Platelet-Derived Growth Factor)

L40 ANSWER 6 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1998351426 MEDLINE
DOCUMENT NUMBER: 98351426 PubMed ID: 9688140
TITLE: Mapping of tyrosine kinase gene family members in a

Xiphophorus melanoma model.
AUTHOR: Morizot D C; McEntire B B; Della Coletta L; Kazianis S;
Schartl M; Nairn R S
CORPORATE SOURCE: The University of Texas M.D. Anderson Cancer Center,
Science Park-Research Division, Smithville 78957, USA.
CONTRACT NUMBER: CA 55245 (NCI)
SOURCE: MOLECULAR CARCINOGENESIS, (1998 Jul) 22 (3) 150-7.
Journal code: 8811105. ISSN: 0899-1987.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199808
ENTRY DATE: Entered STN: 19980820
Last Updated on STN: 19980820
Entered Medline: 19980812

ABSTRACT:

Xiphophorus fish have been the subject of intensive genetic research for more than 60 yr, primarily because of the availability of a number of interspecific hybrids that are malignant melanoma models with apparently simple oncogene and tumor suppressor gene determinants. The gene map of Xiphophorus is one of the most extensive among nonhuman vertebrates, with about 100 genes assigned to at least 20 independently assorting linkage groups (LGs), as well as more than 250 anonymous DNA sequence markers, providing coverage for most of the genome for genetic mapping studies. This characteristic has resulted in the mapping of a tumor suppressor locus, DIFF, which is one of two genetic determinants of melanoma formation in the best-studied hybrid melanoma, the Gordon-Kosswig melanoma model. The other gene responsible for melanoma formation in this model is a sex-linked tyrosine kinase gene related to **EGFR** and called Xiphophorus melanoma receptor kinase (Xmrk). The cellular oncogene homologues of the non-receptor tyrosine kinase family orthologous to *yes* and *fyn* have also been found to be overexpressed in malignant melanomas of Xiphophorus and may be involved in tumor progression. We report here the map location of a Xiphophorus *yes* gene, YES1, in LG VI, closest to the **EGFR** gene and the assignment of a *fyn* gene homologue to newly designated LG XV, linked to the gene for cytosolic alpha-galactosidase. We also confirmed that an **EGFR**-related sequence (EGFRL1) that we previously assigned to Xiphophorus LG VI by cross-hybridization to a viral *erbB* probe was the **EGFR** orthologue. Our results suggest that the presence of expressed duplicates of members of the tyrosine kinase gene family in teleost fishes may increase the potential number of targets in oncogenic cascades in fish tumor models.

CONTROLLED TERM: Check Tags: Animal; Female; Support, U.S. Gov't, P.H.S.
Amino Acid Sequence
Chromosome Mapping
*Cyprinodontiformes: GE, genetics
Disease Models, Animal
Linkage (Genetics)
 Melanoma, Experimental: EN, enzymology
 ***Melanoma, Experimental: GE, genetics**
Molecular Sequence Data
*Multigene Family
 Protein-Tyrosine Kinase: CH, chemistry
 ***Protein-Tyrosine Kinase: GE, genetics**
Proto-Oncogene Proteins: CH, chemistry
*Proto-Oncogene Proteins: GE, genetics
Sequence Homology, Amino Acid
CHEMICAL NAME: 0 (Proto-Oncogene Proteins); 0 (proto-oncogene protein c-fyn); 0 (proto-oncogene protein c-yes); EC 2.7.1.112 (Protein-Tyrosine Kinase)

L40 ANSWER 7 OF 9 MEDLINE on STN
ACCESSION NUMBER: 96327921 MEDLINE
DOCUMENT NUMBER: 96327921 PubMed ID: 8734473

TITLE: Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.
AUTHOR: Kondapaka B S; Reddy K B
CORPORATE SOURCE: Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
CONTRACT NUMBER: R29 CA64248 (NCI)
SOURCE: MOLECULAR AND CELLULAR ENDOCRINOLOGY, (1996 Mar 1) 117 (1) 53-8.
Journal code: 7500844. ISSN: 0303-7207.
PUB. COUNTRY: Ireland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199610
ENTRY DATE: Entered STN: 19961106
Last Updated on STN: 20000303
Entered Medline: 19961024

ABSTRACT:

In prostate cancer cells, the binding of peptide growth factors to specific receptors increases tyrosine kinases (TK) activity to regulate cell proliferation, cell differentiation, and signaling processes. To determine whether inhibition of receptor TK activity inhibits tumor growth, we studied the effects of a tyrosine kinase inhibitor, RG-13022 (tyrphostin), on cultured human prostate cancer cells. RG-13022 significantly inhibited TGF alpha-induced phosphorylation of EGF receptor (EGFR). This compound inhibited TGF alpha-stimulated [3H]thymidine incorporation in a dose-dependent manner with IC50 being 30 microM. Clonogenicity in soft agar was reduced in the presence of RG-13022. Inhibitory effects were also observed in androgen-positive LNCaP cells and androgen-negative PC3 cells. RG-13022 not only inhibited TGF alpha-induced growth but also growth stimulated by epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF) and serum. In addition, RG-13022 also blocked androgen-stimulated cell proliferation, suggesting that functioning TK pathways are required for androgen-induced growth. This novel synthetic inhibitor may be useful in providing a new strategy for future therapeutic intervention for prostate cancer.

CONTROLLED TERM: Check Tags: Human; Male; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
1-Phosphatidylinositol 3-Kinase
Androgens: PD, pharmacology
*Antineoplastic Agents: PD, pharmacology
Cell Division: DE, drug effects
*Enzyme Inhibitors: PD, pharmacology
Epidermal Growth Factor: PD, pharmacology
*Nitriles: PD, pharmacology
Phosphorylation
Phosphotransferases (Alcohol Group Acceptor): DE, drug effects
Phosphotransferases (Alcohol Group Acceptor): ME, metabolism
Prostate: EN, enzymology
*Prostatic Neoplasms: DT, drug therapy
Prostatic Neoplasms: EN, enzymology
Prostatic Neoplasms: PA, pathology
*Protein-Tyrosine Kinase: AI, antagonists & inhibitors
*Pyridines: PD, pharmacology
Receptor, Epidermal Growth Factor: DE, drug effects
Receptor, Epidermal Growth Factor: ME, metabolism
Signal Transduction: DE, drug effects
Transforming Growth Factor alpha: PD, pharmacology
Tumor Cells, Cultured
CAS REGISTRY NO.: 136831-48-6 (RG 13022); 62229-50-9 (Epidermal Growth Factor)

CHEMICAL NAME: 0 (Androgens); 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); 0 (Nitriles); 0 (Pyridines); 0 (Transforming Growth Factor alpha); EC 2.7.1 (Phosphotransferases (Alcohol Group Acceptor)); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase)

L40 ANSWER 8 OF 9 MEDLINE on STN
ACCESSION NUMBER: 93219392 MEDLINE
DOCUMENT NUMBER: 93219392 PubMed ID: 8464905
TITLE: Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.
AUTHOR: Kraus M H; Fedi P; Starks V; Muraro R; Aaronson S A
CORPORATE SOURCE: Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD 20892.
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1993 Apr 1) 90 (7) 2900-4.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199305
ENTRY DATE: Entered STN: 19930521
Last Updated on STN: 20000303
Entered Medline: 19930504

ABSTRACT:

The predicted human erbB-3 gene product is closely related to epidermal growth factor receptor (EGFR) and erbB-2, which have been implicated as oncogenes in model systems and human neoplasia. We expressed the erbB-3 coding sequence in NIH 3T3 fibroblasts and identified its product as a 180-kDa glycoprotein, gp180erbB-3. Tunicamycin and pulse-chase experiments revealed that the mature protein was processed by N-linked glycosylation of a 145-kDa erbB-3 core polypeptide. The intrinsic catalytic function of gp180erbB-3 was shown by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants that express a chimeric EGFR/erbB-3 protein, gp180EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings combined with the detection of constitutive tyrosine phosphorylation of gp180erbB-3 in 4 of 12 human mammary tumor cell lines implicate the activated erbB-3 product in the pathogenesis of some human malignancies.

CONTROLLED TERM: Check Tags: Female; Human; Support, Non-U.S. Gov't
Amino Acid Sequence
Antibodies, Monoclonal
Base Sequence
*Breast Neoplasms: EN, enzymology
*Breast Neoplasms: GE, genetics
Chimeric Proteins: ME, metabolism
Enzyme Activation
Epidermal Growth Factor: PD, pharmacology
Glycosylation
Immunohistochemistry
Molecular Sequence Data
Oligodeoxyribonucleotides
Oligopeptides: CS, chemical synthesis
Oligopeptides: IM, immunology
Phosphorylation
Protein Processing, Post-Translational
Protein-Tyrosine Kinase: GE, genetics
*Protein-Tyrosine Kinase: ME, metabolism
Proto-Oncogene Proteins: AN, analysis

Proto-Oncogene Proteins: GE, genetics
*Proto-Oncogene Proteins: ME, metabolism
Receptor, Epidermal Growth Factor: GE, genetics
Receptor, Epidermal Growth Factor: ME, metabolism
Receptor, erbB-3
Signal Transduction
Transfection
Tumor Cells, Cultured
Tunicamycin: PD, pharmacology
CAS REGISTRY NO.: 11089-65-9 (Tunicamycin); 62229-50-9 (Epidermal Growth Factor)
CHEMICAL NAME: 0 (Antibodies, Monoclonal); 0 (Chimeric Proteins); 0 (Oligodeoxyribonucleotides); 0 (Oligopeptides); 0 (Proto-Oncogene Proteins); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor); EC 2.7.1.112 (Receptor, erbB-3)
GENE NAME: erbB-2; erbB-3

L40 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 93081194 MEDLINE
DOCUMENT NUMBER: 93081194 PubMed ID: 1360229
TITLE: Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia.
AUTHOR: Di Fiore P P; Kraus M H
SOURCE: CANCER TREATMENT AND RESEARCH, (1992) 61 139-60. Ref: 69
Journal code: 8008541. ISSN: 0927-3042.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199301
ENTRY DATE: Entered STN: 19930129
Last Updated on STN: 20000303
Entered Medline: 19930106
CONTROLLED TERM: Check Tags: Animal; Human
Cell Transformation, Neoplastic: GE, genetics
Enzyme Induction
Gene Amplification
Genes, Structural
Mice
Mitosis
*Multigene Family
Neoplasm Proteins: BI, biosynthesis
Neoplasm Proteins: GE, genetics
*Neoplasm Proteins: PH, physiology
*Neoplasms: EN, enzymology
Neoplasms: GE, genetics
Neoplasms, Experimental: GE, genetics
Oncogene Proteins v-erbB
Oncogenes
Protein-Tyrosine Kinase: BI, biosynthesis
Protein-Tyrosine Kinase: GE, genetics
*Protein-Tyrosine Kinase: PH, physiology
Proto-Oncogene Proteins: BI, biosynthesis
Proto-Oncogene Proteins: GE, genetics
*Proto-Oncogene Proteins: PH, physiology
Proto-Oncogenes
Rats
Receptor, Epidermal Growth Factor: BI, biosynthesis
Receptor, Epidermal Growth Factor: GE, genetics
*Receptor, Epidermal Growth Factor: PH, physiology

Receptor, erbB-2
Receptor, erbB-3
Recombinant Fusion Proteins: BI, biosynthesis
Retroviridae Proteins, Oncogenic: BI, biosynthesis
Retroviridae Proteins, Oncogenic: GE, genetics
Retroviridae Proteins, Oncogenic: PH, physiology
Sequence Homology, Amino Acid
Transforming Growth Factor alpha: PH, physiology
CHEMICAL NAME: 0 (Neoplasm Proteins); 0 (Oncogene Proteins v-erbB); 0
(Proto-Oncogene Proteins); 0 (Recombinant Fusion Proteins);
0 (Retroviridae Proteins, Oncogenic); 0 (Transforming
Growth Factor alpha); EC 2.7.1.112 (Protein-Tyrosine
Kinase); EC 2.7.1.112 (Receptor, Epidermal Growth Factor);
EC 2.7.1.112 (Receptor, erbB-2); EC 2.7.1.112 (Receptor,
erbB-3)
GENE NAME: EGFR; HER-2; HER-3; c-erbB; c-erbB2; c-fms; erbB;
erbB2; erbB3; neu; ras; v-erbB; v-fms

FILE 'HOME' ENTERED AT 10:37:41 ON 21 OCT 2003

THIS PAGE BLANK (USPTO)